risperidone has been researched along with haloperidol in 927 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (0.32) | 18.7374 |
| 1990's | 158 (17.04) | 18.2507 |
| 2000's | 488 (52.64) | 29.6817 |
| 2010's | 232 (25.03) | 24.3611 |
| 2020's | 46 (4.96) | 2.80 |
| Authors | Studies |
|---|---|
| Baldy, WJ; Barrett, DL; DiStefano, DL; Elgin, RJ; Fedde, CL; Kesslick, JM; Kukla, MJ; Martin, GE; Mathiasen, JR; Scott, MK | 1 |
| Arnt, J; Bøgesø, KP; Hyttel, J; Perregaard, J; Sánchez, C | 1 |
| Dunn, RW; Errico, CL; Hrib, NJ; Huger, FP; Jurcak, JG | 1 |
| Bordeau, KJ; Chiang, Y; Conway, PG; Corbett, R; Glamkowski, EJ; Hartman, HB; Helsley, GC; Strupczewski, JT; Szewczak, MR; Wilmot, CA | 1 |
| Choudhary, MS; Craigo, SC; Meltzer, HY; Monsma, FJ; Roth, BL; Shen, Y; Sibley, DR; Uluer, A | 1 |
| Burgher, KL; Conway, PG; Hartman, HB; Hrib, NJ; Jurcak, JG; Kerman, LL; Roehr, JE; Woods, AT | 1 |
| Ewing, FE; Furman, JS; Howard, HR; Jackson, E; Johnson, C; Lowe, JA; Maloney, PR; Morrone, J; Newman, ME; Robinson, GL; Schmidt, AW; Seeger, TF; Seymour, PA; Zorn, SH | 1 |
| Anglada, L; Bolós, J; Burgarolas, C; Castelló, JM; Gubert, S; Ortiz, JA; Planas, JM; Sacristán, A | 1 |
| Bregna, DE; Burgher, KL; Corbett, R; Hartman, HB; Hrib, NJ; Jurcak, JG; Kafka, S; Kerman, LL; Kongsamut, S; Roehr, JE; Szewczak, MR; Woods-Kettelberger, AT | 1 |
| De Loore, K; Gommeren, W; Janssen, PF; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van Gompel, P | 1 |
| Cai, J; Hartman, HB; Kerman, LL; Kongsamut, S; Roehr, JE; Sandrasagra, A; Tang, L; Weissensee, P | 1 |
| Baxter, EW; Codd, EE; Davis, CB; Jordan, AD; Maryanoff, BE; Maryanoff, CA; McDonnell, ME; Powell, ET; Reitz, AB; Renzi, MJ; Schott, MR; Scott, MK; Shank, RP; Vaught, JL | 1 |
| Egan, CT; Herrick-Davis, K; Teitler, M | 1 |
| Audinot, V; Chaput, C; Conte, C; Gavaudan, S; Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L | 1 |
| Martin, GE; Maryanoff, BE; McComsey, DF; Shank, RP | 1 |
| Agut, J; Anglada, L; Bolós, J; De la Fuente, N; Gubert, S; Ortiz, JA; Planas, JM; Príncep, M; Sacristán, A | 1 |
| Cadavid, MI; Carotti, A; Carrieri, A; Cid, J; Fontenla, JA; Loza, MI; Lozoya, E; Masaguer, CF; Negreira, J; Raviña, E; Rivas, ME; Rosa, E; Sanz, F; Tristán, H | 1 |
| Birch, AM; Bradley, PA; Gill, JC; Kerrigan, F; Needham, PL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Cadavid, MI; Casariego, I; Demontis, GC; Enguix, MJ; Fontenla, JA; Loza, MI; Masaguer, CF; Montenegro, GY; Raviña, E; Rivas, ME; Villazon, M | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| de Moes, J; Feenstra, RW; Hofma, JJ; Kling, H; Kruse, CG; Kuipers, W; Long, SK; Tulp, MT; van der Heyden, JA | 1 |
| Brea, J; Cadavid, MI; Caro, Y; Carotti, A; Carrieri, A; Centeno, NB; Enguix, MJ; Loza, MI; Masaguer, CF; Mengod, G; Raviña, E; Rodrigo, J; Sanz, F; Villazón, M | 1 |
| Boulton, DW; DeVane, CL; Liston, HL; Markowitz, JS | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S | 1 |
| Glennon, RA | 1 |
| Keserü, GM | 1 |
| Brea, J; Caro, Y; Loza, MI; Masaguer, CF; Padín, F; Raviña, E; Torrado, M | 1 |
| Wermuth, CG | 1 |
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Brasili, L; Costantino, L; Franchini, S; Gandolfi, F; Leonardi, A; Poggesi, E; Prezzavento, O; Ronsisvalle, G; Sorbi, C; Vittorio, F | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Alonso, JM; Andrés, JI; Cid, JM; Díaz, A; Fernández, J; Gil, P; Iturrino, L; Megens, A; Sipido, VK; Trabanco, AA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Huang, AS; Kim, SF; Snowman, AM; Snyder, SH; Teuscher, C | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Areias, FM; Barceló, M; Brea, J; Domínguez, E; Loza, MI; Masaguer, CF; Raviña, E | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Anand, A; Chakrabarty, R; Dua, PR; Rao, J; Roy, AD; Roy, R; Saxena, AK; Shankar, G | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Shahid, M; Walker, GB; Wong, EH; Zorn, SH | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Ablordeppey, SY; Altundas, R; Bricker, B; Jackson, T; Khan, A; Kumar, EV; Roth, BL; Zhu, XY | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Devambatla, RKV; Kumar, MM; Rao, VS; Sekhar, KV | 1 |
| Andreasen, JT; Bernetti, M; Borriello, M; Brindisi, M; Butini, S; Cagnotto, A; Campiani, G; Ceres, N; Coccone, SS; De Angelis, M; Fattorusso, C; Fiorini, I; Franceschini, S; Gemma, S; Mennini, T; Mikkelsen, JD; Nacci, V; Novellino, E; Ros, S; Sandager-Nielsen, K; Scheel-Kruger, J; Trotta, F | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Bleich, S; Kornhuber, J; Rupprecht, R; Terfloth, L; Wiltfang, J | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Giordanetto, F; Leach, AG; Zachariae, U | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Brea, J; Carro, L; Domínguez, E; Loza, MI; Masaguer, CF; Raviña, E | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Sen, S; Sinha, N | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Bartolome, JM; Langlois, X; Macdonald, GJ; Tresadern, G | 1 |
| Chappie, TA; Helal, CJ; Hou, X | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, K; Gao, B; Guo, L; Jiang, H; Li, Z; Liu, H; Qian, W; Sun, H; Yang, H; Zhen, X; Zhou, S; Zhou, Y; Zhu, L | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, Y; Liu, BF; Liu, S; Liu, X; Qiu, Y; Wang, S; Xu, X; Yu, M; Zhang, G; Zhang, T; Zhao, S | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Brea, J; Carro, L; Lage, S; Loza, MI; Masaguer, CF; Raviña, E; Torrado, M | 1 |
| Chen, Y; Lan, Y; Liu, BF; Liu, X; Wang, S; Xu, X; Yu, M; Zhang, G; Zhang, H | 1 |
| Bienkowski, P; Bucki, A; Jaśkowska, J; Kazek, G; Kowalski, P; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Mitka, K; Pawłowski, M; Siwek, A; Wasik, A; Wesołowska, A | 1 |
| Andreassi, M; Brindisi, M; Brogi, S; Butini, S; Cagnotto, A; Campiani, G; Casagni, A; Franceschini, S; Gemma, S; Gorelli, B; Mikkelsen, JD; Novellino, E; Ros, S; Salmona, M; Sandager-Nielsen, K; Saponara, S; Scheel-Kruger, J; Trotta, F; Weikop, P | 1 |
| Bojarski, AJ; Bucki, A; Kazek, G; Kołaczkowski, M; Partyka, A; Pawłowski, M; Satała, G; Siwek, A; Wesołowska, A; Zagórska, A | 1 |
| Chen, B; Huang, L; Song, J; Yin, L; Zhang, W; Zhang, X | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cao, X; Chen, Y; Liu, BF; Liu, X; Qiu, Y; Xu, X; Yu, M; Zhang, G; Zhang, Y | 1 |
| Cao, X; Chen, Y; Liu, BF; Liu, X; Qiu, Y; Xu, X; Yu, M; Zhang, G; Zhang, L; Zhang, Y | 1 |
| Baldanzi, G; Bertoni, A; Capello, D; Fresu, LG; Gesu, A; Graziani, A; Massarotti, A; Ruffo, E; Snow, AL; Talmon, M; Tron, GC; Varma, KSS; Velnati, S | 1 |
| Freeman, BB; Rankovic, Z; Yang, L | 1 |
| Fu, W; Li, W; Li, X; Peng, W; Zhao, B; Zhu, C | 1 |
| Chen, Y; Gao, L; Hu, J; Huang, L; Song, T; Yin, L; Zhang, X | 1 |
| Chen, J; Chen, Y; Gao, L; Hao, C; Jin, J; Liu, BF; Liu, X; Ma, R; Wu, Q; Zhang, G; Zheng, L | 1 |
| Lindström, E; von Knorring, L | 3 |
| Awouters, FH; Janssen, PA; Meert, TF; Megens, AA; Niemegeers, CJ; Schellekens, KH | 1 |
| Awouters, FH; Megens, AA; Niemegeers, CJ | 2 |
| Gommeren, W; Janssen, PA; Janssen, PM; Leysen, JE; Pauwels, PJ; Wynants, J | 1 |
| Bollen, J; Claus, A; De Cuyper, H; Eneman, M; Heylen, S; Malfroid, M; Peuskens, J | 1 |
| Baert, AL; Bollen, J; Claus, A; De Cuyper, H; Eneman, M; Heylen, S; Malfroid, M; Peuskens, J; Van Ongeval, C; Wilms, G | 1 |
| Müller-Spahn, F | 2 |
| Bowden, CR; De Coster, R; Heykants, J; Voina, SJ; Woestenborghs, R | 1 |
| Awouters, F; Janssen, PA; Megens, AA; Niemegeers, CJ | 1 |
| Awouters, F; Janssen, PA; Meert, TF; Megens, AA; Niemegeers, CJ; Schellekens, KH | 1 |
| de Chaffoy de Courcelles, D; Eens, A; Gommeren, W; Janssen, PA; Leysen, JE; Stoof, JC | 1 |
| Ereshefsky, L; Lacombe, S | 1 |
| Ciccocioppo, R; Massi, M; Panocka, I; Pompei, P | 1 |
| Janssen, PF; Leysen, JE; Megens, AA; Schotte, A | 1 |
| Czyrak, A; Frankiewicz, T; Maj, J; Rogóz, Z; Skuza, G | 1 |
| Aghajanian, GK; Gellman, RL | 1 |
| Marder, SR; Meibach, RC | 1 |
| Awouters, FH; Janssen, PA | 1 |
| Kido, H; Mori, H; Sakamoto, H; Shiba, K; Sumiyoshi, T; Suzuki, K; Urasaki, K; Yamaguchi, N; Yokogawa, K | 1 |
| McEvoy, JP | 2 |
| Schooler, NR | 1 |
| Owens, DG | 1 |
| Janssen, PM; Leysen, JE; Megens, AA; Schotte, A | 1 |
| Goodman, WK; McDougle, CJ; Price, LH | 1 |
| Elomaa, E; Raitasuo, V; Vataja, R | 1 |
| Bennett, JA; Keck, PE; Wallhausser, LJ | 1 |
| Janssen, PM; Leysen, JE; Luyten, WH; Megens, AA; Schotte, A | 1 |
| Beaudry, P; Bélanger, MC; Chouinard, G; Miller, R; Roy, JY; Turnier, L; Vainer, JL | 1 |
| Perrault, G; Sanger, DJ | 1 |
| Furukawa, H; Hasegawa, T; Kitaichi, K; Nabeshima, T; Yamada, K | 1 |
| Furukawa, H; Hasegawa, T; Kitaichi, K; Nabeshima, T; Ogita, K; Yamada, K; Yoneda, Y | 1 |
| Honer, WG; Kopala, LC | 1 |
| Chouinard, G | 1 |
| DeVane, CL | 1 |
| Perry, PJ | 1 |
| Borison, RL; Chouinard, G; Möller, HJ; Müller, H; Schooler, NR | 1 |
| Möller, HJ | 2 |
| Kirisci, L; Musser, WS | 1 |
| Benvenga, MJ; Leander, JD | 1 |
| Peuskens, J | 1 |
| Conway, PG; Corbett, R; Cornfeldt, M; Rush, DK; Strupczewski, JT; Szewczak, MR; Wilmot, CA | 1 |
| Czobor, P; Meibach, RC; Volavka, J | 1 |
| Addington, D; Arnott, W; Beauclair, L; Bloom, D; Chouinard, G; Jones, B; Labelle, A; MacEwan, GW; Remington, G | 1 |
| Massi, M; Panocka, I; Pompei, P | 1 |
| Koyama, T; Kusumi, I; Matsubara, R; Matsubara, S; Yamashita, I | 1 |
| Conway, PC; Corbett, R; Dunn, RW; Hartman, H; Helsley, GC; Kerman, LL; Strupczewski, JT; Woods, AT | 1 |
| Hayakawa, H; Kawai, K; Kikumoto, O; Motohashi, N; Okamoto, Y; Yamawaki, S; Yokota, N | 1 |
| Matsubara, R | 1 |
| Czyrak, A; Jaros, T; Maj, J; Moryl, E | 1 |
| Kang, DY; Kim, CE; Min, SK; Rhee, CS | 1 |
| Czobor, P; Volavka, J | 1 |
| Cesková, E; Svestka, J | 2 |
| Dashevsky, B; Frank, RA; Grocki, S; Kehne, JH; Schmidt, CJ; Sorensen, SM; Tsibulsky, V | 1 |
| Fukuda, T; Futamura, T; Haga, K; Ohashi, Y; Takahashi, Y; Yano, K | 1 |
| Hayashi, T; Kagaya, A; Kugaya, A; Motohashi, N; Okamoto, Y; Shinno, H; Takebayashi, M; Uchitomi, Y; Yamaji, T; Yamawaki, S | 1 |
| Mahmood, T; Silverstone, T | 1 |
| Bonaventure, P; Janssen, PF; Leysen, JE; Schotte, A | 1 |
| McCreadie, RG | 1 |
| Bauer, U; Gallhofer, B; Gruppe, H; Krieger, S; Lis, S | 1 |
| Davis, JM; Janicak, PG | 1 |
| Bilsker, D | 1 |
| Peterson, BS | 1 |
| Azorin, JM; Blin, O; Bouhours, P | 1 |
| Raleigh, F | 1 |
| McCoy, L; Richfield, EK | 1 |
| Maany, I | 1 |
| Antoniou, K; Papadopoulou-Daifotis, Z; Rimikis, MN; Stathis, P; Varonos, D | 1 |
| Skarsfeldt, T | 1 |
| Casey, DE | 1 |
| Bakshi, V; Geyer, MA; Swerdlow, NR | 1 |
| Cox, C; McCoy, L; Richfield, EK | 2 |
| Griffon, N; Pilon, C; Sautel, F; Schwartz, JC; Sokoloff, P | 1 |
| Asenbaum, S; Brücke, T; Gössler, R; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J; Topitz-Schratzberger, A; Vesely, C | 1 |
| Bacaltchuk, J; de Castro-e-Silva, E; de Oliveira, IR; de Sena, EP; Miranda-Scippa, AM; Pereira, EL; Ribeiro, MG | 1 |
| Bruggeman, R; Timmerman, W; Westerink, BH | 1 |
| Bauer, KS; Haas, GL; Keshavan, MS; Kroboth, PD; Schooler, NR; Sweeney, JA | 1 |
| Anzallo, C; Contarino, A; Drago, F; Marino, R; Raffaele, R; Rampello, L; Scapagnini, U; Valerio, C | 1 |
| Ames, D; Green, MF; Kern, RS; Marder, SR; Marshall, BD; McGurk, S; Mintz, J; Wirshing, WC | 1 |
| Lindenmayer, JP; Simpson, GM | 1 |
| Borsini, F; Cerutti, M; Fodritto, F; Monferini, E; Volonté, M | 1 |
| DeMaso, DR; Steingard, RJ; Zimnitzky, BM | 1 |
| Dryden-Edwards, RC; Reiss, AL | 1 |
| Albright, PS; Chouinard, G | 1 |
| Aberman, J; Carriero, D; Finn, M; Lyons, M; Salamone, JD; Trevitt, JT | 1 |
| Green, MF; Hayden, JL; Kern, RS; Kuehnel, TG; Marshall, BD; Mintz, J; Robertson, MJ | 1 |
| Heinz, A; Knable, MB; Raedler, T; Weinberger, DR | 1 |
| Linnet, K; Olesen, OV | 1 |
| Fischer, TR; Hitchcock, JM; Lister, S; Wettstein, JG | 1 |
| Fogelson, DL; Payne, D; Sternbach, H | 1 |
| Addington, D; Addington, J | 1 |
| Collins, SP; Mendes, LS | 1 |
| Chouinard, G; Davis, JM; Marder, SR | 1 |
| Hillard, JR | 1 |
| Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H | 1 |
| Cherkerzian, S; Cohen, BM; Ennulat, DJ; Froimowitz, MP; Konieczna, H; Wan, W | 1 |
| Bouman, NH; Dhossche, DM | 1 |
| Docter, GJ; Mijnster, MJ; Schotte, A; Voorn, P | 1 |
| Marder, SR | 1 |
| Frenchman, IB; Prince, T | 1 |
| Benkert, O; Hillert, A; Müller, MJ; Müller-Siecheneder, F; Szegedi, A; Wetzel, H | 1 |
| Asenbaum, S; Barnas, C; Brücke, T; Hesselmann, B; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J | 1 |
| Coppola, R; Gorey, JG; Heinz, A; Jones, DW; Knable, MB; Lee, KS; Weinberger, DR | 1 |
| Dähne, I; Dresel, S; Hahn, K; Mager, T; Scherer, J; Tatsch, K | 1 |
| Green, MF; Kee, KS; Kern, RS; Marshall, BD | 1 |
| Kapur, S; Remington, G; Zipursky, R | 1 |
| Honma, H; Koyama, T; Matsubara, S; Suzuki, I; Watanabe, N | 1 |
| Haas, GL; Keshavan, MS; Pettegrew, JW; Schooler, NR; Sweeney, JA | 1 |
| Green, MF; Kern, RS; Marder, SR; Marshall, BD; McGurk, S; Mintz, J; Wirshing, D; Wirshing, WC | 1 |
| Depoortere, R; Perrault, G; Sanger, DJ | 1 |
| de Boer, P; de Vries, JB; Kruse, CG; Long, SK; Westerink, BH | 1 |
| Drici, MD; Flockhart, DA; Liu, XK; Wang, WX; Woosley, RL | 1 |
| Conley, RR; Kelly, DL; Love, RC; Moore, DB; Sherr, JD | 1 |
| Abraham, D; Kissling, W; Leucht, S; Pitschel-Walz, G | 1 |
| Mazurek, MF; Rosebush, PI | 1 |
| Brown, RE; Genduso, LA; Hamilton, SH; Palmer, CS; Revicki, DA | 1 |
| Breier, A | 1 |
| Kapur, S; Remington, G | 2 |
| Hatzimanolis, J; Lykouras, L; Markianos, M | 4 |
| Alsayegh, L; Backstrom, JR; Berry, SA; Friedman, L; Roth, BL; Sanders-Bush, E; Willins, DL | 1 |
| Bailey, A; Caligiuri, MP; Harris, MJ; Jeste, DV; Lacro, JP; Rockwell, E | 1 |
| Fido, AA; Ibrahim, MM; Maurice, M; Salama, GM; See, RE | 1 |
| Kleven, MS; Koek, W; Prinssen, EP | 1 |
| Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC | 1 |
| Carboni, E; Di Chiara, G; Rolando, MT; Silvagni, A | 1 |
| Green, MF; Kern, RS; Marder, SR; Marshall, BD; McGurk, SR; Mintz, J; Wirshing, D; Wirshing, WC | 1 |
| Chaki, S; Funakoshi, T; Kumagai, T; Nagamine, M; Nakazato, A; Okuyama, S; Tomisawa, K; Yoshikawa, R | 1 |
| Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC | 1 |
| Horikomi, K; Iizuka, K; Mita, N; Miwa, T; Nagase, H; Sakai, K; Sonehara, K; Takagi, K; Takahashi, S | 1 |
| Yui, K | 1 |
| Bocksberger, JP; Dautzenberg, PL; De Deyn, PP; Eriksson, S; Lawlor, BA; Rabheru, K; Rasmussen, A | 1 |
| Chodera, A; Kus, K; Nowakowska, E; Rybakowski, J | 1 |
| Bottlender, R; Möller, HJ | 1 |
| Fukuda, K; Hondo, H; Kuroki, T; Nakahara, T; Tsutsumi, T; Uchimura, H; Yao, H | 1 |
| McGorry, PD | 1 |
| Dittert, S; Möller, HJ; Soyka, M; Winter, C | 1 |
| Branch, RA; Carter, CS; Coley, KC; DaPos, SV; Maxwell, R; Wilson, JW | 1 |
| Chang, CJ; Chen, WJ; Lin, HN; Liu, SK | 1 |
| Ichikawa, J; Meltzer, HY | 1 |
| Addington, D; Breier, A; David, SR; Jones, BD; Labelle, A; Purdon, SE; Stip, E; Tollefson, GD | 1 |
| Hashimoto, K; Hirano, M; Hondo, H; Kuroki, T; Motomura, K; Nakahara, T; Tsutsumi, T; Uchimura, H; Ueki, H | 1 |
| De Deyn, PP | 1 |
| Glazer, WM | 1 |
| Grisold, W; Urbanits, S; Windhaber, J | 1 |
| McCallum, SE; Porter, JH; Vann, RE; Varvel, SA | 1 |
| De Deyn, PP; Katz, IR | 1 |
| Sabel, BA; Schroeder, H; Schroeder, U; Schwegler, H | 1 |
| Coulouvrat, C; Dondey-Nouvel, L; Rein, W | 1 |
| Dan, B; Kornreich, C; Pelc, I; Verbanck, P | 1 |
| Gertz, HJ; Hohdorf, K; Künstler, U; Regenthal, R; Seese, A | 1 |
| Fujimura, M; Hashimoto, K; Yamagami, K | 2 |
| Aloe, L; Angelucci, F; Mathé, AA | 1 |
| Gómez, JC; Gregor, KJ; Montejo, AL; Sacristán, JA; Vieta, E | 1 |
| Elbein, AD; Griffin, ST; Hutton, TL; Karson, CN; Kyosseva, SV; Mrak, RE; Sturner, WQ | 1 |
| Green, B | 1 |
| Gruber, SH; Mathé, AA | 1 |
| Almond, S; O'Donnell, O | 1 |
| Antoniou, K; Bekris, S; Papadopoulou-Daifoti, Z; Rimikis, M; Saranti, M; Stathis, P | 1 |
| Dean, CE | 1 |
| Breier, A; David, SR; Kinon, BJ; Taylor, CC | 1 |
| Meibach, RC | 2 |
| Chiang, HT; Jan, CR; Li, HF; Wu, SN | 1 |
| De Smedt, C; Lemmens, P; Peuskens, J; Van Baelen, B | 1 |
| Robinson, KA | 1 |
| de Groot, IW; Haffmans, PM; Heck, AH; Hoencamp, E | 1 |
| Allikmets, L; Matto, V; Pruus, K; Rudissaar, R; Skrebuhhova-Malmros, T | 1 |
| Gessa, GL; Marchese, G; Pani, L; Ruiu, S; Saba, PL | 1 |
| Currier, GW | 1 |
| Feifel, D | 1 |
| Hilger, E; Kasper, S | 1 |
| Higuchi, H; Shimizu, T; Takahashi, H | 1 |
| Bhana, N; Foster, RH; Olney, R; Plosker, GL | 1 |
| Kapur, S; Seeman, P | 1 |
| Basson, BR; Crawford, AM; Jones, B; Kinon, BJ; Walker, DJ | 1 |
| Azorin, JM | 1 |
| Currier, GW; Simpson, GM | 1 |
| Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S | 1 |
| Andreasen, NC; Boles Ponto, LL; Hichwa, RD; Miller, DD; O'Leary, DS; Watkins, GL | 1 |
| Brar, JS; Ganguli, R; Mullen, B; Vagnucci, AH | 1 |
| Davidson, M; Rabinowitz, J | 1 |
| Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD | 1 |
| Agarwal, V; Kumar, P | 1 |
| Mack, JE; Reeves, RR; Torres, RA | 1 |
| Davidson, M; Hornik, T; Rabinowitz, J | 1 |
| Fleischhacker, WW; Lemmens, P; van Baelen, B | 1 |
| Deslandes, M; Edwardes, MD; Laporta, M; Ricard, N; Sauriol, L; Suissa, S | 1 |
| Flor-Henry, P; Purdon, SE; Woodward, ND | 1 |
| Davis, JM; Dowd, SM; Janicak, PG; Kasckow, JW; Keck, PE; Sharma, RP; Strakowski, SM; Strong, J; Tugrul, K | 1 |
| Howard, HR; Lebel, LA; Schmidt, AW; Zorn, SH | 1 |
| Geurts, M; Maloteaux, JM; Pauwels, PJ; Robinet, EA | 1 |
| Reuss, B; Unsicker, K | 1 |
| Glick, ID; Lemmens, P; Vester-Blokland, E | 1 |
| Christian, BT; Mantil, J; Mukherjee, J; Narayanan, TK; Shi, B | 1 |
| Badía, X; Gómez, JC; Kind, P; Sacristán, JA | 1 |
| Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J | 1 |
| Bauzon, D; Bymaster, FP; Cohen, ML; DeLapp, NW; Falcone, JF; Kennedy, JS; Schenck, K | 1 |
| Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF | 3 |
| Carlsson, A; Carlsson, ML; Nilsson, M; Waters, N; Waters, S | 1 |
| Chan, WC; Chiu, HF; Choy, CN; Lam, LC; Leung, VP; Li, SW | 1 |
| Brenner, R; Csernansky, JG; Mahmoud, R | 1 |
| Geddes, J | 1 |
| de Boer, A; Herings, RM; Jansen, PA; Leufkens, HG; Roos, RA; Schillevoort, I | 1 |
| Chang, WH; Chang, YC; Chiu, CC; Huang, MC; Lane, HY; Su, MH | 1 |
| Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J | 3 |
| Edgell, E; García-Cabeza, I; Gómez, JC; González de Chavez, M; Sacristán, JA | 1 |
| Dai, J; Fowler, WL; Ichikawa, J; Meltzer, HY; O'Laughlin, IA | 1 |
| Boonyanaruthee, V; Chan-Ob, T; Kuntawongse, N | 1 |
| Philibin, SD; Porter, JH; Vann, RE; Varvel, SA; Wise, LE | 1 |
| Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R | 1 |
| Cacchio, M; Di Giovanni, G; Di Giulio, C; Di Matteo, V; Esposito, E | 1 |
| Berg, PH; Glick, ID | 1 |
| Yatham, LN | 1 |
| Alva, G; Arvanitis, LA; Bera, R; Potkin, SG; Thyrum, PT; Yeh, C | 1 |
| Horiguchi, J; Morinobu, S; Nagao, M; Yamashita, H; Yamawaki, S | 1 |
| Huang, XF; Zavitsanou, K | 1 |
| Nomikos, GG; Rodriguez, DE; Shirazi-Southall, S | 1 |
| Gruber, SH; Mathé, AA; Nomikos, GG | 2 |
| Itoh, O; Kamada, H; Ohya-Nishiguchi, H; Yokoyama, H | 1 |
| Bartholini, F; Casu, MA; Gessa, GL; Marchese, G; Pani, L; Ruiu, S; Saba, P | 1 |
| Blair, K; Glynn, SM; Liberman, RP; Marder, SR; Mintz, J; Ross, D; Wirshing, DA; Wirshing, WC | 1 |
| Curtin, F | 1 |
| Stalman, SL | 1 |
| Lieberman, J; Schneider, L; Stroup, S | 1 |
| Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J | 1 |
| Taylor, DM | 1 |
| Gil-ad, I; Shiloh, R; Shtaif, B; Weizman, A | 1 |
| Fleischhacker, WW; Kemmler, G; Weiss, E | 1 |
| Glynn, SM; Green, MF; Liberman, RP; Marder, SR; McGurk, SR; Mintz, J; Wirshing, DA; Wirshing, WC | 1 |
| Chaki, S; Funakoshi, T; Hirota, S; Kameo, K; Takamori, K | 1 |
| Marder, SR; Pierre, JM; Saunders, CS; Wirshing, DA; Wirshing, WC | 1 |
| Bowden, CL; Ghaemi, SN; Grossman, F; Okamoto, A; Sachs, GS | 1 |
| Andersson, C; Hamer, RM; Lawler, CP; Lieberman, JA; Mailman, RB | 1 |
| Kaneko, S; Kondo, T; Mihara, K; Suzuki, A; Yasui-Furukori, N | 1 |
| Chiu, FC; Mahadik, SP; Wakade, CG; Waller, JL | 1 |
| Möller, HJ; Peuskens, J; Puech, A | 1 |
| de Wit, H; Ortengren, A; Wachtel, SR | 1 |
| Quartermain, D; Rosengarten, H | 1 |
| Chaki, S; Funakoshi, T; Kawashima, N; Komurasaki, T; Kumagai, T; Nakazato, A; Ogawa, S; Okuyama, S; Suzuki, Y | 1 |
| De Vries, R; Inoue, Y; Kaneko, S; Kondo, T; Mihara, K; Suzuki, A; Yasui-Furukori, N | 1 |
| Addy, N; Levin, ED | 1 |
| Ashe, P; Chlan-Fourney, J; Juorio, AV; Li, XM; Nylen, K | 1 |
| Andreasen, NC; Corson, PW; Miller, DD; O'Leary, DS | 1 |
| Jainer, AK; Onalaja, D | 1 |
| Ayalon, L; Dagan, Y; Hermesh, H | 1 |
| Emsley, RA; Keyter, L; Keyter, N; Oosthuizen, P; Roberts, MC; Torreman, M; Turner, J | 1 |
| Artiola i Fortuny, L; De Smedt, G; Harvey, PD; Vester-Blockland, E | 1 |
| Ballon, JS; Boyd, JA; Marder, SR; Meng, LR; Wirshing, DA; Wirshing, WC | 1 |
| Bilker, WB; Glasser, DB; Hennessy, S; Kimmel, SE; Knauss, JS; Margolis, DJ; Morrison, MF; Reynolds, RF; Strom, BL | 1 |
| Bilici, M; Cakirbay, H; Guler, M; Tan, U; Tosun, M; Ulgen, M | 1 |
| de Haan, L; van Amelsvoort, T | 1 |
| Hägg, S; Hedenmalm, K; Mortimer, O; Spigset, O; Ståhl, M | 1 |
| Duncan, GE; Lieberman, JA; Marx, CE; Morrow, AL; VanDoren, MJ | 1 |
| Goudie, AJ; Smith, JA | 1 |
| Aguglia, E; De Vanna, M; Ferrara, D; Onor, ML | 1 |
| Desco, M; Gispert, JD; Molina, V; Palomo, T; Pascau, J; Reig, S; Santos, A; Sanz, J | 1 |
| Meltzer, HY; Sumiyoshi, T | 1 |
| Evans, DR; Hill, WD; Mahadik, SP; Parikh, V; Terry, AV; Waller, JL | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Dhawan, BN; Kumar, R; Palit, G | 1 |
| van den Buuse, M | 1 |
| Akhter, A; Osser, DN | 1 |
| Messori, A | 1 |
| Gupta, S | 2 |
| Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H | 1 |
| Brown, CM; Gibson, PJ; Opolka, JL; Rascati, KL | 2 |
| Leander, JD; Wolff, MC | 1 |
| Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R | 1 |
| Abílio, VC; Barbosa, PN; Carvalho, RC; Frussa-Filho, R; Silva, RH | 1 |
| Bromet, EJ; Davidson, M; Rabinowitz, J | 1 |
| Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F | 1 |
| Cross, JT; Doraiswamy, PM; Koller, EA; Schneider, BS | 1 |
| Woods, SW | 1 |
| Lindborg, SR; Purdon, SE; Stip, E; Woodward, N | 1 |
| Conley, RR; Kelly, DL; Love, RC; McMahon, RP | 1 |
| Altar, CA; Burris, KD; Dunn, B; Hirose, T; Imaoka, T; Kikuchi, T; Miwa, T; Molinoff, PB; Nakai, M; Nakai, S; Okazaki, H; Tottori, K; Uwahodo, Y; Yamada, S | 1 |
| Morishita, S | 1 |
| Ganguly, R; Martin, BC; Miller, LS | 1 |
| Blair, KE; Glynn, SM; Liberman, RP; Marder, SR; Mintz, J; Ross, D; Widmark, C; Wirshing, DA; Wirshing, WC | 1 |
| Khan, MM; Mahadik, SP; Parikh, VV | 1 |
| Angelone, SM; Bassi, T; Bellodi, L; Cavallaro, R; Cavedini, P; Mistretta, P; Ubbiali, A | 1 |
| Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H | 1 |
| Higuchi, H; Kamata, M; Naitoh, S; Shimizu, T; Sugita, T; Takahashi, H; Yoshida, K | 1 |
| Gordon, E; Green, MJ; Harris, AW; Loughland, CM; Williams, LM | 1 |
| Brunnauer, A; Geiger, E; Laux, G | 1 |
| Bashford, RA; Hamer, RM; Lieberman, JA; Sheitman, BB; Sikich, L | 1 |
| Hamann, J; Kissling, W; Leucht, S; Rummel, C | 1 |
| Apiquian, R; de la Fuente-Sandoval, C; Fresán, A; Gutiérrez, D; Herrera, K; Lóyzaga, C; Nicolini, H; Ulloa, RE | 1 |
| Hashimoto, E; Ikeda, H; Saito, T; Yamamoto, M | 1 |
| Hugyecz, M; Janka, Z; Kálmán, J; Molnár, J; Pákáski, M; Palotás, A; Palotás, M; Penke, B | 1 |
| Khan, MM; Mahadik, SP; Parikh, V; Terry, AV | 1 |
| Fukunaga, K; Takeuchi, Y | 1 |
| Tamminga, CA | 1 |
| Kabanov, SO; Mosolov, SN | 1 |
| Davey, NJ; Puri, BK; Zaman, R | 1 |
| Anziano, R; Cutler, NR; Harrigan, EP; Miceli, JJ; Middle, M; Reeves, KR; Shiovitz, T; Sramek, J; Watsky, E | 1 |
| Baba, A; Hashimoto, H; Shintani, N; Tanaka, K | 1 |
| Bartholini, F; Casti, P; Casu, MA; Congeddu, E; Marchese, G; Pani, L; Ruiu, S; Tambaro, S | 1 |
| Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J | 1 |
| Chong, MY; Lung, FW; Yen, YC | 1 |
| Levin, ED; Rezvani, AH | 1 |
| Csernansky, JG; DeLisi, LE; Heydebrand, G; Hoff, AL; Rabinowitz, J; Weiser, M | 1 |
| Casteelen, G; de Haan, L; Güzelcan, Y; Sluys, M | 1 |
| Burnet, PW; Harrison, PJ; Hutchinson, LJ; Law, AJ | 1 |
| Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M | 1 |
| Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM | 1 |
| Bossie, CA; Chou, JC; Currier, GW; Feifel, D; Gharabawi, GM; Mahmoud, RA; Turkoz, I | 1 |
| Chopde, CT; Hirani, K; Morelli, M; Ugale, RR | 1 |
| Juang, YY; Liang, HY; Lin, NC; Liu, CY; Yeh, EK | 1 |
| Citrome, L; Czobor, P; Kennedy, JL; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Ni, X; Nolan, K; Sheitman, B; Volavka, J | 1 |
| Apiquian, R; de la Fuente-Sandoval, C; Fresán, A; Nicolini, H; Ulloa, RE | 1 |
| Choi, JH; Kim, SH; Lee, JS; Nam, JH; Son, H; Yang, BH | 1 |
| Hashimoto, E; Ozawa, H; Saito, T; Tateno, M; Ukai, W | 1 |
| Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M | 1 |
| Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Nolan, K; Sheitman, B; Volavka, J | 1 |
| Budin, R; Davidson, P; Fleming, AS; Kapur, S; Li, M | 1 |
| Ito, C; Ojima, T; Sakurai, E; Watanabe, T; Yanai, K | 1 |
| Grigor'eva, EA; Ritskov, AS | 1 |
| Heagerty, PJ; Kurland, BF | 1 |
| de Sena, EP; Miranda-Scippa, A; Oliveira, IR; Quarantini, Lde C; Santos-Jesus, R | 1 |
| Fell, MJ; Marshall, KM; Neill, JC | 1 |
| Conn, PJ; Mallorga, PJ; Pettibone, DJ; Sur, C; Williams, JB | 1 |
| Girimaji, SC; Jairam, R; Seshadri, SP; Srinath, S | 1 |
| Borza, C; Mindreci, I; Nechifor, M; Palamaru, I; Vaideanu, C | 1 |
| Bryois, Ch; Sahli, Ch | 1 |
| Bäumer, D; Ebert, D; Tebartz van Elst, L; Trimble, MR | 1 |
| Brunnauer, M; Kagerer, S; Laux, G; Möller, HJ; Soyka, M; Winter, C | 1 |
| Jainer, AK; Sundararajan, V | 1 |
| Andrade, C | 1 |
| Floresca, CZ; Schetz, JA | 1 |
| Lawrie, S; McIntosh, A; Nadeem, Z | 2 |
| Dobmeier, P; Kuhn, K; Scherer, J; Schmaus, W | 1 |
| Eerdekens, M; Grossman, F; Karcher, K; Khanna, S; Kramer, M; Smulevich, AB | 1 |
| Lambert, M; Naber, D | 1 |
| Bobes, J; Cañas, F; Mackell, J; Rejas, J | 1 |
| Rosenheck, RA | 1 |
| Arya, P; Butler, R; Warner, J | 1 |
| Harris, MS; Keshavan, MS; Reilly, JL; Sweeney, JA | 2 |
| Barna, I; Gazdag, G; Iványi, Z; Tolna, J | 1 |
| Kato, R; Sato, J; Suzuki, H | 1 |
| Cho, SH; Han, C; Jung, IK; Kim, JY; Kim, L; Kim, SH; Kim, YK; Lee, BH; Lee, HJ | 1 |
| Winter, AS; Witschy, JK | 1 |
| Davidson, M; De Smedt, G; Eerdekens, M; Emsley, R; Harvey, PD; Kopala, L; McGorry, PD; Rabinowitz, J; Schooler, N; Swyzen, W; Van Hove, I | 1 |
| Lawrie, S; McIntosh, A | 1 |
| Cao, LY; Shen, YC; Wu, GY; Zhang, XY; Zhou, DF | 2 |
| Honer, WG; Kopala, LC; Rabinowitz, J | 1 |
| Burris, KD; Kikuchi, T; Miwa, T; Mori, T; Stark, A; Tadori, Y; Tottori, K | 1 |
| Ballard, ME; Cowart, M; Decker, MW; Esbenshade, TA; Faghih, R; Fox, GB; Hancock, AA; Pan, L; Roberts, S; Rueter, LE; Zhang, M | 1 |
| Citrome, L; Czobor, P; Kline, L; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Nolan, KA; Sheitman, B; Volavka, J | 1 |
| Bjelik, A; Bódi, N; Bogáts, G; Fehér, LZ; Gyülvészi, G; Hugyecz, M; Janka, Z; Juhász, A; Kálmán, J; Kitajka, K; Matin, K; Molnár, J; Pákáski, M; Palotás, A; Palotás, M; Penke, B; Puskás, LG; Samarova, EI; Zvara, A | 1 |
| Baxter, LR; Flournoy, JM; Jackson, WT; Li, X; May, RS; Tolbert, LC | 1 |
| Chaatouf, el H; Ferrer, JM; Montes, MI | 1 |
| Matsui-Sakata, A; Ohtani, H; Sawada, Y | 1 |
| Christensen, JD; Garver, DL; Holcomb, JA | 1 |
| Bersani, G; Clemente, R; Conti, CM; Conti, P; Di Giannantonio, M; Doyle, R; Exton, MS; Gherardelli, S; Grilli, A; Pancheri, P | 1 |
| Adams, AS; Kanavos, P; Park, S; Ross-Degnan, D; Sabin, J; Soumerai, SB | 1 |
| Bitter, I; Czobor, P; Dossenbach, M; Volavka, J | 1 |
| Aguilar, J; Arango-Dávila, C; Assunção, S; Caro, O; Dossenbach, M; Landa, E; Leadbetter, J; Silva Ibarra, H | 1 |
| Alimohamad, H; Mouyal, J; Rajakumar, N; Rushlow, WJ; Sutton, L | 1 |
| Machida, N; Semba, J; Shiotsuka, S | 1 |
| Barbui, C; Fortino, I; Percudani, M; Petrovich, L; Tansella, M | 1 |
| Cohen, H; Pourcher, E; Rémillard, S | 2 |
| Altman, C; de Nayer, A; Jones, AM; Larmo, I; Lindenbauer, B; Platz, T; Rittmannsberger, H; Windhager, E | 1 |
| Becker, A; Grecksch, G | 2 |
| Himei, A; Okamura, T | 1 |
| Davidson, M; Eerdekens, M; Harvey, PD; Rabinowitz, J | 2 |
| Baser, O; Engelhart, L; Finkel, S; Greenspan, A; Kozma, C; Long, S; Mahmoud, R | 1 |
| Breier, A; Gold, JM; Keefe, RS; Purdon, SE; Rock, SL; Young, CA | 1 |
| Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R | 1 |
| Basu, A; Dukic, V; Meltzer, HY | 1 |
| Balit, CR; Isbister, GK; Kilham, HA | 1 |
| Shah, A; Suh, GH | 1 |
| Ascher-Svanum, H; Kinon, BJ; Stensland, MD; Tollefson, GD | 1 |
| Fletcher, PJ; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE | 1 |
| Cooper, T; Gao, XM; Suckow, RF; Tamminga, CA | 1 |
| Beljean, M; Cutroneo, P; Luu, RP; Siouffi, AM | 1 |
| Caleo, S; De Graeve, D; Lecompte, D; Mehnert, A; Miadi-Fargier, H; Mosqueda, GJ; Peuskens, J; Smet, A | 1 |
| Heeg, B; Laux, G; Mehnert, A; van Hout, BA | 1 |
| Buskens, E; Chue, PS; Heeg, B; van Hout, BA | 1 |
| Bauer, MS; Geddes, GR; Gijsman, HJ; Goodwin, GM; Rendell, JM | 1 |
| Mahadik, SP; Pillai, A; Terry, AV | 1 |
| Janka, Z; Kelemen, O; Kéri, S | 1 |
| Bai, O; Li, XM; Xu, H | 1 |
| Arango, C; Artaloytia, JF; Cubero, P; Lahti, A; Palomo, T; Pascual, A; Prieto, D; Sanz, J | 1 |
| Akram, A; Anders, M; Araszkiewicz, A; Dossenbach, M; Dyachkova, Y; Khalil, A; McBride, M; Pecenak, J; Pirildar, S; Shakhnovich, T; Treuer, T | 1 |
| Birinyi-Strachan, L; Davey, P; Kongsakon, R; Leelahanaj, T; Price, N | 1 |
| Mahadik, SP; Parikh, V; Pillai, A; Terry, AV | 1 |
| Bastianetto, S; Danik, M; Mennicken, F; Quirion, R; Williams, S | 1 |
| Emsley, R; Medori, R; Rabinowitz, J | 2 |
| Bloch, MH; Bracken, MB; Coric, V; Kelmendi, B; Landeros-Weisenberger, A; Leckman, JF | 1 |
| Bossie, CA; Gharabawi, GM; Zhu, Y | 1 |
| Dedova, I; Duffy, L; Karl, T; Matsumoto, I; O'brien, E | 1 |
| Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM | 1 |
| Currier, GW; McMullan, JT; Veser, BD; Veser, FH; Zealberg, J | 1 |
| Bedi, KS; Bryan-Lluka, LJ; Catts, SV; Catts, VS; Naiker, DV | 1 |
| Fletcher, PJ; Kapur, S; Li, M | 1 |
| Crespo-Facorro, B; Martínez-García, O; Pardo-García, G; Pelayo-Terán, JM; Pérez-Iglesias, R; Ramírez-Bonilla, M; Vázquez-Barquero, JL | 1 |
| DeVane, CL; Donovan, JL; Markowitz, JS; Wang, JS; Zhu, HJ | 1 |
| Egashira, N; Fujiwara, M; Iwasaki, K; Mishima, K; Mizuki, A; Nagai, H; Nishimura, R; Ogata, A; Sano, K; Shoyama, Y | 1 |
| Choi, SK; Greenspan, AJ; Suh, GH | 2 |
| Gorobets, LN | 1 |
| Cipriani, A; Geddes, JR; Rendell, JM | 1 |
| Glick, ID; Schreiner, A; Shkedy, Z | 1 |
| Koopmans, RT; Olde Rikkert, MG; van Iersel, MB; Verhey, FR; Zuidema, SU | 1 |
| Dedova, I; Duffy, L; Herzog, H; Karl, T; Lee, NJ; Lin, EJ; Matsumoto, I; O'brien, E; Sainsbury, A; Slack, K | 1 |
| Arranz, MJ; Carrasco-Marín, E; Crespo-Facorro, B; Leyva-Cobían, F; Mata, I; Pelayo-Terán, JM; Pérez-Iglesias, R; Vázquez-Barquero, JL | 1 |
| Dawe, GS; Han, SP; Lim, EP; Nagarajah, R; Verma, V | 1 |
| Hayashida, M; Horiguchi, J; Inagaki, T; Miyaoka, T; Yasuda, H; Yasukawa, R | 1 |
| Cheng, W; Mou, X; Reynolds, GP; Zhang, X; Zhang, Z | 1 |
| Duncan, GE; Koller, BH; Lieberman, JA; Moy, SS | 1 |
| Crespo-Facorro, B; Llorca, J; Luis Vázquez-Barquero, J; Martínez-García, O; Pérez-Iglesias, R; Ramirez-Bonilla, M | 1 |
| Bares, R; Bartels, M; Beneke, M; Glaser, T; Machulla, HJ; Noda, S; Reimold, M; Schaefer, JE; Solbach, C; Wormstall, H | 1 |
| Boshoven, W; Duncan, E; Dunlop, BW; Hamer, RM; Phillips, LS; Woolson, SL | 1 |
| Barbanoj, MJ; Clos, S; Giménez, S; Grasa, E; Morte, A; Romero, S | 1 |
| Dai, J; Huang, M; Li, Z; Meltzer, HY; Prus, AJ | 2 |
| DeFeo, JR; Dixon, CE; Kline, AE; Massucci, JL; Rogers, EH; Zafonte, RD | 1 |
| Jackson, GA | 1 |
| Hirano, K; Kagawa, Y; Kato, Y; Uchida, S; Yamada, S | 1 |
| Dierks, T; Irisawa, S; Isotani, T; Kikuchi, M; Kinoshita, T; Koenig, T; Okugawa, G; Strik, W; Yagyu, T; Yamada, K; Yoshimura, M | 1 |
| Limosin, F | 1 |
| Hashioka, S; Kanba, S; Kato, T; Monji, A | 1 |
| Harada, D; Hayashida, K; Ishino, H; Ito, H; Nakayama, K | 1 |
| Bishnoi, M; Chopra, K; Kulkarni, SK; Kumar, A | 1 |
| Arnt, J; Didriksen, M; Skarsfeldt, T | 1 |
| Chou, YH; Lee, SM; Li, MH; Wan, FJ; Yen, MH | 2 |
| Bartlett, MG; Beck, WD; Gearhart, DA; Mahadik, SP; Middlemore, ML; Terry, AV; Waller, JL; Warner, SE; Zhang, G | 1 |
| Britton, AM; Lonergan, E; Luxenberg, J; Wyller, T | 1 |
| Backes, V; Gaebel, W; Habel, U; Jon Shah, N; Kellermann, T; Reske, M; Schneider, F; Stöcker, T; von Wilmsdorff, M | 1 |
| Ascher-Svanum, H; Marcus, SC; Olfson, M | 1 |
| Borek, LL; Chou, KL; Friedman, JH | 1 |
| Hoshino, S; Miyaji, S; Miyaoka, H; Sakai, Y; Yamamoto, H; Yamamoto, K | 1 |
| Ganguli, R; Keshavan, M; Miewald, J; Strassnig, M | 1 |
| Amitai, N; Markou, A; Semenova, S | 1 |
| Joo, YH; Kim, B; Kim, SJ; Son, JI | 1 |
| Bernardo, M; Cardellach, F; Casademont, J; Garrabou, G; López, S; Miró, O; Pons, A | 1 |
| Bounthavong, M; Okamoto, MP | 1 |
| Anderson, GT; Barido, R; Bonhaus, DW; Brann, MR; Brunmark, P; Davis, RE; Dyssegaard, A; Gardell, LR; Hacksell, U; Johnson, RW; Pounds, L; Tabatabaei, A; Vanover, KE; Veinbergs, I | 1 |
| Carlsson, A; Stening, G; Timdahl, K | 1 |
| Feifel, D; Melendez, G; Priebe, K; Shilling, PD | 1 |
| Cilia, J; Hatcher, P; Jones, DN; Reavill, C | 1 |
| Harrison, BE; Therrien, B | 1 |
| Axelsson, S; Eriksson, AC; Hägg, S; Lindahl, TL; Whiss, PA | 1 |
| Gearhart, DA; Terry, AV | 1 |
| Choe, BM; Conley, RR; Jae, YM; Kelly, DL; Kim, HC; Kim, JG; Kim, SG; Oh, MK; Shim, JC | 1 |
| Amato, L; Davoli, M; Minozzi, S; Pani, PP | 1 |
| Hemrick-Luecke, SK; Hsu, MA; Johnson, BG; Noone, S; Rasmussen, K; Thompson, LK | 1 |
| Braff, DL; Erhart, S; Green, MF; Light, GA; Marder, SR; Mintz, J; Reist, C; Sprock, J; Widmark, C; Wynn, JK | 1 |
| Beach, AJ; Calamaras, MR; DeVane, CL; Donovan, J; Gibson, BB; Knight, BT; Nemeroff, CB; Newport, DJ; Owens, MJ; Stowe, ZN; Viguera, AC; Winn, S | 1 |
| Hamann, J; Heres, S; Kissling, W; Leucht, S | 1 |
| Arnt, J; Bang-Andersen, B; Brennum, LT; Christoffersen, CT; Di Matteo, V; Didriksen, M; Esposito, E; Hertel, P; Larsen, AK; Marcus, MM; Pouzet, B; Ramirez, T; Svensson, TH; Søby, KK | 1 |
| Bartlett, MG; Terry, AV; Zhang, G | 1 |
| Azorin, JM; Besnier, N; Blin, O; Fakra, E; Salgado-Pineda, P | 1 |
| Akkaya, C; Cangur, S; Kirli, S; Sarandol, A | 1 |
| Gardner, MP; Graulich, A; Lamy, C; Liégeois, JF; Moran-Gates, T; Tarazi, FI | 1 |
| Levine, SZ; Rabinowitz, J | 2 |
| Kaneko, S; Katagai, H; Kikuchi, A; Yasui-Furukori, N | 1 |
| Byun, HJ; Kim, JH | 1 |
| Castro, AP; Elkis, H | 1 |
| Braff, DL; Erhart, S; Green, MF; Kee, KS; Marder, SR; Mintz, J; Reist, C; Sergi, MJ; Widmark, C | 1 |
| Bogetto, F; Fonzo, V; Montemagni, C; Pandullo, P; Rocca, P; Villari, V | 1 |
| Hassan, M; Islam, S; Kalsekar, ID; Kavookjian, J; Madhavan, SS; Makela, EH; Miller, LA; Rajagopalan, K | 1 |
| Bartlett, MG; Gearhart, DA; Hohnadel, EJ; Mahadik, SP; Middlemore, ML; Terry, AV; Warner, S; Zhang, G | 1 |
| Barnett, MJ; Perry, PJ; Wehring, H | 1 |
| Baykara, A; Baykara, B; Dirik, E; Emiroglu, FN; Gencer, O; Miral, S | 1 |
| Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Gonzalez-Blanch, C; Martinez-Garcia, O; Perez-Iglesias, R; Ramirez-Bonilla, ML; Vazquez-Barquero, JL | 1 |
| Bechdolf, A; Bender, S; Buchkremer, G; Degner, D; Eickhoff, M; Falkai, P; Gaebel, W; Häfner, H; Jäger, M; Jockers-Scherübl, MC; Klimke, A; Klingberg, S; Köpcke, W; Kühn, KU; Lemke, M; Maier, W; Möller, HJ; Ohmann, C; Riesbeck, M; Salize, HJ; Schlösser, R; Schmidt, LG; Schmitt, A; Schneider, F; von Wilmsdorff, M; Wölwer, W | 1 |
| Akhtar, S; Ameen, S; Manjunatha, N; Saddichha, S | 1 |
| Alvarez-Jimenez, M; Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Pelayo-Teran, JM; Perez-Iglesias, R; Ramirez-Bonilla, ML; Vazquez-Barquero, JL | 1 |
| Awouters, FH; Lewi, PJ | 1 |
| Inada, T; Oda, T; Yamamoto, N | 2 |
| Arai, H; Hatta, K; Miyakawa, K; Nakamura, H; Ota, T; Usui, C | 1 |
| Dawe, GS; Grigoryan, GA; Gross, KW; Jones, CA; Ong, WY; Ratty, AK; Salvi, R; Stolzberg, D; Tan, CH; Verma, V | 1 |
| Henken, S; Hiemke, C; Kirschbaum, KM; Schmitt, U | 1 |
| Matson, JL; Wilkins, J | 1 |
| Ahmed, Z; Bhaumik, S; Bouras, N; Cooray, S; Crawford, M; Deb, S; Eliahoo, J; Hare, M; Harley, D; Karatela, S; Kramo, K; Meade, M; Murphy, D; North, B; Oliver-Africano, PC; Rao, B; Reece, B; Regan, A; Soni, A; Thomas, D; Tyrer, P | 1 |
| Guo, CM; Si, TM; Su, YA; Wang, XD; Yang, Y | 1 |
| Boggs, DL; Carpenter, WT; Davis, JM; Hu, Q; Kelly, DL; Li, L; McMahon, RP | 1 |
| Kaiser, RM; Ozbolt, LB; Paniagua, MA | 1 |
| Bubenikova-Valesova, V; Bures, J; Stuchlik, A; Svoboda, J; Vales, K | 1 |
| Akhtar, S; Ameen, S; Saddichha, S | 1 |
| Calabrese, JR; Gajwani, P; Ganocy, SJ; Gao, K; Kemp, DE; Muzina, DJ | 1 |
| Carrasco-Marín, E; Crespo-Facorro, B; Fernandez-Prieto, L; Leyva-Cobián, F; Pelayo-Terán, JM; Pérez-Iglesias, R; Vázquez-Barquero, JL | 1 |
| De Luxán, A; Domínguez-Gil, A; Martin, C; Molina, V; Montes, C; Rivas, N; Sancho, C; Tamayo, P | 1 |
| Beck, JP; McLean, SL; Neill, JC; Woolley, ML | 1 |
| Aarsland, D; Nygaard, HA; Ruths, S; Straand, J | 1 |
| Brennum, LT; Kreilgaard, M; Olsen, CK | 1 |
| Britvić, D; Ille, T; Stanković, Z; Vuković, O | 1 |
| Danilov, DS; Tiul'pin, IuG | 1 |
| Dias, R; Goetghebeur, P | 1 |
| Harvey, I; Lilford, R; Song, F | 1 |
| Agoston, T; István, S; Tamás, T; Zoltán, J | 1 |
| Palencia-Herrejón, E; Romera, MA; Silva, JA | 1 |
| Allingham, B; Citrome, L; Jaffe, A; Levine, J; Martello, D | 1 |
| Engedal, K; Selbaek, G | 1 |
| Somerville, ER; Somerville, HM; Trollor, JN | 1 |
| Braus, DF; Buchkremer, G; Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klosterkötter, J; Kühn, KU; Maier, W; Möller, HJ; Ohmann, C; Riedel, M; Riesbeck, M; Schlösser, R; Schneider, F; Wickelmaier, F | 1 |
| Amado, JA; Berja, A; Carrasco-Marín, E; Crespo-Facorro, B; Garcia-Unzueta, MT; Mata, I; Pelayo-Terán, JM; Perez-Iglesias, R; Vazquez-Barquero, JL | 1 |
| Benmessaoud, D; Boni, C; Gorwood, P; Hamdani, N; Hamon, M; Kacha, F; Ramoz, N | 1 |
| Berning, J; Frommann, I; Kühn, KU; Maier, W; Quednow, BB; Wagner, M | 1 |
| Romeo, F; Rossi, A; Tiradritti, P; Vita, A | 1 |
| Hempel, RJ; Hengeveld, MW; Röder, CH; Tulen, JH; van Beveren, NJ | 1 |
| Andreazza, AC; Belmonte-de-Abreu, PS; Berk, M; Cereser, KM; Fries, G; Gama, CS; Kapczinski, F; Medeiros, D; Palha, J; Stertz, L; Vargas, HE | 1 |
| Dolzan, V; Kastelic, M; Koprivsek, J; Mandelli, L; Plesnicar, BK; Serretti, A | 1 |
| Azorin, JM; Besnier, N; Blin, O; Da Fonseca, D; Delaveau, P; Fakra, E; Khalfa, S | 1 |
| Kutscher, E; Peterson, E; Stoebner, A; Weatherill, J | 1 |
| Gagnon, PR | 1 |
| Crabbe, JC; Philibin, SD; Porter, JH; Vunck, SA; Walentiny, DM | 1 |
| Bogeski, M; Gogos, A; van den Buuse, M | 1 |
| Barlow, KB; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE | 1 |
| Chai, YG; Choi, J; Choi, MR; Kim, D; Kim, DJ; Kim, SH; Lee, JS; Park, YC; Roh, K; Roh, S; Yang, BH | 1 |
| Funatogawa, I; Funatogawa, T; Takeuchi, M | 1 |
| Kristensen, T; Mulvany, MJ; Nielsen, KB; Nourian, Z; Pickering, DS | 1 |
| Endo, S; Hamamura, T; Ishihara, T; Kuroda, S; Miyata, S; Taoka, H; Toma, K | 1 |
| Cheng, JP; Hoffman, AN; Kline, AE; Zafonte, RD | 1 |
| Becker, A; Grecksch, G; Hiemke, C; Ladstaetter, E; Schmitt, U; Zernig, G | 1 |
| Cretaz, E; Diniz, BS; Forlenza, OV | 1 |
| Cvetanovska, G; Gaebel, W; Kühn, KU; Maier, W; Mössner, R; Quednow, BB; Rietschel, M; Rujescu, D; Schuhmacher, A; Wagner, M; Wölwer, W; Zill, P | 1 |
| Crespo-Facorro, B; de Lucas, EM; Gutiérrez, A; Martínez, O; Pelayo-Terán, JM; Pérez-Iglesias, R; Ramírez, M; Rodríguez-Sánchez, JM; Roiz-Santiáñez, R; Tordesillas-Gutiérrez, D; Vázquez-Barquero, JL | 1 |
| Cheng, JP; Hoffman, AN; Kline, AE; Massucci, JL; Zafonte, RD | 1 |
| Amado, JA; Berja, A; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Mata, I; Pelayo-Teran, JM; Perez-Iglesias, R; Vazquez-Barquero, JL | 1 |
| Anders, M; Dossenbach, M; Irimia, V; Kotler, M; Logozar-Perkovic, D; Lowry, AJ; Pecenak, J; Peciukaitiene, D; Smulevich, AB; Szulc, A; Treuer, T; West, TM | 1 |
| Contreras, D; Ehrlichman, RS; Finkel, LH; Gandal, MJ; Lazarewicz, MT; Maxwell, CR; Siegel, SJ; Turetsky, BI | 1 |
| Backes, V; Gaebel, W; Habel, U; Jon Shah, N; Kellermann, T; Reske, M; Schneider, F; von Wilmsdorff, M; Zilles, K | 1 |
| Alvarez-Jiménez, M; Crespo-Facorro, B; González-Blanch, C; Martínez-García, O; Pelayo-Terán, JM; Pérez-Iglesias, R; Rodríguez-Sánchez, JM; Vázquez-Barquero, JL | 1 |
| Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B | 1 |
| Beegum, MN; Jayakrishnan, MP; Krishnakumar, P; Riyaz, A | 1 |
| Futamura, T; Maeda, K; Marunaka, Y; Mitsumoto, Y; Sugino, H | 1 |
| Cao, LY; Chen, DC; Chen, S; Kosten, TA; Kosten, TR; Lu, L; Qi, LY; Wang, F; Wu, GY; Xiu, MH; Zhang, XY; Zhou, DF | 1 |
| Ikarashi, Y; Kase, Y; Sekiguchi, K; Tabuchi, M; Yamaguchi, T | 1 |
| Emsley, R; Koen, L; Medori, R; Niehaus, DJ; Oosthuizen, P; Rabinowitz, J | 1 |
| Rahn, A | 1 |
| Assunção-Talbott, S; Crandall, DT; Eudicone, JM; Glick, ID; Janicak, PG; Marcus, RN; Marder, SR; McQuade, RD | 1 |
| Bender, S; Buchkremer, G; Falkai, P; Gaebel, W; Gruber, O; Klosterkötter, J; Maier, W; Möller, HJ; Riesbeck, M; Schlösser, R; Schmitt, A; Schneider, F; Schneider-Axmann, T; Wobrock, T; Wölwer, W | 1 |
| Bjelica, A; Rajakumar, N; Rushlow, WJ; Seah, C; Sutton, LP | 1 |
| Bagati, D; Nizamie, SH; Prakash, R | 1 |
| Callegaro-Filho, D; Carvalho, RC; Frussa-Filho, R; Fukushiro, DF; Helfer, DC; Sanday, L; Silva, RH; Trombin, TF; Zanlorenci, LH | 1 |
| Li, M; Mead, A | 1 |
| Carlström, EL; Jazin, E; Jiang, L; Saetre, P | 1 |
| Chitaia, NN; Danilov, DS; Tiuvina, NA | 1 |
| Marras, C; Pringsheim, T | 1 |
| Ayesa, R; Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Pérez-Iglesias, R; Ramirez-Bonilla, M; Rodríguez-Sánchez, JM; Vázquez-Barquero, JL | 1 |
| Ahmed, Z; Bhaumik, S; Bouras, N; Cooray, S; Crawford, M; Deb, S; Dickens, S; Eliahoo, J; Hare, M; Harley, D; Karatela, S; Knapp, M; Kramo, K; Lenôtre, L; Meade, M; Murphy, D; North, B; Oliver-Africano, P; Rao, B; Reece, B; Regan, A; Romeo, R; Soni, A; Thomas, D; Tyrer, P; Watson, J | 1 |
| Crawford, M; Knapp, M; Oliver-Africano, P; Romeo, R; Tyrer, P | 1 |
| Hashimoto, E; Kashem, MA; Matsumoto, I; Mcgregor, IS; Saito, T; Ukai, W; Ummehany, R | 1 |
| Auclair, AL; Barret-Grévoz, C; Barreto, M; Depoortère, R; Kleven, MS; Newman-Tancredi, A | 1 |
| Dziuba, J; Keshavan, M; Lachover, L; Manji, S; Pizzuti, A; Rajarethinam, R | 1 |
| Duncan, EJ; Dunlop, BW; Hamer, RM; Woolson, SL | 1 |
| Arnt, J; Mørk, A; Witten, LM | 1 |
| Akkaya, C; Alptekin, K; Brook, S; Danaci, AE; El Tallawy, H; Hafez, J; Karayal, ON; Lowe, W; Tzebelikos, E; Ucok, A | 1 |
| Becker, A; Bernstein, HG; Grecksch, G; Keilhoff, G; Roskoden, T | 1 |
| Csernansky, JG; Deberdt, W; Keefe, RS; Kollack-Walker, S; Lipkovich, IA; Sabbe, B | 1 |
| Mahieu, M; Nordquist, RE; Pouzet, B; Schuurman, T; van der Staay, FJ | 1 |
| Ade Thomas, D; Ahmed, Z; Bhaumik, S; Bouras, N; Cooray, S; Deb, S; Dickens, S; Dzendrowskyj, T; Hare, M; Harley, D; Karatela, S; Knapp, M; Lenôtre, L; Meade, M; Oliver-Africano, P; Piachaud, J; Rao, B; Reece, B; Regan, A; Tyrer, P; Watson, J | 1 |
| Becker, A; Grecksch, G; Höllt, V; Rüthrich, H | 1 |
| Farias, MR; Grohs, GE; Lindner, LM; Marasciulo, AC | 1 |
| Dietrich-Muszalska, A; Olas, B; Rabe-Jabłońska, J | 1 |
| Gaszner, P | 1 |
| Bundzikova, J; Kiss, A; Mikkelsen, JD; Pirnik, Z | 1 |
| Bates, B; Brandon, NJ; Graf, R; Grauer, SM; Hughes, Z; Liu, F; Logue, SF; Marquis, KL; Paulsen, J; Pausch, M; Pulito, VL; Rosenzweig-Lipson, S; Sung, MA; Taylor, N; Zhang, L | 1 |
| Edimansyah, A; Liew, A; Subramaniam, M; Vaingankar, J; Verma, S | 1 |
| Bambini-Junior, V; Bobermin, LD; Gottfried, C; Quincozes-Santos, A; Riesgo, R; Tonial, RP | 1 |
| Cohen, D; Correll, CU; De Hert, M | 1 |
| Kastania, A; Katsafouros, K; Laskos, E; Lykouras, L; Michalopoulou, PG; Papadopoulou, A; Rizos, EN; Vasilopoulos, D | 1 |
| Dietrich-Muszalska, A; Kontek, B; Nowak, P; Rabe-Jablonska, J | 1 |
| Cheng, WR; Jenkins, TA; Reynolds, GP; Zhang, XR; Zhang, ZJ | 1 |
| Cicale, M; de Bartolomeis, A; Fiore, G; Iasevoli, F; Muscettola, G | 1 |
| Mihaljević-Peles, A; Mihanović, M; Sagud, M; Silić, A; Zivković, M | 1 |
| Citrome, L; Jaffe, A; Levine, J | 1 |
| Munhoz, RP; Teive, HA; Werneck, LC | 1 |
| Arakawa, R; Ito, H; Maeda, J; Okubo, Y; Okumura, M; Suhara, T; Takahashi, H; Takano, A; Takano, H | 1 |
| Graff-Guerrero, A; Kapur, S; McCormick, PN; Nobrega, JN; Raymond, R; Wilson, AA | 1 |
| Buyukoglan, H; Kaya, MG; Ulusoy, HB; Yagmur, F | 1 |
| Barr, AM; Boyda, HN; Pang, CC; Procyshyn, RM; Tse, L; Wong, D; Wu, TK | 1 |
| Kenchaiah, BK; Kumar, S; Tharyan, P | 1 |
| Chiu, NY; Hsu, WY; Huang, SS; Lee, BS | 1 |
| Dysken, MW; Lederle, FA; Rector, TS; Rossom, RC | 1 |
| Albaugh, VL; Breazeale, S; Elich, TD; Ilkayeva, O; Joyal, JL; Lang, CH; Lynch, CJ; Maresca, KP; Vary, TC; Wenner, BR | 1 |
| Gaebel, W; Gastpar, M; Häfner, H; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Maier, W; Mayr, A; Möller, HJ; Riedel, M; Sauer, H; Schennach-Wolff, R; Schneider, F; Seemüller, FH | 1 |
| Kim, JJ; Lee, C; Lee, CU; Lim, HK; Pae, CU; Paik, IH | 1 |
| Ciobica, A; Dobrin, I; Padurariu, M; Stefanescu, C | 1 |
| Araki, H; Hidaka, N; Suemaru, K | 1 |
| Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG | 1 |
| Eickhoff, M; Gaebel, W; Heuser, I; Huff, W; Klimke, A; Klingberg, S; Köpcke, W; Lemke, M; Maier, W; Möller, HJ; Ohmann, C; Riedel, M; Riesbeck, M; Sauer, H; Schmitt, A; von Wilmsdorff, M; Wölwer, W | 1 |
| Chatterjee, M; Ganguly, S; Palit, G; Srivastava, M | 1 |
| Federley, M; Fjällström, AK; Persson, P; Stenqvist, P; Wadenberg, ML | 1 |
| Chen, CC; Chen, YH; Chou, LS; Huang, KH; Kuo, CC; Lane, HY; Lin, CH | 1 |
| Caseiro, O; Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Pardo, G; Pelayo-Terán, JM; Pérez-Iglesias, R; Ramirez-Bonilla, M; Vázquez-Barquero, JL | 1 |
| Arai, Y; Nakagawasai, O; Nakaya, K; Niijima, F; Onogi, H; Sato, A; Tadano, T; Tan-No, K | 1 |
| Bak, M; de Haan, L; Delespaul, PA; Lardinois, M; Lataster, J; Lataster, T; Myin-Germeys, I; Thewissen, V; van Os, J | 1 |
| Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Kühn, KU; Mayr, A; Meyer, S; Möller, HJ; Riedel, M; Schennach-Wolff, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F | 1 |
| Dencker, D; Fink-Jensen, A; Schmidt, LS; Schülein, C; Wess, J; Woldbye, DP; Wörtwein, G | 1 |
| Caseiro, O; Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Pardo-Garcia, G; Pelayo-Terán, JM; Pérez-Iglesias, R; Ramirez-Bonilla, M; Vázquez-Barquero, JL | 1 |
| Gründer, G; Klomp, M; Schiffl, K; Schorn, H; Vernaleken, IB; Veselinović, T | 1 |
| Alves, I; Nuss, P; Salgado, GF; Staneva, G; Tessier, C | 1 |
| MacGillivray, L; Mazurek, MF; Reynolds, KB; Rosebush, PI; Zettler, M | 1 |
| He, E; Li, M; Volf, N | 1 |
| Akhondzadeh, S; Boroumand, MA; Ghaleiha, A; Honarbakhsh, N; Jafarinia, M; Raznahan, M; Rezaei, F; Tabrizi, M | 1 |
| Govorin, NV; Vasil'eva, AI | 1 |
| Bogdan, F; Bogdan, M; Popescu, F | 1 |
| Cole-Strauss, A; Jandacek, R; Lipton, JW; McNamara, RK; Rider, T; Tso, P | 1 |
| Suzuki, T | 1 |
| Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Maier, W; Mayr, A; Möller, HJ; Riedel, M; Sauer, H; Schennach-Wolff, R; Schmitt, A; Schneider, F; Seemüller, F | 1 |
| Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Ortiz, V; Pelayo-Terán, JM; Pérez-Iglesias, R; Valdizan, E; Vazquez-Barquero, JL | 1 |
| Chen, ML; Lee, MC; Lin, YY; Tsai, FM; Tsai, TC; Tsai, YM; Wang, LK | 2 |
| Eberhard, J; Fors, BM; Hansen, K; Lindström, E; Sapin, C | 1 |
| Faludi, G; Fejes, L; Inczédy-Farkas, G; Kassai-Farkas, A; Lazáry, J; Makkos, Z | 1 |
| Bernardo, M; Gassó, P; Lafuente, A; Mas, S; Molina, O; Parellada, E | 1 |
| Ariano, RE; Sokoro, AA; Zivot, J | 1 |
| Constant, E; Jacques, D; Manceaux, P; Reynaert, C; Zdanowicz, N | 1 |
| Chakrabarti, S; Grover, S; Kumar, V | 1 |
| Jardemark, K; Malmerfelt, A; Marcus, MM; Shahid, M; Svensson, TH | 1 |
| Popović, I; Popović, V; Ravanić, D; Stanojević, A; Stojanović, M; Vladejić, S | 1 |
| Chan, HY; Chen, CH; Chen, JJ; Gau, SS; Hwu, HG | 1 |
| Citrome, L; Hochfeld, M; Meng, X; Stahl, SM | 1 |
| Dudova, I; Hrdlicka, M; Urbanek, T; Zedkova, I | 1 |
| Nakamae, T | 1 |
| Blow, FC; Chiang, C; Cunningham, F; Kales, HC; Kim, HM; Schneider, LS; Seyfried, LS; Valenstein, M; Zivin, K | 1 |
| Bisson, J; Farewell, D; Tahir, TA | 1 |
| Czernikiewicz, A; Kucharska-Pietura, K; Mortimer, A; Tylec, A | 1 |
| Grohmann, R; Holl, AK; Letmaier, M; Painold, A; Vergin, H | 1 |
| Chen, DC; Kosten, TA; Kosten, TR; Liang, J; Shen, YC; Xiu, MH; Zhang, PY; Zhang, WF; Zhang, XY; Zhou, DF | 1 |
| Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S | 1 |
| Chung, YC; Huang, GB; Lee, KH; Park, CH; Park, MS; Park, TW; Tong, Z; Yang, JC | 1 |
| Aghajanian, P; Dossett, E; Ghaffari, N; Lee, RH | 1 |
| Chrisphonte, P; Ostroff, RB; Rosenheck, RA | 1 |
| Chang, CH; Kao Yang, YH; Lai, EC; Lin, CY; Lin, SJ | 1 |
| Djukić-Dejanović, S; Janjić, V; Janković, S; Jovanović-Mihajlović, N; Mihajlović, G; Milovanović, N; Petrović, D; Radmanović, B; Radonjić, K; Tomić, K | 1 |
| Avorn, J; Crystal, S; Gerhard, T; Huybrechts, KF; Levin, R; Lucas, JA; Olfson, M; Schneeweiss, S | 1 |
| Hsu, MC; Kuo, CC; Ouyang, WC; Yeh, IN | 1 |
| Covell, NH; Essock, SM; Jackson, CT; McEvoy, JP; Rojas, IA; Schooler, NR; Stroup, TS | 1 |
| Enzensperger, C; Fleck, C; Lehmann, J; Mueller, FK; Robaa, D; Schulze, M; Siol, O | 1 |
| Li, L; Reynolds, GP; Wang, YX; Zhang, XR; Zhang, ZJ | 1 |
| Burmeister, HP; Gussew, A; Langbein, K; Reichenbach, JR; Rzanny, R; Sauer, H; Smesny, S | 1 |
| Ahmed, EU; Ahmed, S; Kashem, MA; Kemp, A; Matsumoto, I; McGregor, IS; Ukai, W | 1 |
| Adzu, B; Chindo, BA; Gamaniel, KS; Yahaya, TA | 1 |
| Bauer, M; Doucette, S; Lewitzka, U; Meyer, S; Möller, HJ; Musil, R; Riedel, M; Schennach, R; Seemüller, F | 1 |
| Gurwitz, D; Morag, A; Oved, K | 2 |
| Chiba, S; Hattori, K; Higuchi, T; Hori, H; Iijima, Y; Kajiwara, M; Kawamoto, Y; Kinoshita, Y; Kunugi, H; Matsuo, J; Ota, M; Ozeki, Y; Sasayama, D; Tanaka, H; Terada, S; Teraishi, T; Yamamoto, N | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; Gutiérrez, A; Ortíz-García de la Foz, V; Roiz-Santiáñez, R; Tabarés-Seisdedos, R; Tordesillas-Gutiérrez, D; Vázquez-Barquero, JL | 1 |
| Aguglia, E; Dipasquale, S; Minutolo, G; Petralia, A | 1 |
| Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingenberg, S; Klosterkötter, J; Lewitzka, U; Maier, W; Mayr, A; Möller, HJ; Musil, R; Ohmann, C; Riedel, M; Schennach, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F | 1 |
| Elkis, H; Hacksell, U; Meltzer, HY; Peters, P; van Kammen, DP; Vanover, K; Weiner, DM | 1 |
| Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingberg, S; Klosterkötter, J; Maier, W; Mayr, A; Möller, HJ; Riedel, M; Riesbeck, M; Sauer, H; Schennach, R; Schmitt, A; Schneider, F; Seemüller, F; Wölwer, W | 1 |
| Chen, ML | 1 |
| Chung, YC; Han, EH; Huang, GB; Kang, NI; Li, CR; Sui, ZY; Zhao, T | 1 |
| Gen, K; Suzuki, H | 1 |
| Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E | 1 |
| Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martínez-García, O; Mata, I; Pérez-Iglesias, R; Valdizán, EM; Vázquez-Barquero, JL | 1 |
| Chung, YC; Huang, GB; Kim, MG; Oh, KY; Park, TW; Yang, JC; Zhao, T | 1 |
| Crespo-Facorro, B; Díaz, I; Mata, I; Pelayo-Terán, JM; Pérez-Iglesias, R; Suárez-Pinilla, P; Tabarés-Seisdedos, R; Vázquez-Barquero, JL | 1 |
| de Souza, DF; Gonçalves, CA; Guerra, MC; Hansen, F; Lunardi, P; Nardin, P; Wartchow, K | 1 |
| Cheung, C; Chua, SE; Collier, DA; Deng, W; Gong, Q; Huang, C; Jiang, L; Li, M; Li, T; Ma, X; McAlonan, GM; Sham, PC; Wang, Q; Wang, Y | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; Martínez-García, O; Pérez-Iglesias, R; Rodríguez-Sánchez, JM; Roiz-Santiáñez, R; Sánchez-Moreno, J; Tabarés-Seisdedos, R; Vázquez-Barquero, JL | 1 |
| Crespo-Facorro, B; de León, J; Diaz, FJ; Pelayo-Terán, JM; Pérez-Iglesias, R; Suárez-Pinilla, P; Tabarés-Seisdedos, R | 1 |
| Furuya, M; Horiguchi, J; Ieda, M; Liaury, K; Miyaoka, T; Takechi, M; Tsuchie, K; Wake, R | 1 |
| Kirk Morton, N; Zubek, D | 1 |
| Dunne, C; Hannon, N; Leonard, M; McLoughlin, L; Meagher, DJ; O'Regan, N | 1 |
| Ghose, S; Joho, RH; Shukla, AA; Southcott, SA; Tamminga, CA; Yanagi, M | 1 |
| Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E | 1 |
| Iwata, N; Kishi, T; Matsuda, Y; Mukai, T | 1 |
| Fijał, K; Nikiforuk, A; Popik, P | 1 |
| Aarsland, D; Ballard, C; Engdahl, B; Langballe, EM; Nordeng, H; Selbæk, G | 1 |
| Hutchings, EJ; Terry, AV; Waller, JL | 1 |
| Choi, SH; Choi, WJ; Kim, JJ; Park, JY; Park, KM; Seok, JH; Yoon, HJ | 1 |
| Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martínez-García, O; Pardo-Garcia, G; Pérez-Iglesias, R; Tabares-Seisdedos, R | 1 |
| Buckley, PF; Hoda, MN; Kutiyanawalla, A; Pandya, CD; Pillai, A | 1 |
| Bø, CN; Einarson, TR; Hemels, ME; Jensen, R; Piwko, C; Pudas, H; Vicente, C; Zilbershtein, R | 1 |
| Citrome, L; Czobor, P; Van Dorn, RA; Volavka, J | 1 |
| Abderhalden, C; Horn, H; Maier, N; Moggi, F; Moskvitin, K; Müller, TJ; Strik, W; Walther, S | 1 |
| Leucht, S; Zhao, J | 1 |
| Arnaiz, JA; Bernardo, M; Fernández de Bobadilla, R; Gassó, P; Lafuente, A; Mas, S | 1 |
| Alaqeel, B | 1 |
| Kozumplik, O; Mihaljevic-Peles, A; Muck-Seler, D; Nedic Erjavec, G; Nikolac Perkovic, M; Pivac, N; Sagud, M; Uzun, S; Zivkovic, M | 1 |
| Artigas, F; Celada, P; Riga, MS; Soria, G; Tudela, R | 1 |
| Bahramzi, M; Campillo, A; Minassian, A; Vilke, GM; Wilson, MP | 1 |
| Flores, C; Grant, A; Manitt, C | 1 |
| Abílio, VC; Belangero, SI; Bressan, RA; Diana, MC; Gadelha, A; Han, SW; Melaragno, MI; Ota, VK; Santoro, ML; Santos, CM; Silva, PN; Stilhano, RS | 1 |
| Chen, KP; Lung, FW; Yang, MC | 1 |
| Elmorsy, E; Elsheikha, HM; Elzalabany, LM; Smith, PA | 1 |
| Boettger, S; Breitbart, W; Jenewein, J | 1 |
| Brogna, C; Manna, R; Mariotti, P | 1 |
| Ahmed, RH; Bondi, CO; Kline, AE; Olugbade, YT; Phelps, TI | 1 |
| De Luca, MA; Di Chiara, G; Perra, V; Serra, GP; Tanda, G; Valentini, V | 1 |
| Castle, DJ; Slott Jensen, JK | 1 |
| Baker, TW; Beninger, RJ; Florczynski, MM | 1 |
| Aiello, R; Citraro, R; De Sarro, G; Leo, A; Pugliese, M; Russo, E | 1 |
| Chen, ML; Tsai, FM; Tsai, TC; Wang, LK; Wu, S | 1 |
| Goya, S; Kai, T; Kanemura, S; Kashiwagi, Y; Maeda, I; Matsuda, Y; Nakajima, S; Okamoto, Y; Taira, T; Takei, K; Tanimukai, H; Tokoro, A; Tokuyama, M; Tsujimoto, H; Tsujio, I; Watanabe, M | 1 |
| Berardi, MA; Caraceni, A; Caruso, R; Grassi, L; Mitchell, AJ; Nanni, MG; Riba, M | 1 |
| Chiang, C; Kales, HC; Kavanagh, J; Kim, HM; Maust, DT; Schneider, LS; Seyfried, LS | 1 |
| Baba, S; Enomoto, T; Ikeda, K; Murai, T; Nakako, T; Ono, M; Shimizu, I | 1 |
| Choi, NK; Lee, J; Lee, SH; Park, BJ; Park, MJ; Shin, JY | 1 |
| van der Weide, J; van der Weide, K | 1 |
| Aracil-Fernández, A; Berbel, P; Manzanares, J; Navarrete, F; Navarro, D; Ortega-Álvaro, A | 1 |
| Bozza, FA; do Brasil, PE; Ely, EW; Salluh, JI; Serafim, RB; Soares, M; Tura, BR | 1 |
| Babigumira, JB; Lubinga, SJ; Mutamba, BB; Nganizi, A | 1 |
| DiPaula, BA; Feldman, S; Kelly, DL; Love, RC; McMahon, RP; Miller, J; Morris, AA; Raley, H; Wehring, H | 1 |
| Alici, Y; Forcen, FE; Matsoukas, K | 1 |
| Ahonen, R; Hartikainen, S; Koponen, M; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM | 1 |
| Abilio, VC; Belangero, SI; Bressan, RA; Diana, MC; Moretti, PN; Ota, VK; Santoro, ML; Santos, CM; Spindola, LN; Xavier, G | 1 |
| Cimino, CR; Hergert, DC; Sanchez-Ramos, J | 1 |
| Azzolin, VF; Barbisan, F; Bochi, GV; da Cruz Jung, IE; da Cruz, IB; do Prado-Lima, PA; Duarte, MM; Duarte, T; Machado, AK; Moresco, RN; Scola, G | 1 |
| Chang, WH; Chen, KC; Chen, PS; Chi, MH; Hsiao, CY; Hui Lee, I; Lee, LT; Yang, YK; Yu, HY | 1 |
| Artigas, F; Bortolozzi, A; Campa, L; Celada, P; Riga, MS | 1 |
| Lee, SY; Lee, TL; Shyu, YC; Wang, LJ; Yang, CJ; Yang, KC; Yuan, SS | 1 |
| Campos, JD; Cortez, CM; de Araújo-Jorge, TC; de Azevedo, MJ; de Oliveira, GM; Fragoso, VM; Hoppe, LY | 1 |
| Hammarlund-Udenaes, M; Jansson, B; König, F; Loryan, I; Melander, E; Payan, M; Svensson, M | 1 |
| Dold, M; Gianatsi, M; Helfer, B; Leucht, S; Nikolakopoulou, A; Salanti, G; Samara, MT | 1 |
| Kamijo, Y | 1 |
| Cai, H; Dang, R; Guo, Y; Jiang, P; Liang, D; Lv, C; Yang, R | 1 |
| Baymeeva, NV; Burminskiy, DS; Miroshnichenko, II; Morozova, MA; Platova, AI; Potanin, SS | 1 |
| Amato, L; Indave, BI; Minozzi, S; Pani, PP | 1 |
| Bereza, BG; Einarson, TR; Goswami, P; Maia-Lopes, S; Van Impe, K | 1 |
| De Freitas, CM; Duarte, MM; Fachinetto, R; Ferrari, MC; Leal, CQ; Peroza, LR; Schaffer, LF | 1 |
| Barbosa, DS; Bonifácio, KL; Brinholi, FF; Casagrande, R; Farias, CC; Higachi, L; Moreira, EG | 1 |
| Alphs, L; Correll, CU; Kim, E; Mao, L; Starr, HL | 1 |
| Agar, MR; Caplan, GA; Currow, DC; Devilee, L; Draper, B; Eckermann, S; Fazekas, B; Hardy, J; Hill, M; Lawlor, PG; Le, B; McCaffrey, N; Quinn, S; Rowett, D; Sanderson, C | 1 |
| Ain, R; Drumm, M; Joshi, RS; Panicker, MM; Quadros, R | 1 |
| Alonso, A; Meyvisch, P; Van der Elst, W | 1 |
| de Alvarenga, KAF; de Rezende, VB; Romano-Silva, MA; Rosa, DV; Sacramento, EK; Souza, BR | 1 |
| Holbrook, A; Lee, J | 1 |
| Barber, S; Cipriani, A; Corsi, M; Olotu, U | 1 |
| Bielecka-Wajdman, AM; Nowacka, M; Obuchowicz, E; Paul-Samojedny, M | 1 |
| Arndt, HD; Enzensperger, C; Fleck, C; Seeling, A; Zergiebel, S | 1 |
| Crespo-Facorro, B; Gomez-Arnau, J; Juncal-Ruiz, M; Martinez-Garcia, O; Neergaard, KD; Ortiz-Garcia de la Foz, V; Ramirez-Bonilla, M; Suarez-Pinilla, P; Tabares-Seisdedos, R | 1 |
| De Vos, C; Decuypere, F; Denee, TR; Geerts, P; Lamotte, M; Malfait, B; Mulder, CL; Sermon, J | 1 |
| Bruera, E; Hui, D; Valentine, A | 1 |
| Bogman, ACCF; Schieveld, JNM | 1 |
| Elsayem, AF; Fisch, MJ | 1 |
| Morgan, AA; Sinclair, CT | 1 |
| Agar, MR; Caplan, GA; Draper, B | 1 |
| Arango-Lopez, C; Canellas-Dols, F; Delgado, C; Peraita-Adrados, R | 1 |
| Aggour, AM; Al-Ghafari, A; Amer, S; Elmorsy, E; Khan, R | 1 |
| Bereza, BG; Denee, TR; Dries, PJT; Einarson, TR; Tedouri, F; Van Impe, K | 1 |
| Ago, Y; Hara, Y; Hasebe, S; Hashimoto, H; Kawase, H; Matsuda, T; Nakazawa, T; Takuma, K; Tanabe, W; Taruta, A; Tsukada, S | 1 |
| Mock, CK; Teslyar, P; Thom, RP | 1 |
| Chen, RA; Huang, TL | 1 |
| Bertolino, A; Dukart, J; Hawkins, PCT; Mazibuko, N; Mehta, MA; Merlo-Pich, E; Risterucci, C; Sambataro, F; Silber-Baumann, H; Vernon, AC; Walsh, E; Wood, TC; Zelaya, FO | 1 |
| Doblhammer, G; Eriksdotter, M; Garcia-Ptacek, S; Haenisch, B; Johnell, K; Nerius, M | 1 |
| Aggarwal, N; Kataria, D; Prakash, R; Prasad, S | 1 |
| Sakamoto, S; Sato, K; Takaki, M; Yamada, N; Yoshimura, B | 1 |
| Aderibigbe, AO; Ajayi, AM; Ben-Azu, B; Eneni, AO; Iwalewa, EO; Umukoro, S | 1 |
| Tagne Nouemssi, AB | 1 |
| Bobermin, LD; da Silva, A; Quincozes-Santos, A; Souza, DO | 1 |
| Bell, C; Burry, L; Fergusson, DA; Hutton, B; Luxenberg, JS; Mehta, S; Perreault, MM; Rose, L; Siddiqi, N | 1 |
| Alonso, A; Molenberghs, G; Van der Elst, W | 1 |
| Li, JT; Liu, R; Si, TM; Su, YA; Wang, H; Wang, XD; Zhang, Y | 1 |
| Aguirre, C; Erezuma, I; Garcia, M; Hernandez, R; Lertxundi, U; Medrano, J | 1 |
| Bertolino, A; Dipasquale, O; Dukart, J; Hawkins, PCT; Mehta, MA; Pergola, G; Rizzo, G; Sambataro, F; Selvaggi, P; Turkheimer, F; Veronese, M; Williams, SCR; Zelaya, F | 1 |
| Lin, JR; Nakagawasai, O; Nemoto, W; Odaira, T; Onogi, H; Sakuma, W; Srivastava, LK; Takahashi, K; Tan-No, K | 1 |
| Gao, L; Huang, X; Jiang, X; Li, J; Liu, X; Liu, Z; Zeng, T | 1 |
| Gleason, K; Lee, BJ; MacDonald, ML; Margolis, RL; Norris, AL; Nucifora, FC; Nucifora, LG; Orsburn, BC; Peters, ME; Pevsner, J; Ross, CA; Sawa, A; Sweet, RA; Tamminga, CA; Yang, K | 1 |
| Uguz, F | 1 |
| Ansolabehere, X; Guillon, P; Harmand, S | 1 |
| Cho, SW; Choi, G; Joo, SW; Koh, M; Lee, J; Shon, SH | 1 |
| Alemany-González, M; Chanovas, J; Delgado-Sallent, C; Gener, T; Nebot, P; Puig, MV; Tauste Campo, A | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Hirai, T; Kose, E; Seki, T; Yasuno, N | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; Gómez-Revuelta, M; Juncal-Ruiz, M; Pelayo-Terán, JM; Romero-Jiménez, R; Setién Suero, E; Suárez-Pinilla, P; Vázquez-Bourgon, J | 1 |
| Chen, Z; Cheng, J; Fan, L; Luo, Z; Nie, F; Qi, J; Tan, L; Wang, S | 1 |
| Arditti, R; Drancourt, N; Hamdani, N; Hotier, S; Laguerre, A; Mongin, Y | 1 |
| Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA | 1 |
| Hernández-Salas, LP; Herrera-Huerta, CA; Magallanes-Cano, EM | 1 |
| Han, C; Han, KM; Kim, H; Kim, MS; Pae, CU; Park, A; Patkar, AA; Rhim, HC | 1 |
| Chandrasekaran, S; Dhandapani, VR; Iyer, S; Mohan, G; Mohan, M; Pattabiraman, R; Paul, V; Ramachandran, P; Rangaswamy, T; Singh, SP | 1 |
| Chipps, J | 1 |
| Makiguchi, A; Okada, T; Shioda, K; Suda, S | 1 |
| Dong, Y; Huang, C; Li, X; Shi, Y; You, S; Yu, X; Zhu, R | 1 |
| Babinska, Z; Hammer, T; Horska, K; Karpisek, M; Kotolova, H; Micale, V; Prochazka, J; Ruda-Kucerova, J; Stark, T | 1 |
| Barbe, N; Coffey, BJ; Miller, M; Poulsen, RJ | 1 |
| Bienertova-Vasku, J; Horska, K; Hruska, P; Kucera, J; Kuruczova, D; Micale, V; Ruda-Kucerova, J | 1 |
| Chen, A; Cloutier, A; Copeli, F; Metzger, E; Osser, DN | 1 |
| Likhitsathian, S; Maneeton, B; Maneeton, N; Oon-Arom, A; Srisurapanont, M; Suradom, C; Suttajit, S | 1 |
| Barbui, C; Bertolini, F; Bovo, C; Correll, CU; Del Giovane, C; Gastaldon, C; Nosé, M; Ogheri, F; Ostuzzi, G; Papola, D; Purgato, M; Tedeschi, F; Turrini, G | 1 |
| Liviskie, C; McPherson, C | 1 |
| Kucic, N; Marcelic, M; Petric, D; Racki, V; Stimac, I | 1 |
| Dziedzicka-Wasylewska, M; Jankowska, U; Kedracka-Krok, S; Prus, G; Skupien-Rabian, B; Swiderska, B | 1 |
| Bakker, IM; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; Veraart, JKE; Visser, BAE | 1 |
| Lodha, D; Prakash, S; Rawat, KS | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Nomura, I; Okuya, M; Sakuma, K | 1 |
| Govorin, NV; Ozornin, AS; Sakharov, AV; Tereshkov, PP | 1 |
| Delgado-Sallent, C; Fath, AB; Gener, T; Nebot, P; Puig, MV; Timplalexi, M | 1 |
| Sood, S | 1 |
| Byeon, SJ; Chung, SJ; Oh, S | 1 |
| Osman, E; Yıldız, M | 1 |
| Arango, C; Leucht, S; Lopez-Morinigo, JD | 1 |
| Fujii, Y; Misawa, F; Takeuchi, H | 1 |
| Cao, D; Hong, Y; Huang, W; Wang, L; Wei, H; Xu, J; Zhang, J | 1 |
| Boesen, MS; Ladefoged, MR; Marloth, PV | 1 |
| Chen, Q; Deng, W; Du, X; Hao, Q; Hu, X; Li, C; Li, K; Li, L; Li, T; Li, X; Lu, T; Lv, L; Ma, X; Ren, H; Tan, L; Tan, Q; Tang, Y; Wang, C; Wang, L; Wang, Q; Wang, Y; Wu, Y; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, G; Zhang, H; Zhang, Y; Zhao, L | 1 |
| Chen, Q; Coid, J; Deng, W; Guo, W; Li, K; Li, L; Li, T; Lu, T; Lv, L; Ma, X; Tan, L; Tan, Q; Tao, S; Wang, C; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L | 1 |
| Akazawa, M; Inada, K; Okada, Y | 1 |
| Berdud, M; Lindgren, P; Towse, A; Wallin-Bernhardsson, N; Zamora, B | 1 |
| Carvalho, AF; Hsu, CW; Hsu, TW; Liang, CS; Thompson, T; Tsai, TC; Tseng, PT; Yu, CL | 1 |
| Bayraktutan, Z; Bulent Yazici, A; Cadirci, E; Cinar, I; Dincer, B; Selli, J; Toktay, E; Yazici, E | 1 |
| Anczewska, M; Balicki, M; Droździkowska, A; Gorczyca, P; Janus, J; Paciorek, S; Plisko, R; Zięba, M | 1 |
| Huang, J; Li, Y; Long, Y; Shen, Y; Wang, Y; Wu, R; Zhao, J | 1 |
| Bateman, BT; Ely, EW; Inouye, SK; Jones, RN; Kim, DH; Lee, SB; Levin, R; Marcantonio, ER; Metzger, E; Pandharipande, PP; Park, CM; Pisani, MA | 1 |
| Assunção, AJ; Beirão, EMDCSP; Marques, RM; Matos, CRC; Neves, RS | 1 |
100 review(s) available for risperidone and haloperidol
| Article | Year |
|---|---|
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
Topics: Animals; Humans; Ligands; Receptors, Serotonin; Serotonin Agents; Serotonin Antagonists; Serotonin Receptor Agonists | 2003 |
Selective optimization of side activities: another way for drug discovery.
Topics: Animals; Biological Availability; Combinatorial Chemistry Techniques; Databases, Factual; Drug Design; Humans; Patents as Topic; Pharmaceutical Preparations; Structure-Activity Relationship | 2004 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
Topics: Animals; Blood-Brain Barrier; Central Nervous System; Central Nervous System Agents; Drug Delivery Systems; Drug Discovery; Humans; Molecular Structure; Structure-Activity Relationship | 2019 |
Pharmacological profile of risperidone.
Topics: Antipsychotic Agents; Brain; Dose-Response Relationship, Drug; Haloperidol; Humans; Isoxazoles; Metabolic Clearance Rate; Piperidines; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Schizophrenia; Schizophrenic Psychology | 1993 |
Extrapyramidal side effects and tolerability of risperidone: a review.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Dystonia; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Clomipramine; Clozapine; Dopamine Antagonists; Drug Therapy, Combination; Female; Fluvoxamine; Haloperidol; Humans; Isoxazoles; Male; Obsessive-Compulsive Disorder; Piperidines; Risperidone; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tic Disorders; Tourette Syndrome | 1994 |
Brief comparison of the pharmacokinetics and pharmacodynamics of the traditional and newer antipsychotic drugs.
Topics: Antipsychotic Agents; Chlorpromazine; Clozapine; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Time Factors | 1995 |
Clinical use of the newer antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Female; Formularies as Topic; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia | 1995 |
The negative component in schizophrenia.
Topics: Affective Symptoms; Antipsychotic Agents; Haloperidol; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Risperidone; Schizophrenia; Schizophrenic Psychology | 1995 |
Antipsychotic dosing strategies in acute schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Haloperidol; Humans; Risperidone; Schizophrenia | 1996 |
Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Child; Clozapine; Disease Progression; Diseases in Twins; Dopamine; Haloperidol; Humans; Obsessive-Compulsive Disorder; Phenotype; Pimozide; Risperidone; Tourette Syndrome; Treatment Outcome | 1996 |
Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety.
Topics: Antiparkinson Agents; Antipsychotic Agents; Haloperidol; Humans; Risperidone; Schizophrenia | 1996 |
Emergency treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Decision Trees; Drug Administration Schedule; Emergency Services, Psychiatric; Emergency Treatment; Haloperidol; History, 20th Century; Humans; Lorazepam; Olanzapine; Pirenzepine; Psychotic Disorders; Risperidone | 1998 |
Facilitating compliance with antipsychotic medication.
Topics: Antipsychotic Agents; Clozapine; Cognition; Drug Monitoring; Haloperidol; Health Care Costs; Humans; Patient Compliance; Quality of Life; Risk Factors; Risperidone; Schizophrenia; Treatment Refusal | 1998 |
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Imidazoles; Indoles; Olanzapine; Pirenzepine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 1999 |
Cognitive deficit in schizophrenia and its neurochemical basis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Glutamic Acid; Haloperidol; Humans; N-Methylaspartate; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Schizophrenic Psychology | 1999 |
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.
Topics: Amoxapine; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dopamine Antagonists; Haloperidol; Humans; In Vitro Techniques; Loxapine; Olanzapine; Pirenzepine; Quetiapine Fumarate; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Serotonin Antagonists; Tomography, Emission-Computed | 1999 |
[Clinical efficacy of olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Binding Sites; Clinical Trials as Topic; Clozapine; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Serotonin | 1999 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Haloperidol; Humans; Incidence; Molindone; Olanzapine; Pirenzepine; Prospective Studies; Risk Factors; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Survival Analysis | 2000 |
Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Canada; Dementia; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Haloperidol; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risperidone; United States | 2000 |
Amisulpride: a review of its efficacy in schizophrenia.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; Clinical Trials as Topic; Flupenthixol; Haloperidol; Humans; Risperidone; Schizophrenia; Sulpiride; Treatment Outcome | 2000 |
Safety profile of amisulpride in short- and long-term use.
Topics: Amisulpride; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Risperidone; Schizophrenia; Sulpiride; Treatment Outcome | 2000 |
Focus on risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders; Risperidone; Schizophrenia | 2000 |
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Dose-Response Relationship, Drug; Haloperidol; Humans; Olanzapine; Pirenzepine; Prolactin; Risperidone; Schizophrenia | 2000 |
Effects of risperidone on affective symptoms in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Mood Disorders; Patient Dropouts; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology | 2000 |
Atypical antipsychotic medications in the psychiatric emergency service.
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Emergency Services, Psychiatric; Haloperidol; Humans; Injections, Intramuscular; Pilot Projects; Practice Guidelines as Topic; Psychomotor Agitation; Psychotic Disorders; Risperidone; Treatment Outcome | 2000 |
Rationale and guidelines for the inpatient treatment of acute psychosis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Haloperidol; Hospitalization; Hostility; Humans; Olanzapine; Pirenzepine; Practice Guidelines as Topic; Psychomotor Agitation; Psychotic Disorders; Risperidone; Treatment Outcome | 2000 |
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Dopamine Antagonists; Drug Monitoring; Haloperidol; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Receptors, Dopamine D2; Receptors, Dopamine D4; Risperidone; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Sulpiride; Thiazoles; Treatment Outcome | 2001 |
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Topics: Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Dibenzothiepins; Haloperidol; Humans; Imidazoles; Indoles; Multicenter Studies as Topic; Olanzapine; Piperazines; Pirenzepine; Placebos; Quetiapine Fumarate; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sulpiride; Thiazoles | 2000 |
Olanzapine: an updated review of its use in the management of schizophrenia.
Topics: Adolescent; Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cognition Disorders; Cost-Benefit Analysis; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Haloperidol; Humans; Olanzapine; Pirenzepine; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Serotonin; Risperidone; Schizophrenia | 2001 |
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Serotonin; Risperidone; Schizophrenia; Terminology as Topic; Tomography, Emission-Computed | 2001 |
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up Studies; Haloperidol; Health Behavior; Humans; Obesity; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Weight Gain | 2001 |
Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Therapy, Combination; Haloperidol; Humans; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2001 |
Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Haloperidol; Humans; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2001 |
The role of novel antipsychotics in bipolar disorders.
Topics: Acute Disease; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Lithium; Olanzapine; Pirenzepine; Randomized Controlled Trials as Topic; Risperidone | 2002 |
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyskinesias; Haloperidol; Humans; Hyperglycemia; Hyperprolactinemia; Olanzapine; Pirenzepine; Quetiapine Fumarate; Risperidone; Thioridazine; Weight Gain | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles | 2003 |
[Late schizophrenia].
Topics: Adult; Age of Onset; Aged; Antipsychotic Agents; Chlorpromazine; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Electroconvulsive Therapy; Haloperidol; Humans; Middle Aged; Reference Standards; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology | 2003 |
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Antagonists; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Placebos; Randomized Controlled Trials as Topic; Retrospective Studies; Risperidone; Schizophrenia | 2003 |
New generation antipsychotics for first episode schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2003 |
[Alcohol hallucinosis].
Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Dopamine; Hallucinations; Haloperidol; Humans; International Classification of Diseases; Psychoses, Alcoholic; Risperidone | 2003 |
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Clinical Trials as Topic; Clozapine; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dibenzothiazepines; Female; Glucose; Haloperidol; Humans; Intellectual Disability; Male; Mental Disorders; Metabolic Syndrome; Middle Aged; Olanzapine; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Time Factors; Weight Gain | 2003 |
[The features of atypical neuroleptic amisulpride action].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Risperidone; Schizophrenia; Sulpiride | 2004 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Child; Clozapine; Dibenzothiazepines; Double-Blind Method; Female; Fructose; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Piperazines; Placebos; Psychotropic Drugs; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Socioeconomic Factors; Sulpiride; Thiazoles; Time Factors; Topiramate; Valproic Acid; Weight Gain | 2004 |
Dopamine receptor microdomains involved in molecular recognition and the regulation of drug affinity and function.
Topics: Animals; Arginine; Aspartic Acid; Binding Sites; Clozapine; Dopamine; Dopamine Antagonists; Haloperidol; Humans; Ligands; Protein Structure, Tertiary; Receptors, Dopamine; Risperidone; Serine | 2004 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Cognitive Behavioral Therapy; Dibenzothiepins; Haloperidol; Humans; Olanzapine; Patient Compliance; Perazine; Pimozide; Risperidone; Schizophrenia; Sulpiride | 2003 |
Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials, Phase III as Topic; Haloperidol; Humans; Meta-Analysis as Topic; Piperazines; Quinolones; Risperidone; Schizophrenia; Time Factors | 2004 |
Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Clinical Trials as Topic; Depression; Female; Haloperidol; Humans; Male; Movement Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology | 2005 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamine; Ginkgo biloba; Haloperidol; Humans; Indans; Memantine; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Risperidone; Rivastigmine; Selegiline; Tacrine; Vitamin E | 2004 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Haloperidol; Humans; Olanzapine; Patient Compliance; Perazine; Pimozide; Risperidone; Schizophrenia; Sulpiride | 2004 |
Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach.
Topics: Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Computer Simulation; Decision Making; Haloperidol; Humans; Markov Chains; Models, Psychological; Monte Carlo Method; Olanzapine; Risperidone; Schizophrenia | 2006 |
Antipsychotic poisoning in young children: a systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Chlorpromazine; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Infant; Infant, Newborn; Olanzapine; Pimozide; Piperazines; Poisoning; Quetiapine Fumarate; Quinolones; Risperidone | 2005 |
Risperidone alone or in combination for acute mania.
Topics: Antipsychotic Agents; Bipolar Disorder; Chemotherapy, Adjuvant; Haloperidol; Humans; Lithium; Randomized Controlled Trials as Topic; Risperidone | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive Disorder; Dibenzothiazepines; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans; Middle Aged; Obsessive-Compulsive Disorder; Olanzapine; Patient Dropouts; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Selective Serotonin Reuptake Inhibitors; Tic Disorders; Treatment Outcome | 2006 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Chlorpromazine; Clozapine; Cognitive Behavioral Therapy; Dibenzothiepins; Family Therapy; Haloperidol; Humans; Patient Compliance; Risperidone; Schizophrenia; Secondary Prevention; Sulpiride; Thioridazine | 2005 |
Risks versus benefits of different types of long-acting injectable antipsychotics.
Topics: Administration, Oral; Antipsychotic Agents; Fluphenazine; Haloperidol; Health Care Costs; Humans; Injections, Intramuscular; Microspheres; Quality of Life; Risk Assessment; Risperidone; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Refusal | 2006 |
Haloperidol alone or in combination for acute mania.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Dibenzothiazepines; Drug Therapy, Combination; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Sulpiride; Valproic Acid | 2006 |
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Dementia; Haloperidol; Humans; Olanzapine; Psychotic Disorders; Risperidone; Treatment Outcome | 2006 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition Disorders; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sulpiride; Time Factors | 2006 |
Antipsychotics for delirium.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Humans; Male; Olanzapine; Randomized Controlled Trials as Topic; Risperidone | 2007 |
The management of psychosis in movement disorder patients.
Topics: Antipsychotic Agents; Clozapine; Haloperidol; Humans; Huntington Disease; Lewy Body Disease; Parkinson Disease; Patient Education as Topic; Psychotic Disorders; Risperidone | 2007 |
An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dibenzothiazepines; Female; Haloperidol; Humans; Incidence; Male; Middle Aged; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2007 |
Antipsychotic medications for cocaine dependence.
Topics: Antipsychotic Agents; Benzodiazepines; Cocaine-Related Disorders; Haloperidol; Humans; Olanzapine; Randomized Controlled Trials as Topic; Risperidone | 2007 |
Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen.
Topics: Antipsychotic Agents; Haloperidol; History, 20th Century; History, 21st Century; Humans; Isoxazoles; Paliperidone Palmitate; Pimozide; Psychotic Disorders; Pyrimidines; Risperidone; Structure-Activity Relationship | 2007 |
Atypical antipsychotics for the treatment of delirious elders.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Delirium; Geriatrics; Haloperidol; Humans; Olanzapine; Risk Factors; Risperidone | 2008 |
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Sleep Stages; Thiazoles; Treatment Outcome | 2008 |
Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bias; Bupropion; Data Interpretation, Statistical; Drug Therapy; Fluoxetine; Haloperidol; Humans; Imipramine; Meta-Analysis as Topic; Nicotine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Smoking Cessation; Treatment Outcome | 2008 |
[Delusion in the critical patient].
Topics: Antipsychotic Agents; Benzodiazepines; Critical Illness; Delusions; Diagnostic and Statistical Manual of Mental Disorders; Haloperidol; Humans; Olanzapine; Propofol; Risk Factors; Risperidone; Severity of Illness Index; Surveys and Questionnaires | 2008 |
Treatment of delirium in supportive and palliative care.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Dopamine Antagonists; Haloperidol; Humans; Olanzapine; Palliative Care; Prognosis; Risperidone; Serotonin Antagonists; Severity of Illness Index; Time Factors | 2008 |
[The use of antipsychotics in patients with dementia].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebrovascular Disorders; Dementia; Dementia, Vascular; Dibenzothiazepines; Double-Blind Method; Evidence-Based Medicine; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Treatment Outcome | 2008 |
[Delirium--management in the hospital: diagnosis and treatment].
Topics: Aged; Antipsychotic Agents; Confusion; Delirium; Frail Elderly; Haloperidol; Hospitalization; Humans; Prescription Drugs; Risk Factors; Risperidone; Social Environment; Treatment Outcome | 2008 |
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Evidence-Based Medicine; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2009 |
Pimozide for tics in Tourette's syndrome.
Topics: Anti-Dyskinesia Agents; Haloperidol; Humans; Pimozide; Randomized Controlled Trials as Topic; Risperidone; Tics; Tourette Syndrome | 2009 |
Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature.
Topics: Age Factors; Antipsychotic Agents; Benzodiazepines; Chemical and Drug Induced Liver Injury; Clozapine; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Liver; Middle Aged; Olanzapine; Perazine; Risk Factors; Risperidone; Transaminases | 2011 |
[Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
Topics: Antipsychotic Agents; Autistic Disorder; Body Dysmorphic Disorders; Clomipramine; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Drug Therapy, Combination; Feeding and Eating Disorders; Haloperidol; Humans; Obsessive-Compulsive Disorder; Randomized Controlled Trials as Topic; Risperidone; Selective Serotonin Reuptake Inhibitors; Tourette Syndrome | 2011 |
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Depression; Depressive Disorder; Dibenzothiazepines; Double-Blind Method; Drug Industry; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Support as Topic; Risperidone; Thiazoles | 2013 |
What do we really know about the treatment of delirium with antipsychotics? Ten key issues for delirium pharmacotherapy.
Topics: Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Haloperidol; Humans; Risperidone | 2013 |
Current use of atypical antipsychotics.
Topics: Antipsychotic Agents; Autoreceptors; Brain; Dose-Response Relationship, Drug; Flupenthixol; Haloperidol; Humans; Medication Adherence; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Presynaptic; Risperidone; Schizophrenia; Schizophrenic Psychology; Synaptic Transmission; Treatment Outcome | 2002 |
Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
Topics: Antipsychotic Agents; Constipation; Double-Blind Method; Drug Therapy, Combination; Granisetron; Haloperidol; Humans; Indoles; Nausea; Ondansetron; Randomized Controlled Trials as Topic; Receptors, Serotonin, 5-HT3; Risperidone; Schizophrenia; Serotonin 5-HT3 Receptor Antagonists; Severity of Illness Index; Symptom Assessment; Treatment Outcome; Tropisetron; Vomiting | 2014 |
Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzocycloheptenes; Haloperidol; Heterocyclic Compounds, 4 or More Rings; Humans; Olanzapine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Risperidone; Schizophrenia; Sensitivity and Specificity; Treatment Outcome | 2014 |
Management of delirium in palliative care: a review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholinesterase Inhibitors; Delirium; Disease Management; Haloperidol; Health Personnel; Humans; Olanzapine; Palliative Care; Quetiapine Fumarate; Risperidone | 2015 |
Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review.
Topics: Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Dexmedetomidine; Haloperidol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; Intensive Care Units; Length of Stay; Neuroprotective Agents; Postoperative Complications; Quetiapine Fumarate; Respiration, Artificial; Risperidone; Rivastigmine; Treatment Outcome | 2015 |
Antipsychotic-induced akathisia in delirium: A systematic review.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Delirium; Haloperidol; Humans; Prevalence; Risperidone | 2016 |
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Topics: Adult; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Clozapine; Double-Blind Method; Drug Resistance; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Acceptance of Health Care; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Single-Blind Method; Treatment Outcome | 2016 |
[Dangerous drugs: products containing synthetic chemicals].
Topics: Alkaloids; Antipsychotic Agents; Cannabinoids; Central Nervous System Diseases; Consciousness Disorders; Delusions; Diazepam; Fluid Therapy; Hallucinations; Haloperidol; Humans; Illicit Drugs; Midazolam; Prognosis; Renal Dialysis; Respiration, Artificial; Rhabdomyolysis; Risperidone | 2016 |
Antipsychotic medications for cocaine dependence.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cocaine-Related Disorders; Haloperidol; Humans; Lamotrigine; Olanzapine; Patient Dropouts; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Reserpine; Risperidone; Triazines | 2016 |
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Drug Resistance; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain | 2017 |
Delirium in hospitalized patients: Risks and benefits of antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Haloperidol; Hospitalization; Humans; Olanzapine; Quetiapine Fumarate; Risperidone | 2017 |
Antipsychotics for treatment of delirium in hospitalised non-ICU patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Hospitalization; Humans; Male; Olanzapine; Placebo Effect; Randomized Controlled Trials as Topic; Risperidone | 2018 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Network Meta-Analysis; Risperidone | 2020 |
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia.
Topics: Academic Medical Centers; Aged; Algorithms; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Citalopram; Dementia; Electroconvulsive Therapy; Haloperidol; Humans; Olanzapine; Psychopharmacology; Risperidone | 2021 |
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Methamphetamine; Network Meta-Analysis; Olanzapine; Patient Dropouts; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia | 2021 |
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Patient Acceptance of Health Care; Phenothiazines; Psychotic Disorders; Risperidone; Schizophrenia; Secondary Prevention | 2021 |
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depression; Drug Interactions; Female; Haloperidol; Humans; Ketamine; Lithium; Male; Olanzapine; Psychotropic Drugs; Risperidone; Schizophrenia; Treatment Outcome | 2021 |
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Female; Haloperidol; Humans; Lithium; Male; Mania; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Tamoxifen; Valproic Acid | 2022 |
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Humans; Lurasidone Hydrochloride; Molindone; Olanzapine; Paliperidone Palmitate; Quality of Life; Quetiapine Fumarate; Risperidone; Schizophrenia; Systematic Reviews as Topic | 2022 |
A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Carbamazepine; Dibenzocycloheptenes; Haloperidol; Humans; Lithium; Mania; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Piperazines; Quetiapine Fumarate; Risperidone; Tamoxifen; Thiazoles; Valproic Acid | 2022 |
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Haloperidol; Humans; Mania; Olanzapine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2023 |
209 trial(s) available for risperidone and haloperidol
| Article | Year |
|---|---|
The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability.
Topics: Antipsychotic Agents; Chronic Disease; Cross-Cultural Comparison; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Observer Variation; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Reproducibility of Results; Risperidone; Schizophrenia; Schizophrenic Psychology; Sweden | 1992 |
Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Hospitalization; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1992 |
Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients.
Topics: Adult; Aged; Antipsychotic Agents; Brain; Cerebral Ventricles; Chronic Disease; Dilatation, Pathologic; Double-Blind Method; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology; Tomography, X-Ray Computed | 1992 |
Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group.
Topics: Antipsychotic Agents; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1992 |
Risperidone in the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Placebos; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1994 |
Symptoms in schizophrenic syndromes in relation to age, sex, duration of illness and number of previous hospitalizations.
Topics: Adult; Age Factors; Age of Onset; Aged; Antipsychotic Agents; Female; Haloperidol; Hospitalization; Hospitals, Psychiatric; Humans; Isoxazoles; Male; Middle Aged; Patient Admission; Piperidines; Risperidone; Ritanserin; Schizophrenia; Schizophrenic Psychology; Sex Factors | 1994 |
Efficacy of risperidone on positive features of schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Schizophrenia; Treatment Outcome | 1994 |
Negative symptoms in schizophrenia: assessment of the effect of risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia; Single-Blind Method | 1994 |
Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol.
Topics: Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Desmopressin for risperidone-induced enuresis.
Topics: Administration, Intranasal; Adult; Antipsychotic Agents; Deamino Arginine Vasopressin; Double-Blind Method; Enuresis; Female; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Psychoses, Substance-Induced; Risperidone; Schizophrenia; Schizophrenic Psychology; Sex Characteristics | 1994 |
Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia | 1995 |
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1995 |
The negative component in schizophrenia.
Topics: Affective Symptoms; Antipsychotic Agents; Haloperidol; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Risperidone; Schizophrenia; Schizophrenic Psychology | 1995 |
Critique of the Canadian Multicenter Placebo-Controlled Study of Risperidone and Haloperidol.
Topics: Canada; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Research Design; Risperidone; Schizophrenia | 1995 |
Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Isoxazoles; Male; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1995 |
Effect of risperidone on hostility in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Haloperidol; Hostility; Humans; Middle Aged; Psychiatric Status Rating Scales; Psychometrics; Risperidone; Schizophrenia; Schizophrenic Psychology | 1995 |
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Neurologic Examination; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 1993 |
Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial.
Topics: Adolescent; Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia | 1993 |
Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dominance, Cerebral; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Evoked Potentials; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Behavior | 1993 |
Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Haloperidol; Humans; Isoxazoles; Male; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology | 1993 |
[Efficacy and tolerance of risperidone in various doses (report of a study)].
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Male; Perphenazine; Risperidone; Schizophrenia | 1996 |
Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Methotrimeprazine; Middle Aged; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1996 |
Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Eye Movements; Female; Haloperidol; Humans; Male; Prospective Studies; Risperidone; Saccades; Schizophrenia | 1997 |
Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
Topics: Adult; Benztropine; Double-Blind Method; Female; Haloperidol; Humans; Male; Memory; Neuropsychological Tests; Placebos; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Risperidone; Schizophrenia; Schizophrenic Psychology; Verbal Behavior | 1997 |
Extrapyramidal symptoms in patients treated with risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine Antagonists; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Risperidone; Schizophrenia; Surveys and Questionnaires | 1997 |
Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Canada; Chronic Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Haloperidol; Health Status; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology | 1997 |
Effects of risperidone on polydipsia in chronic schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Chronic Disease; Combined Modality Therapy; Double-Blind Method; Drinking; Haloperidol; Humans; Male; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Water Intoxication | 1997 |
Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol.
Topics: Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Haloperidol; Humans; Neuropsychological Tests; Prospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1997 |
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Factor Analysis, Statistical; Female; Haloperidol; Humans; Male; Middle Aged; Placebos; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome | 1997 |
Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland.
Topics: Adult; Antipsychotic Agents; Austria; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Female; Germany; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Switzerland | 1997 |
Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances.
Topics: Aged; Antipsychotic Agents; Chi-Square Distribution; Dementia; Haloperidol; Humans; Retrospective Studies; Risperidone; Social Behavior Disorders; Thioridazine; Treatment Outcome | 1997 |
Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depressive Disorder; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone | 1998 |
Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Emotions; Female; Haloperidol; Humans; Male; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1998 |
Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Female; Haloperidol; Humans; Learning; Male; Motor Skills; Psychiatric Status Rating Scales; Psychomotor Performance; Reaction Time; Risperidone; Schizophrenic Psychology | 1998 |
Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male; Norepinephrine; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1999 |
Novel antipsychotics: comparison of weight gain liabilities.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Pirenzepine; Placebos; Retrospective Studies; Risperidone; Schizophrenia; Weight Gain | 1999 |
Risperidone versus haloperidol on secondary memory: can newer medications aid learning?
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; Male; Mental Recall; Middle Aged; Neuropsychological Tests; Psychiatric Status Rating Scales; Retention, Psychology; Risperidone; Verbal Learning | 1999 |
Risperidone in treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Cholinergic Antagonists; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Placebos; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome | 1999 |
A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.
Topics: Aged; Aged, 80 and over; Behavior; Dementia; Double-Blind Method; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Risperidone | 1999 |
[Cognition and driving in schizophrenic patients under treatment with risperidone vs. haloperidol].
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Auditory Perception; Automobile Driving; Cognition; Female; Flicker Fusion; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychomotor Performance; Reaction Time; Risperidone; Schizophrenia; Schizophrenic Psychology | 1999 |
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Child; Cholinergic Antagonists; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Costs; Female; Follow-Up Studies; Haloperidol; Hospital Costs; Hospitalization; Humans; Male; Mental Disorders; Middle Aged; Patient Readmission; Perphenazine; Psychotic Disorders; Retrospective Studies; Risperidone; Treatment Outcome | 1999 |
Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol.
Topics: Adult; Antipsychotic Agents; Attention; Double-Blind Method; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Risperidone; Schizophrenia; Schizophrenic Psychology | 2000 |
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Motor Skills; Neuropsychological Tests; Olanzapine; Pirenzepine; Psychomotor Performance; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2000 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Haloperidol; Humans; Incidence; Molindone; Olanzapine; Pirenzepine; Prospective Studies; Risk Factors; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Survival Analysis | 2000 |
Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; Male; Psychotic Disorders; Risperidone; Schizophrenia; Severity of Illness Index | 2000 |
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Electrocardiography; Female; Haloperidol; Humans; Incidence; Long QT Syndrome; Male; Middle Aged; Olanzapine; Pirenzepine; Placebos; Risperidone; Schizophrenia | 2001 |
Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Cerebrovascular Circulation; Female; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Risperidone; Schizophrenia; Tomography, Emission-Computed | 2001 |
Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis.
Topics: Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Hospitalization; Humans; Length of Stay; Long-Term Care; Male; Risperidone; Schizophrenia | 2001 |
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Body Weight; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Racial Groups; Retrospective Studies; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Treatment Outcome; Weight Gain | 2001 |
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2001 |
A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone | 2001 |
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Blind Method; Emotions; Female; Haloperidol; Hostility; Humans; Linear Models; Male; Olanzapine; Pirenzepine; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Statistics, Nonparametric; Survival Analysis | 2001 |
Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Pituitary Gland; Prolactin; Receptors, Dopamine D2; Risperidone; Schizophrenia; Sulpiride | 2001 |
Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.
Topics: Adult; Antipsychotic Agents; Asian People; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Inpatients; Male; Middle Aged; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 2001 |
A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia, Vascular; Double-Blind Method; Female; Haloperidol; Hong Kong; Humans; Male; Risperidone; Social Behavior Disorders; Treatment Outcome | 2001 |
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Disease-Free Survival; Female; Haloperidol; Humans; Male; Middle Aged; Patient Compliance; Proportional Hazards Models; Risk; Risperidone; Schizophrenia; Secondary Prevention | 2002 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Admission; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2002 |
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Recurrence; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Survival Analysis; Time Factors; Treatment Outcome; Treatment Refusal | 2002 |
The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Metabolic Clearance Rate; Middle Aged; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thioridazine | 2002 |
Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia.
Topics: Activities of Daily Living; Adult; Ambulatory Care; Antipsychotic Agents; Behavior Therapy; Clinical Protocols; Combined Modality Therapy; Female; Haloperidol; Humans; Male; Manuals as Topic; Psychiatric Status Rating Scales; Quality of Life; Risperidone; Schizophrenia; Social Adjustment; Social Support; Treatment Outcome | 2002 |
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Double-Blind Method; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Pirenzepine; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2002 |
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone.
Topics: Adult; Antipsychotic Agents; Cognition; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Risperidone; Schizophrenia; Schizophrenic Psychology | 2002 |
Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Brief Psychiatric Rating Scale; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Haloperidol; Humans; Lithium; Male; Middle Aged; Placebos; Psychiatric Status Rating Scales; Risperidone; Treatment Outcome; Valproic Acid | 2002 |
The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers.
Topics: Adolescent; Adult; Affect; Central Nervous System Stimulants; Dopamine; Dopamine Antagonists; Double-Blind Method; Emotions; Female; Haloperidol; Humans; Male; Methamphetamine; Risperidone; Serotonin; Serotonin Antagonists | 2002 |
Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Cross-Over Studies; Cytochrome P-450 CYP2D6; Female; Haloperidol; Humans; Male; Middle Aged; Polymorphism, Genetic; Risperidone; Schizophrenia | 2002 |
The effects of neuroleptic medications on basal ganglia blood flow in schizophreniform disorders: a comparison between the neuroleptic-naïve and medicated states.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Cerebrovascular Circulation; Female; Follow-Up Studies; Haloperidol; Humans; Male; Psychotic Disorders; Putamen; Retrospective Studies; Risperidone; Tomography, Emission-Computed | 2002 |
Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Depression; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Predictive Value of Tests; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index | 2002 |
Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study.
Topics: Adult; Antipsychotic Agents; Australia; Austria; Canada; Clinical Trials as Topic; Cognition Disorders; Cross-Cultural Comparison; Feasibility Studies; Finland; France; Germany; Haloperidol; Humans; Israel; Neuropsychological Tests; Risperidone; Schizophrenia; South Africa; United Kingdom; United States | 2003 |
Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Bone Density; Clopenthixol; Clozapine; Female; Fluphenazine; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Risperidone; Schizophrenia | 2002 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Hospitalization; Humans; Hypercholesterolemia; Hyperglycemia; Male; Middle Aged; Olanzapine; Pirenzepine; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Weight Gain | 2003 |
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depression; Dopamine Antagonists; Dyskinesia, Drug-Induced; Fatigue; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Treatment Outcome | 2003 |
Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice?
Topics: Adolescent; Adult; Antipsychotic Agents; Cohort Studies; Cross-Cultural Comparison; Female; Haloperidol; Humans; Male; Middle Aged; New York; Patient Selection; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Selection Bias | 2003 |
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Double-Blind Method; Female; Haloperidol; Humans; Learning; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Outpatients; Pirenzepine; Risperidone; Schizophrenia; Time Factors | 2003 |
Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Behavior Therapy; Brief Psychiatric Rating Scale; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Treatment Outcome | 2003 |
Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol.
Topics: Adult; Antipsychotic Agents; Attention; Chronic Disease; Emotions; Eye Movements; Facial Expression; Female; Fixation, Ocular; Haloperidol; Humans; Male; Middle Aged; Pattern Recognition, Visual; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Perception | 2003 |
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Olanzapine; Pilot Projects; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Time Factors; Treatment Outcome | 2004 |
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Mexico; Neurologic Examination; Olanzapine; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2003 |
A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.
Topics: Adolescent; Adult; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Benzodiazepines; Biotransformation; Clozapine; Dibenzothiazepines; Electrocardiography; Female; Haloperidol; Heart Conduction System; Humans; Long QT Syndrome; Male; Middle Aged; Olanzapine; Quetiapine Fumarate; Risperidone; Thioridazine | 2004 |
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Prolactin; Risperidone; Schizophrenia; Sexual Dysfunction, Physiological | 2004 |
Adverse effects of risperidone and haloperidol treatment in schizophrenia.
Topics: Adult; Blood Pressure; Case-Control Studies; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Haloperidol; Heart Rate; Humans; Male; Middle Aged; Muscle Rigidity; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Single-Blind Method; Time Factors; Treatment Outcome; Tremor | 2004 |
Correlates of cognitive deficits in first episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Haloperidol; Humans; Male; Memory Disorders; Middle Aged; Neuropsychological Tests; Risperidone; Schizophrenia; Severity of Illness Index | 2004 |
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Cluster Analysis; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Lorazepam; Male; Middle Aged; Prospective Studies; Psychomotor Agitation; Risperidone; Severity of Illness Index; Single-Blind Method | 2004 |
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Factor Analysis, Statistical; Female; Haloperidol; Humans; Male; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2004 |
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Movement Disorders; Psychiatric Status Rating Scales; Risperidone; Schizophrenia | 2004 |
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; Olanzapine; Psychiatric Status Rating Scales; Psychometrics; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology | 2004 |
Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Prolactin; Radioimmunoassay; Risperidone; Schizophrenia | 2005 |
Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Haloperidol; Hospitalization; Humans; Immunity, Cellular; Interleukin-2; Interleukin-6; Interleukin-8; Male; Radioimmunoassay; Risperidone; Schizophrenia; Treatment Outcome | 2004 |
Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Follow-Up Studies; Haloperidol; Hospitalization; Humans; Male; Prospective Studies; Risperidone; Schizophrenia; Secondary Prevention | 2003 |
A prospective 4-5 year follow-up of juvenile onset bipolar disorder.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Chlorpromazine; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Follow-Up Studies; Haloperidol; Humans; Imipramine; Lithium Carbonate; Male; Phenotype; Prospective Studies; Recovery of Function; Risperidone; Secondary Prevention; Severity of Illness Index; Valproic Acid | 2004 |
The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Biomarkers; Calcium; Copper; Erythrocytes; Female; Haloperidol; Humans; Magnesium; Male; Middle Aged; Risperidone; Schizophrenia, Paranoid; Spectrophotometry; Zinc | 2004 |
Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
Topics: Adult; Antipsychotic Agents; Attention; Automobile Driving; Case-Control Studies; Female; Haloperidol; Humans; Male; Psychomotor Disorders; Reaction Time; Risperidone; Schizophrenia; Visual Perception | 2005 |
[Incidence of rigor during treatment with flupentixol decanoate in comparison to risperidone].
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Body Weight; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Flupenthixol; Haloperidol; Humans; Incidence; Male; Middle Aged; Muscle Rigidity; Neurologic Examination; Prospective Studies; Risperidone | 2004 |
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Bipolar Disorder; Dopamine Antagonists; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Haloperidol; Humans; Lorazepam; Male; Middle Aged; Placebos; Psychiatric Status Rating Scales; Risperidone; Serotonin Antagonists; Time Factors; Treatment Outcome | 2005 |
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dyskinesia, Drug-Induced; Follow-Up Studies; Haloperidol; Hospitalization; Humans; Mental Disorders; Models, Econometric; Olanzapine; Outpatients; Patient Compliance; Piperazines; Psychiatric Status Rating Scales; Retrospective Studies; Risperidone; Sensitivity and Specificity; Spain; Survival Analysis; Thiazoles; Treatment Outcome; Weight Gain | 2004 |
Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Brain Stem; Female; Fixation, Ocular; Follow-Up Studies; Haloperidol; Humans; Male; Matched-Pair Analysis; Neocortex; Neural Inhibition; Reaction Time; Reference Values; Risperidone; Saccades; Schizophrenia | 2005 |
Antipsychotics and dopamine transporter gene polymorphisms in delirium patients.
Topics: Adult; Antipsychotic Agents; Delirium; Dopamine Plasma Membrane Transport Proteins; Female; Haloperidol; Humans; Korea; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Polymorphism, Genetic; Psychiatric Status Rating Scales; Reverse Transcriptase Polymerase Chain Reaction; Risperidone | 2005 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Hyperprolactinemia; Longitudinal Studies; Male; Obesity; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome; Weight Gain | 2005 |
Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Double-Blind Method; Drug Resistance; Female; Haloperidol; Humans; Hydrocortisone; Interleukin-2; Interleukin-6; Male; Middle Aged; Psychiatric Status Rating Scales; Radioimmunoassay; Risperidone; Schizophrenia; Time Factors; Treatment Outcome | 2005 |
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Parkinson Disease; Psychotic Disorders; Risk Factors; Risperidone; Schizophrenia; Social Behavior | 2005 |
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; Nursing Assessment; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2005 |
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Obsessive-Compulsive Disorder; Personality Inventory; Psychiatric Status Rating Scales; Risperidone; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2005 |
Cerebral cortical gray expansion associated with two second-generation antipsychotics.
Topics: Adult; Antipsychotic Agents; Atrophy; Cerebral Cortex; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Nerve Growth Factors; Piperazines; Psychiatric Status Rating Scales; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2005 |
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Cohort Studies; Dibenzothiazepines; Female; Haloperidol; Hostility; Humans; Male; Olanzapine; Outpatients; Prospective Studies; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2005 |
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cross-Cultural Comparison; Dibenzothiazepines; Drug Therapy, Combination; Female; Follow-Up Studies; Haloperidol; Humans; International Classification of Diseases; Male; Olanzapine; Patient Compliance; Prospective Studies; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2005 |
The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.
Topics: Adult; Antipsychotic Agents; Brain; Cognition; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Risperidone; Schizophrenia | 2005 |
Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Quetiapine Fumarate; Risperidone; Schizophrenia; Time Factors; Treatment Outcome | 2005 |
Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
Topics: Adult; Antipsychotic Agents; Biperiden; Cholinergic Antagonists; Cytochrome P-450 CYP2D6; Drug Therapy, Combination; Female; Genotype; Haloperidol; Humans; Male; Muscarinic Antagonists; Polymorphism, Genetic; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2005 |
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Haloperidol; Humans; Male; Neuropsychological Tests; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2005 |
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Reaction Time; Risperidone; Schizophrenia; Treatment Outcome | 2006 |
The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study.
Topics: Antipsychotic Agents; Double-Blind Method; Haloperidol; Humans; Prolactin; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Superoxide Dismutase | 2006 |
[Therapy of mental states at high risk for psychosis: preliminary results from Hungary].
Topics: Adult; Antipsychotic Agents; Female; Follow-Up Studies; Haloperidol; Humans; Hungary; Male; Psychotherapy; Psychotic Disorders; Risperidone; Treatment Outcome | 2006 |
Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Behavioral Symptoms; Brief Psychiatric Rating Scale; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Health Status; Humans; Male; Middle Aged; Placebos; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Sleep Stages; Surveys and Questionnaires | 2006 |
Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; Health Surveys; Humans; Male; Odds Ratio; Olanzapine; Outpatients; Prevalence; Prospective Studies; Quetiapine Fumarate; Risperidone; Schizophrenia; Sexual Dysfunction, Physiological; Time; Treatment Outcome | 2006 |
Time course for antipsychotic treatment response in first-episode schizophrenia.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Haloperidol; Humans; Longitudinal Studies; Proportional Hazards Models; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2006 |
Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Haloperidol; Humans; Lorazepam; Male; Middle Aged; Pilot Projects; Prospective Studies; Psychomotor Agitation; Risperidone; Severity of Illness Index; Treatment Outcome | 2006 |
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Haloperidol; Humans; Longitudinal Studies; Male; Middle Aged; Olanzapine; Prognosis; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Schizotypal Personality Disorder; Socioeconomic Factors; Spain; Treatment Outcome | 2007 |
Premorbid functioning and treatment response in recent-onset schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Prognosis; Psychiatric Status Rating Scales; Psychometrics; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2006 |
Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety Disorders; Cross-Over Studies; Dementia; Double-Blind Method; Female; Haloperidol; Humans; Male; Mood Disorders; Nursing Homes; Psychomotor Agitation; Risperidone; Treatment Outcome | 2006 |
Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Clopenthixol; Double-Blind Method; Female; Haloperidol; Humans; Male; Perphenazine; Risperidone; Schizophrenia; Treatment Outcome | 2006 |
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Haloperidol; Humans; Long-Term Care; Male; Motivation; Psychiatric Status Rating Scales; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Sick Role; Social Adjustment; Treatment Outcome | 2007 |
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Haloperidol; Humans; Longitudinal Studies; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome | 2006 |
Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Corpus Striatum; Female; Flupenthixol; Frontal Lobe; Haloperidol; Humans; Male; Middle Aged; Positron-Emission Tomography; Radioligand Assay; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D1; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology | 2007 |
Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Male; Olanzapine; Polysomnography; Reference Values; Risperidone; Sleep; Sleep, REM; Time Factors; Wakefulness | 2007 |
A pharmaco-EEG study on antipsychotic drugs in healthy volunteers.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Cross-Over Studies; Dibenzothiazepines; Electroencephalography; Fourier Analysis; Haloperidol; Humans; Indoles; Isoindoles; Male; Olanzapine; Quetiapine Fumarate; Reference Values; Risperidone; Single-Blind Method; Thiazoles; Time Factors | 2007 |
Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Cerebral Cortex; Cerebrovascular Circulation; Double-Blind Method; Female; Haloperidol; Humans; Male; Risperidone; Schizophrenia | 2008 |
Stability of emotional dysfunctions? A long-term fMRI study in first-episode schizophrenia.
Topics: Adult; Affect; Affective Symptoms; Antipsychotic Agents; Cerebral Cortex; Double-Blind Method; Female; Follow-Up Studies; Frontal Lobe; Gyrus Cinguli; Haloperidol; Hippocampus; Humans; Limbic System; Magnetic Resonance Imaging; Male; Middle Aged; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Temporal Lobe | 2007 |
Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Psychiatric Status Rating Scales; Psychomotor Performance; Risperidone; Schizophrenia; Schizophrenic Psychology | 2007 |
Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients.
Topics: Adult; Antipsychotic Agents; Clozapine; Cross-Sectional Studies; Electron Transport; Electron Transport Complex I; Female; Haloperidol; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Neuroleptic Malignant Syndrome; Risperidone; Schizophrenia | 2007 |
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.
Topics: Acoustic Stimulation; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Electromyography; Female; Habituation, Psychophysiologic; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Psychotic Disorders; Reflex, Startle; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2007 |
Risperidone versus haloperidol for facial affect recognition in schizophrenia: findings from a randomised study.
Topics: Acute Disease; Adolescent; Adult; Affect; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; Facial Expression; Female; Haloperidol; Humans; Male; Middle Aged; Prospective Studies; Recognition, Psychology; Risperidone; Schizophrenia; Severity of Illness Index; Young Adult | 2009 |
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale; Dibenzothiazepines; Emergency Services, Psychiatric; Female; Haloperidol; Hostility; Humans; Italy; Male; Middle Aged; Olanzapine; Prospective Studies; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study.
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; Male; Prospective Studies; Risperidone; Time; Treatment Outcome; Weight Gain | 2008 |
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Diagnostic and Statistical Manual of Mental Disorders; Dyslipidemias; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Prevalence; Prospective Studies; Psychotic Disorders; Risperidone; Severity of Illness Index; Weight Gain | 2007 |
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Algorithms; Antipsychotic Agents; Biomedical Research; Cooperative Behavior; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Germany; Haloperidol; Humans; Male; Middle Aged; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Surveys and Questionnaires | 2007 |
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
Topics: Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Haloperidol; Humans; India; Male; Obesity; Olanzapine; Prevalence; Prospective Studies; Risperidone; Schizophrenia; Time Factors | 2007 |
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Chronic Disease; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Haloperidol; Humans; Long-Term Care; Male; Middle Aged; Olanzapine; Risperidone; Spain; Treatment Outcome; Weight Gain | 2008 |
Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Attention; Behavioral Symptoms; Case-Control Studies; Cross-Over Studies; Double-Blind Method; Female; Haloperidol; Humans; Longitudinal Studies; Male; Memory; Middle Aged; Neuropsychological Tests; Psychiatric Status Rating Scales; Reaction Time; Risperidone; Schizophrenia; Schizophrenic Psychology; Time; Verbal Learning | 2008 |
Antipsychotic drugs for aggression in intellectual disability.
Topics: Aggression; Antipsychotic Agents; Haloperidol; Humans; Intellectual Disability; Risperidone | 2008 |
Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.
Topics: Adult; Aged; Aggression; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Mental Competency; Mental Disorders; Middle Aged; Patient Compliance; Risperidone | 2008 |
Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Female; Haloperidol; Humans; Male; Olanzapine; Prognosis; Prospective Studies; Risperidone; Schizophrenia; Weight Gain | 2008 |
Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Demography; Diagnostic and Statistical Manual of Mental Disorders; Female; Haloperidol; Haplotypes; Humans; Interleukin-12; Male; Olanzapine; Psychotic Disorders; Risperidone; Time Factors | 2008 |
Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS).
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Double-Blind Method; Female; Haloperidol; Humans; Long-Term Care; Male; Neuropsychological Tests; Norway; Nursing Homes; Olanzapine; Risperidone; Withholding Treatment | 2008 |
Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germany; Haloperidol; Humans; Male; Middle Aged; Regression Analysis; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2008 |
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Mass Index; Dose-Response Relationship, Drug; Energy Metabolism; Female; Ghrelin; Haloperidol; Humans; Insulin; Leptin; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Olanzapine; Prospective Studies; Psychotic Disorders; Resistin; Risperidone; Schizophrenia; Weight Gain | 2008 |
Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia.
Topics: Acoustic Stimulation; Adult; Analysis of Variance; Antipsychotic Agents; Case-Control Studies; Female; Gait Disorders, Neurologic; Habituation, Psychophysiologic; Haloperidol; Humans; Inhibition, Psychological; Male; Neuropsychological Tests; Psychiatric Status Rating Scales; Reflex, Startle; Risperidone; Schizophrenia; Young Adult | 2008 |
Decreased serum neurotrophin 3 in chronically medicated schizophrenic males.
Topics: Adult; Antipsychotic Agents; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Enzyme-Linked Immunosorbent Assay; Haloperidol; Humans; Longitudinal Studies; Male; Middle Aged; Neurotrophin 3; Phlebotomy; Risperidone; Schizophrenia | 2008 |
Effect of risperidone versus haloperidol on emotional responding in schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Corpus Striatum; Dopamine; Dopamine D2 Receptor Antagonists; Emotions; Facial Expression; Female; Haloperidol; Humans; Male; Middle Aged; Prospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology; Serotonin; Video Recording; Young Adult | 2008 |
Trajectories and antecedents of treatment response over time in early-episode psychosis.
Topics: Adult; Age of Onset; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Early Diagnosis; Female; Follow-Up Studies; Haloperidol; Humans; Male; Prognosis; Psychiatric Status Rating Scales; Psychometrics; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2010 |
Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Genotype; Haloperidol; Humans; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Receptor, Serotonin, 5-HT1A; Risperidone; Schizophrenia; Young Adult | 2009 |
Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Brain; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Mental Disorders; Olanzapine; Psychiatric Status Rating Scales; Risperidone; Young Adult | 2008 |
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Haloperidol; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Olanzapine; Prospective Studies; Risk Factors; Risperidone; Schizophrenia; Spain; Triglycerides; Weight Gain; Young Adult | 2009 |
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Psychiatric Status Rating Scales; Psychometrics; Psychotic Disorders; Risperidone; Schizophrenia; Statistics as Topic; Young Adult | 2008 |
Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Interleukin-2; Interleukin-6; Male; Middle Aged; Oxidative Stress; Risperidone; Schizophrenia; Sex Factors; Superoxide Dismutase; Time Factors; Treatment Outcome | 2009 |
Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study.
Topics: Adult; Antipsychotic Agents; Female; Hallucinations; Haloperidol; Humans; International Classification of Diseases; Male; Risperidone; Schizophrenia; Severity of Illness Index; Transcranial Magnetic Stimulation | 2009 |
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Perphenazine; Piperazines; Prospective Studies; Psychotic Disorders; Risperidone; Severity of Illness Index; Sulpiride; Thiazoles | 2009 |
Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID).
Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; England; Female; Haloperidol; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Persons with Mental Disabilities; Placebos; Risperidone; Severity of Illness Index; Young Adult | 2009 |
The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis.
Topics: Adult; Aggression; Antipsychotic Agents; Combined Modality Therapy; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; England; Female; Follow-Up Studies; Haloperidol; Humans; Intellectual Disability; Male; Mental Disorders; Middle Aged; Quality of Life; Risperidone; Wales | 2009 |
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles | 2009 |
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Psychiatric Status Rating Scales; Psychometrics; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2009 |
Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities.
Topics: Adult; Aggression; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Evidence-Based Medicine; Female; Haloperidol; Humans; Intellectual Disability; Male; Patient Selection; Personality Assessment; Psychometrics; Queensland; Risperidone; Social Behavior Disorders; Treatment Outcome; United Kingdom | 2010 |
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.
Topics: Acute Disease; Administration, Oral; Adult; Benzodiazepines; Disease Management; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Pharmaceutical Solutions; Prospective Studies; Psychiatric Department, Hospital; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Risperidone; Solubility; Tablets; Taiwan; Treatment Outcome | 2010 |
Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Risperidone; Time Factors; Treatment Outcome; Young Adult | 2010 |
A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Middle Aged; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2011 |
Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Female; Germany; Haloperidol; Humans; Long-Term Care; Male; Middle Aged; Patient Education as Topic; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Schizotypal Personality Disorder; Secondary Prevention | 2011 |
A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Prolactin; Prospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2010 |
Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Secondary Prevention; Treatment Outcome; Young Adult | 2011 |
Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Predictive Value of Tests; Psychiatric Status Rating Scales; Recurrence; Retrospective Studies; Risperidone; Schizophrenia; Statistics, Nonparametric; Treatment Outcome; Young Adult | 2011 |
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Severity of Illness Index; Treatment Failure | 2011 |
Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Prolactin; Quinolones; Receptors, Dopamine D2; Risperidone; Single-Blind Method; Young Adult | 2011 |
Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial.
Topics: Adenosine; Adenosine Deaminase; Adult; Chronic Disease; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Prospective Studies; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2011 |
Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Depression; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Hospitals, Psychiatric; Humans; Inpatients; Male; Middle Aged; Psychiatric Status Rating Scales; Remission Induction; Risperidone; Schizophrenia; Schizophrenic Psychology; Suicidal Ideation; Treatment Outcome; Young Adult | 2012 |
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis.
Topics: Adult; Benzodiazepines; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Haloperidol; Humans; Longitudinal Studies; Male; Olanzapine; Prospective Studies; Psychotic Disorders; Risperidone; Time Factors; Treatment Outcome; Young Adult | 2012 |
Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Delirium; Drug Administration Schedule; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Risperidone; Single-Blind Method; Treatment Outcome | 2011 |
First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Substitution; Female; Fluphenazine; Haloperidol; Hospitalization; Humans; Long-Term Care; Male; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Serbia; Treatment Outcome | 2011 |
Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Single-Blind Method; Trifluoperazine | 2012 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Labeling; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Nitric Oxide; Oxidative Stress; Risperidone; Schizophrenia; Superoxide Dismutase | 2012 |
Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia.
Topics: Administration, Oral; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; China; Clonazepam; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Drug Therapy, Combination; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Male; Psychomotor Agitation; Risperidone; Schizophrenia; Severity of Illness Index; Young Adult | 2012 |
No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Dizziness; Double-Blind Method; Female; Haloperidol; Humans; Hypnotics and Sedatives; Male; Neurotoxicity Syndromes; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Severity of Illness Index; Sulpiride; Time Factors; Young Adult | 2012 |
Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Weight; Child; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Hospitals, Psychiatric; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Risperidone; Treatment Outcome; Valproic Acid; Young Adult | 2012 |
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
Topics: Antipsychotic Agents; Connecticut; Delayed-Action Preparations; Drug Substitution; Female; Fluphenazine; Follow-Up Studies; Haloperidol; Humans; Hyperprolactinemia; Injections; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Microspheres; Middle Aged; Patient Compliance; Proportional Hazards Models; Risperidone; Schizophrenia; Weight Gain | 2012 |
Antipsychotic drug effects on left prefrontal phospholipid metabolism: a follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Cerebellum; Cerebral Cortex; Female; Haloperidol; Humans; Lipid Metabolism; Magnetic Resonance Spectroscopy; Male; Membrane Lipids; Middle Aged; Phospholipids; Phosphorus Isotopes; Risperidone; Schizophrenia | 2012 |
The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone.
Topics: Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Female; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Suicidal Ideation | 2012 |
Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Psychiatric Status Rating Scales; Retrospective Studies; Risperidone; Schizophrenia; Young Adult | 2012 |
Akathisia and suicidal ideation in first-episode schizophrenia.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Depression; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; Humans; Male; Propranolol; Psychiatric Status Rating Scales; Psychomotor Agitation; Risperidone; Schizophrenia; Suicidal Ideation; Young Adult | 2012 |
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Time Factors; Urea; Young Adult | 2012 |
Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients?
Topics: Adult; Antipsychotic Agents; Disease Progression; Double-Blind Method; Female; Haloperidol; Humans; Longitudinal Studies; Male; Risperidone; ROC Curve; Schizophrenia; Time Factors; Treatment Outcome; Young Adult | 2013 |
The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Cognition Disorders; Delayed-Action Preparations; Diagnosis, Computer-Assisted; Executive Function; Female; Haloperidol; Humans; Injections; Male; Memory; Middle Aged; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Time Factors; Treatment Outcome | 2012 |
Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Prolactin; Prospective Studies; Psychotic Disorders; Risperidone; Time Factors; Treatment Outcome; Young Adult | 2012 |
Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Cognition; Double-Blind Method; Female; Haloperidol; Humans; Hypnotics and Sedatives; Male; Piperazines; Psychomotor Performance; Quinolones; Risperidone; Sulpiride; Treatment Outcome; Young Adult | 2012 |
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Educational Status; Female; Haloperidol; Humans; Logistic Models; Longitudinal Studies; Male; Olanzapine; Prognosis; Psychotic Disorders; Remission Induction; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Time-to-Treatment; Young Adult | 2013 |
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Female; Follow-Up Studies; Haloperidol; Humans; Longitudinal Studies; Male; Olanzapine; Prospective Studies; Psychotic Disorders; Risperidone; Schizophrenia; Time Factors; Treatment Outcome; Young Adult | 2013 |
Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Female; Haloperidol; Humans; Male; Marijuana Smoking; Middle Aged; Models, Psychological; Olanzapine; Prognosis; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Sex Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Metabolic Diseases; Middle Aged; Olanzapine; Prospective Studies; Psychotic Disorders; Risk Factors; Risperidone; Time Factors; Weight Gain; Young Adult | 2014 |
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Hostility; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles | 2014 |
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Sex Factors; Switzerland; Time Factors; Treatment Outcome; Young Adult | 2014 |
Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Corpus Striatum; Cross-Over Studies; Double-Blind Method; Female; Haloperidol; Humans; Male; Receptors, Dopamine D2; Risperidone; Young Adult | 2013 |
Management of depressive symptoms in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzocycloheptenes; Double-Blind Method; Female; Haloperidol; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2015 |
Urine testing for antipsychotics: a pilot trial for a method to determine detection levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biological Assay; Chromatography, Liquid; Haloperidol; Humans; Male; Mass Spectrometry; Medication Adherence; Middle Aged; Olanzapine; Pilot Projects; Quetiapine Fumarate; Risperidone | 2015 |
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Delayed-Action Preparations; Female; Haloperidol; Humans; Hyperprolactinemia; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Perphenazine; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Failure; Treatment Outcome | 2016 |
Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Australia; Delirium; Double-Blind Method; Female; Geriatric Assessment; Haloperidol; Humans; Male; Palliative Care; Placebos; Risperidone; Treatment Outcome | 2017 |
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2017 |
An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Brain Mapping; Cerebrovascular Circulation; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Risperidone; Young Adult | 2018 |
Increased cerebral blood flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles.
Topics: Adult; Antipsychotic Agents; Benzamides; Brain; Cerebrovascular Circulation; Cross-Over Studies; Dopamine D2 Receptor Antagonists; Double-Blind Method; Fluorine Radioisotopes; Haloperidol; Healthy Volunteers; Humans; Olanzapine; Positron-Emission Tomography; Receptors, Dopamine D2; Risperidone; RNA, Messenger; Spin Labels | 2019 |
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2020 |
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Neoplasms; Olanzapine; Risperidone | 2020 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fumarate; Risperidone; Schizophrenia; Treatment Outcome | 2023 |
The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Glucose; Haloperidol; Humans; Inflammation; Olanzapine; Perphenazine; Quetiapine Fumarate; Risperidone; Schizophrenia | 2024 |
620 other study(ies) available for risperidone and haloperidol
| Article | Year |
|---|---|
Pyrrole mannich bases as potential antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Male; Mannich Bases; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Serotonin; Structure-Activity Relationship | 1992 |
Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles.
Topics: Animals; Antipsychotic Agents; Dopamine Antagonists; Imidazoles; Indoles; Male; Mice; Piperazines; Quipazine; Rats; Rats, Inbred Strains; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship | 1992 |
Synthesis and biological evaluation of a series of substituted N-alkoxyimides and -amides as potential atypical antipsychotic agents.
Topics: Amides; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Catalepsy; Chemical Phenomena; Chemistry; Drug Evaluation, Preclinical; Imides; Male; Mice; Molecular Structure; Motor Activity; Phthalimides; Piperazines; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Serotonin; Self Stimulation; Social Behavior; Spiro Compounds; Stereotyped Behavior; Thiazoles | 1991 |
3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873).
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Dopamine Antagonists; In Vitro Techniques; Isoxazoles; Male; Piperidines; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship | 1995 |
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.
Topics: Animals; Antipsychotic Agents; Cell Line; Molecular Structure; Rats; Receptors, Serotonin | 1994 |
Benzisoxazole- and benzisothiazole-3-carboxamides as potential atypical antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Isoxazoles; Male; Mice; Rats; Rats, Wistar; Stereotyped Behavior; Structure-Activity Relationship; Thiazoles | 1994 |
3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Brain; Catalepsy; Clozapine; Dopamine; Drug Design; Humans; Molecular Structure; Phosphatidylinositols; Piperazines; Prazosin; Rats; Receptors, Adrenergic; Receptors, Dopamine; Serotonin Antagonists; Thiazoles | 1996 |
7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Biological Availability; Catalepsy; Chromones; Male; Mice; Molecular Structure; Motor Activity; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Structure-Activity Relationship | 1996 |
Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Binding, Competitive; Cell Line; CHO Cells; Cricetinae; Humans; Male; Molecular Structure; Motor Activity; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Serotonin; Spiperone; Spiro Compounds; Stereotyped Behavior; Structure-Activity Relationship; Thiazoles; Thiazolidines | 1996 |
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Topics: Animals; Antipsychotic Agents; Brain; Cells, Cultured; Clozapine; Haloperidol; Humans; Male; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Risperidone | 1996 |
Iloperidone binding to human and rat dopamine and 5-HT receptors.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; CHO Cells; Cricetinae; Humans; Isoxazoles; Kinetics; Piperidines; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D4; Receptors, Dopamine D5; Receptors, Serotonin | 1996 |
Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptors.
Topics: Adrenergic Agents; Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Cerebral Cortex; Conditioning, Psychological; Corpus Striatum; Dopamine Agents; Humans; Male; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Agents; Structure-Activity Relationship | 1998 |
Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; COS Cells; Mutagenesis, Site-Directed; Phosphatidylinositols; Protein Conformation; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Serotonin; Serotonin Receptor Agonists; Structure-Activity Relationship | 1998 |
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
Topics: Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Agents; Sulfur Radioisotopes | 1998 |
Azepinoindole derivatives with high affinity for brain dopamine and serotonin receptors.
Topics: Animals; Antipsychotic Agents; Azepines; Benzazepines; Brain; Dopamine Antagonists; Drug Design; Indicators and Reagents; Indoles; Molecular Conformation; Molecular Structure; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Structure-Activity Relationship | 1998 |
7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602).
Topics: Administration, Oral; Animals; Antipsychotic Agents; Brain; Catalepsy; Cell Line; Chromones; Drug Evaluation, Preclinical; Guinea Pigs; Humans; Isoxazoles; Male; Mice; Motor Activity; Prolactin; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Neurotransmitter; Stereotyped Behavior; Structure-Activity Relationship | 1998 |
Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical an
Topics: Animals; Antipsychotic Agents; Aorta, Thoracic; Brain; Catalepsy; Cattle; Dopamine Agents; In Vitro Techniques; Isoxazoles; Male; Mice; Models, Molecular; Motor Activity; Muscle Contraction; Muscle, Smooth, Vascular; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Agents; Structure-Activity Relationship; Thiophenes | 1999 |
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Dioxanes; Dopamine Antagonists; Drug Evaluation, Preclinical; Humans; In Vitro Techniques; Male; Mice; Motor Activity; Piperidines; Rats; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Recombinant Proteins; Serotonin Receptor Agonists; Stereoisomerism; Stereotyped Behavior; Structure-Activity Relationship; Swine | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Binding, Competitive; Butyrophenones; Catalepsy; Cattle; Corpus Striatum; Frontal Lobe; Humans; In Vitro Techniques; Isoxazoles; Male; Mice; Piperidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2B; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Serotonin; Retina | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzoxazoles; Dopamine Antagonists; Drug Design; Drug Evaluation, Preclinical; Mice; Piperazines; Rats; Receptors, Dopamine D2; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Receptor Agonists; Spiperone; Structure-Activity Relationship | 2001 |
New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.
Topics: Animals; Aorta; Butyrophenones; CHO Cells; Cricetinae; Cycloparaffins; Frontal Lobe; Heterocyclic Compounds; Humans; In Vitro Techniques; Ligands; Male; Models, Molecular; Muscle, Smooth, Vascular; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2B; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Serotonin Antagonists; Stomach | 2002 |
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.
Topics: Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodiazepines; Binding, Competitive; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Humans; Kinetics; Olanzapine; Pirenzepine; Quetiapine Fumarate; Recombinant Proteins; Risperidone | 2002 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Chemoenzymatic synthesis and binding affinity of novel (R)- and (S)-3-aminomethyl-1-tetralones, potential atypical antipsychotics.
Topics: Antipsychotic Agents; Binding Sites; Haloperidol; Lipase; Pseudomonas fluorescens; Receptors, Dopamine D2; Receptors, Serotonin; Stereoisomerism; Tetralones | 2004 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.
Topics: Animals; Binding Sites; Biochemistry; Cells, Cultured; Drug Evaluation, Preclinical; Guinea Pigs; Humans; Inhibitory Concentration 50; Ligands; Piperazines; Piperidines; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Opioid; Receptors, sigma; Serotonin 5-HT1 Receptor Agonists; Sigma-1 Receptor; Structure-Activity Relationship | 2005 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Furans; Heterocyclic Compounds, 4 or More Rings; Humans; In Vitro Techniques; Mice; Psychotropic Drugs; Radioligand Assay; Rats; Stereoisomerism; Structure-Activity Relationship | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemistry; Mice; Phosphorylation; Receptors, Histamine H1; Weight Gain | 2007 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Synthesis and binding affinity of new pyrazole and isoxazole derivatives as potential atypical antipsychotics.
Topics: Antipsychotic Agents; Chemistry, Pharmaceutical; Drug Design; Humans; Hydrogen Bonding; Isoxazoles; Kinetics; Models, Chemical; Molecular Conformation; Protein Binding; Pyrazoles; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D2; Software | 2007 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Rational design, synthesis and evaluation of (6aR( *),11bS( *))-1-(4-fluorophenyl)-4-{7-[4-(4-fluorophenyl)-4-oxobutyl]1,2,3,4,6,6a,7,11b,12,12a(RS)-decahydropyrazino[2',1':6,1]pyrido[3,4-b]indol-2-yl}-butan-1-one as a potential neuroleptic agent.
Topics: Antipsychotic Agents; Binding, Competitive; Butanones; Dopamine D2 Receptor Antagonists; Drug Design; Indoles; Molecular Structure; Receptors, Dopamine D1; Serotonin 5-HT2 Receptor Antagonists; Stereoisomerism; Structure-Activity Relationship | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
Topics: Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Cloning, Molecular; Clozapine; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Histamine Release; Humans; Inhibitory Concentration 50; Molecular Structure; Olanzapine; Psychotropic Drugs; Radioligand Assay; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Muscarinic; Receptors, Serotonin; Schizophrenia; Substrate Specificity | 2009 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
Topics: Animals; Antipsychotic Agents; Apomorphine; Azepines; Butyrophenones; Clozapine; Haloperidol; Lethal Dose 50; Male; Mice; Molecular Structure; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents.
Topics: Acetamides; Animals; Antipsychotic Agents; Combinatorial Chemistry Techniques; Disease Models, Animal; Head Movements; Mice; Molecular Structure; Motor Activity; Piperazines; Quipazine; Serotonin 5-HT2 Receptor Antagonists | 2008 |
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Binding Sites; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mice; Models, Molecular; Molecular Structure; Protein Binding; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Structure-Activity Relationship | 2009 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors.
Topics: Binding Sites; Computer Simulation; Databases, Factual; Models, Chemical; Models, Molecular; Molecular Structure; Molecular Weight; Psychotropic Drugs; Serotonin 5-HT3 Receptor Antagonists; Structure-Activity Relationship | 2009 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Topics: Binding Sites; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Models, Molecular; Potassium Channel Blockers; Protein Binding; Protein Conformation | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif.
Topics: Animals; Antipsychotic Agents; Blood-Brain Barrier; CHO Cells; Cricetinae; Cricetulus; Humans; Quinazolinones; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
Molecular properties affecting fast dissociation from the D2 receptor.
Topics: Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Drug Design; Humans; Molecular Structure; Receptors, Dopamine D2; Structure-Activity Relationship | 2011 |
Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
Topics: Animals; Cyclic AMP; Cyclic GMP; Humans; Hydrolysis; Mice; Models, Molecular; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.
Topics: Animals; Antipsychotic Agents; Berberine; Berberine Alkaloids; CHO Cells; Cricetinae; Cricetulus; Dopamine D2 Receptor Antagonists; HEK293 Cells; Humans; Microwaves; Motor Activity; Protein Binding; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D1; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship | 2013 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Biological Availability; Coumarins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; In Vitro Techniques; Isoxazoles; Lethal Dose 50; Mice; Motor Activity; Prolactin; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Dopamine D3; Structure-Activity Relationship; Weight Gain | 2013 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Synthesis and biological evaluation of a series of aminoalkyl-tetralones and tetralols as dual dopamine/serotonin ligands.
Topics: Antipsychotic Agents; Dopamine; Dopamine D2 Receptor Antagonists; Humans; Ligands; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Tetralones | 2014 |
Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Coumarins; Magnetic Resonance Spectroscopy; Mice; Spectrometry, Mass, Electrospray Ionization | 2014 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; CHO Cells; Cricetulus; Dementia; Dopamine D2 Receptor Antagonists; HEK293 Cells; Humans; Male; Models, Molecular; Motor Activity; Radioligand Assay; Rats, Wistar; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Sulfonamides | 2014 |
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
Topics: Amides; Animals; Antipsychotic Agents; Behavior, Animal; Dizocilpine Maleate; Dopamine Antagonists; Drug Evaluation, Preclinical; Female; Kinetics; Ligands; Male; Mice; Prefrontal Cortex; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Schizophrenia; Serotonin Receptor Agonists; Structure-Activity Relationship | 2014 |
Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Binding Sites; Disease Models, Animal; Models, Molecular; Molecular Structure; Piperazine; Piperazines; Purines; Pyrimidinones; Structure-Activity Relationship | 2015 |
Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics.
Topics: Animals; Antipsychotic Agents; Ether-A-Go-Go Potassium Channels; Humans; Mice; Oxazoles; Patch-Clamp Techniques; Piperazines; Piperidines; Potassium Channel Blockers; Rats; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Agonists; Structure-Activity Relationship; Swine | 2015 |
Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics.
Topics: Animals; Antipsychotic Agents; Binding Sites; Drug Delivery Systems; Drug Design; Mice; Molecular Structure; Nitroimidazoles; Protein Binding; Pyridazines; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A | 2016 |
Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.
Topics: Animals; Antipsychotic Agents; Body Weight; Chemistry Techniques, Synthetic; Drug Design; Ether-A-Go-Go Potassium Channels; Heterocyclic Compounds; Memory; Mice; Piperazine; Rats; Schizophrenia; Structure-Activity Relationship; Tissue Distribution | 2018 |
Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
Topics: Cell Death; Computer Simulation; Diacylglycerol Kinase; Drug Evaluation, Preclinical; Humans; Lymphoproliferative Disorders; Piperidines; Protein Kinase Inhibitors; Pyrimidinones; Quinazolinones; Ritanserin; Thiazoles | 2019 |
Discovery of aryl-piperidine derivatives as potential antipsychotic agents using molecular hybridization strategy.
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Discovery; HEK293 Cells; Humans; Mice; Mice, Inbred ICR; Models, Molecular; Molecular Structure; Piperidines; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Serotonin Antagonists; Structure-Activity Relationship | 2020 |
Synthesis and pharmacological evaluation of piperidine (piperazine)-amide substituted derivatives as multi-target antipsychotics.
Topics: Amides; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Humans; Ligands; Molecular Structure; Piperazine; Piperidines; Rats; Receptors, Dopamine D2; Receptors, Serotonin; Schizophrenia; Structure-Activity Relationship | 2020 |
Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition; Dopamine; Drug Design; Humans; Hyperprolactinemia; Mice; Models, Animal; Movement; Piperidines; Protein Binding; Receptors, Histamine H3; Risperidone; Serotonin; Structure-Activity Relationship; Weight Gain | 2021 |
Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Topics: Animals; Antiemetics; Antipsychotic Agents; Apomorphine; Behavior, Animal; Body Temperature; Dogs; Dopamine Agents; Dopamine Antagonists; Eating; Female; Haloperidol; Isoxazoles; Lethal Dose 50; Locomotion; Male; Mice; Motor Activity; Muscles; Neurotransmitter Agents; Piperidines; Posture; Pyrimidinones; Rats; Rats, Inbred Strains; Risperidone; Ritanserin; Serotonin; Serotonin Antagonists; Synaptic Transmission | 1992 |
Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Isoxazoles; Male; Motor Activity; Piperidines; Pyrimidinones; Rats; Rats, Inbred Strains; Risperidone | 1992 |
In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
Topics: Animals; Antipsychotic Agents; Biogenic Monoamines; Brain; Female; Haloperidol; In Vitro Techniques; Isoxazoles; Male; Neurotransmitter Agents; Piperidines; Pyrimidinones; Rats; Rats, Inbred Strains; Receptors, Cell Surface; Risperidone; Spiperone; Tissue Distribution | 1992 |
Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Haloperidol; Isoxazoles; Ketanserin; Male; Piperidines; Pituitary Gland; Prolactin; Rats; Rats, Inbred Strains; Risperidone; Spiro Compounds; Stimulation, Chemical | 1992 |
Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine.
Topics: Animals; Antipsychotic Agents; Apomorphine; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Injections, Intravenous; Isoxazoles; Male; Piperidines; Rats; Rats, Inbred Strains; Risperidone; Ritanserin; Seizures; Serotonin; Serotonin Antagonists; Synaptic Transmission; Tryptamines | 1990 |
Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Conditioning, Psychological; Dogs; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Haloperidol; Isoxazoles; Male; Motor Activity; Oxazoles; Piperidines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D2; Risperidone; Serotonin Antagonists | 1988 |
Biochemical profile of risperidone, a new antipsychotic.
Topics: Animals; Antipsychotic Agents; Blood Platelets; Cerebral Cortex; Dopamine; Ergolines; Female; Haloperidol; Isoxazoles; Models, Molecular; Norepinephrine; Oxazoles; Phosphatidic Acids; Piperidines; Quinpirole; Radioligand Assay; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Ritanserin; X-Ray Diffraction | 1988 |
Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol.
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Haloperidol; Isoxazoles; Male; Motor Activity; Oxazoles; Piperidines; Rats; Rats, Inbred Strains; Risperidone | 1988 |
5-HT2 receptor antagonists do not reduce ethanol preference in Sardinian alcohol-preferring (sP) rats.
Topics: Alcohol Drinking; Animals; Antipsychotic Agents; Haloperidol; Isoxazoles; Male; Piperidines; Rats; Risperidone; Ritanserin; Serotonin Antagonists | 1993 |
Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
Topics: Animals; Antipsychotic Agents; Apomorphine; Autoradiography; Behavior, Animal; Clozapine; Guinea Pigs; Haloperidol; In Vitro Techniques; Iodine Radioisotopes; Isoxazoles; Male; Mescaline; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Neurotransmitter; Receptors, Serotonin; Risperidone; Stereotyped Behavior | 1993 |
Pharmacological action of zotepine and other antipsychotics on central 5-hydroxytryptamine receptor subtypes.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Body Temperature; Clozapine; Dibenzothiepins; Exploratory Behavior; Haloperidol; Isoxazoles; Male; Mice; Motor Activity; Piperazines; Piperidines; Rats; Rats, Wistar; Receptors, Serotonin; Risperidone; Serotonin Antagonists; Serotonin Receptor Agonists | 1994 |
Serotonin2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs.
Topics: Action Potentials; Animals; Antipsychotic Agents; Bicuculline; Cerebral Cortex; Chlorpromazine; Clozapine; Electrophysiology; gamma-Aminobutyric Acid; Haloperidol; In Vitro Techniques; Interneurons; Isoxazoles; Male; Membrane Potentials; Piperidines; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Risperidone; Serotonin Antagonists | 1994 |
Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Butyrophenones; Dogs; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; In Vitro Techniques; Isoxazoles; Lysergic Acid Diethylamide; Motor Activity; Neostriatum; Oxygen Consumption; Piperidines; Rats; Risperidone; Schizophrenia; Serotonin Antagonists; Species Specificity; Tryptamines | 1994 |
In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol.
Topics: Animals; Antipsychotic Agents; Benzamides; Brain; Cerebellum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; In Vitro Techniques; Isoxazoles; Ketanserin; Ligands; Male; Neostriatum; Piperidines; Prefrontal Cortex; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone | 1994 |
Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Topics: Animals; Antipsychotic Agents; Brain; Clone Cells; Clozapine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Guinea Pigs; Haloperidol; Humans; Isoxazoles; Paliperidone Palmitate; Piperidines; Pyrimidines; Rats; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Serotonin Antagonists | 1994 |
Risperidone-induced neuroleptic malignant syndrome in young patient.
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Isoxazoles; Male; Neuroleptic Malignant Syndrome; Piperidines; Risperidone | 1994 |
Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.
Topics: Animals; Antipsychotic Agents; Autoradiography; Clozapine; Haloperidol; In Vitro Techniques; Isoxazoles; Male; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Receptors, Neurotransmitter; Receptors, Serotonin; Risperidone | 1993 |
Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Conditioning, Operant; Dose-Response Relationship, Drug; Haloperidol; Isoxazoles; Male; Piperidines; Rats; Rats, Wistar; Remoxipride; Risperidone; Serotonin Antagonists; Sulpiride | 1995 |
Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Frontal Lobe; Haloperidol; Homovanillic Acid; Hydroxyindoleacetic Acid; Injections, Intraperitoneal; Isoxazoles; Locomotion; Male; Phencyclidine; Piperidines; Random Allocation; Rats; Rats, Wistar; Risperidone; Ritanserin; Schizophrenia; Serotonin; Stereotyped Behavior | 1994 |
Risperidone prevents the development of supersensitivity, but not tolerance, to phencyclidine in rats treated with subacute phencyclidine.
Topics: Animals; Antipsychotic Agents; Dizocilpine Maleate; Drug Tolerance; Haloperidol; Isoxazoles; Male; Methamphetamine; Motor Activity; Phencyclidine; Piperidines; Rats; Rats, Wistar; Receptors, Phencyclidine; Receptors, Serotonin; Risperidone; Ritanserin | 1995 |
Schizophrenia and severe tardive dyskinesia responsive to risperidone.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Isoxazoles; Neurologic Examination; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Chlordiazepoxide; Clozapine; Columbidae; Conditioning, Operant; Dose-Response Relationship, Drug; Haloperidol; Isoxazoles; Male; Olanzapine; Piperidines; Pirenzepine; Punishment; Risperidone | 1995 |
The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Clozapine; Dopamine Antagonists; Haloperidol; Isoxazoles; Male; Mice; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Risperidone; Saimiri; Serotonin Antagonists | 1995 |
Suppression of alcohol preference in rats induced by risperidone, a serotonin 5-HT2 and dopamine D2 receptor antagonist.
Topics: Alcohol Drinking; Animals; Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Haloperidol; Isoxazoles; Male; Piperidines; Rats; Rats, Wistar; Risperidone; Serotonin Antagonists | 1993 |
Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo.
Topics: Animals; Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Haloperidol; Isoxazoles; Male; Piperidines; Quinolines; Rats; Rats, Wistar; Receptors, Dopamine D1; Risperidone; Serotonin Antagonists | 1993 |
Effects of atypical antipsychotic agents on social behavior in rodents.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Apomorphine; Benzazepines; Catalepsy; Chlorpromazine; Clozapine; Diazepam; Haloperidol; Isoxazoles; Male; Mice; Mice, Inbred Strains; Piperidines; Raclopride; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Salicylamides; Social Behavior | 1993 |
[Effects of risperidone on catalepsy and cerebral dopamine, serotonin and GABA metabolism in the rat: comparison with haloperidol].
Topics: Animals; Antipsychotic Agents; Brain; Catalepsy; Dopamine; gamma-Aminobutyric Acid; Haloperidol; Isoxazoles; Male; Piperidines; Rats; Rats, Wistar; Risperidone; Serotonin | 1993 |
[A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
Topics: Animals; Antipsychotic Agents; Autoradiography; Brain; Chlorpromazine; Clozapine; Dibenzothiepins; Flupenthixol; Haloperidol; In Vitro Techniques; Isoxazoles; Male; Piperidines; Pyrimidinones; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Risperidone | 1993 |
Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors.
Topics: Animals; Antipsychotic Agents; Clozapine; Dibenzothiepins; Haloperidol; Isoxazoles; Male; Piperidines; Rats; Rats, Wistar; Receptors, Serotonin; Risperidone | 1993 |
Mixed D2/5-HT2A antagonism of amphetamine-induced facilitation of brain stimulation reward.
Topics: Amphetamine; Animals; Brain; Dose-Response Relationship, Drug; Haloperidol; Male; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Serotonin; Reward; Risperidone | 1995 |
[The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors].
Topics: Antipsychotic Agents; Benzazepines; Cell Line; Clozapine; Haloperidol; Humans; Raclopride; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Dopamine D5; Risperidone; Salicylamides; Spiperone | 1996 |
Cyclic GMP generation mediated by 5-HT-2 receptors via nitric oxide-dependent pathway and its effect on the desensitization of 5-HT-2 receptors in C6 glioma cells.
Topics: Animals; Arginine; Calcium; Chelating Agents; Cyclic GMP; Dopamine Antagonists; Edetic Acid; Egtazic Acid; Glioma; Haloperidol; Ketanserin; Nitric Oxide; omega-N-Methylarginine; Rats; Receptors, Serotonin; Risperidone; Serotonin Antagonists; Tropanes; Tumor Cells, Cultured | 1995 |
Comments on "Clozapine treatment after agranulocytosis induced by classic neuroleptics".
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Haloperidol; Humans; Male; Risperidone; Schizophrenia; Trifluoperazine | 1996 |
In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used.
Topics: Animals; Antipsychotic Agents; Autoradiography; Binding, Competitive; Brain; Dose-Response Relationship, Drug; Guinea Pigs; Haloperidol; In Vitro Techniques; Male; Radioligand Assay; Rats; Rats, Wistar; Risperidone | 1995 |
Managing the first episode of schizophrenia: the role of new therapies.
Topics: Haloperidol; Humans; Risperidone; Schizophrenia | 1996 |
Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.
Topics: Clozapine; Cognition; Fluphenazine; Haloperidol; Humans; Maze Learning; Risperidone; Schizophrenia | 1996 |
Cost-benefits of risperidone.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Haloperidol; Humans; Risperidone; Schizophrenia | 1996 |
Assessing a drug's cost-benefits.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Haloperidol; Humans; Psychiatric Status Rating Scales; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology | 1996 |
Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Autoradiography; Binding, Competitive; Brain Chemistry; Clozapine; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Glycine; Haloperidol; Male; Pimozide; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Risperidone; Time Factors; Tritium | 1996 |
Adverse interaction of tacrine and haloperidol.
Topics: Aged; Dementia; Drug Interactions; Drug Therapy, Combination; Female; Haloperidol; Humans; Parkinson Disease, Secondary; Risperidone; Tacrine | 1996 |
Risperidone: a novel antipsychotic with many "atypical" properties?
Topics: Animals; Antipsychotic Agents; Brain; Dopamine; Haloperidol; Male; Rats; Rats, Wistar; Risperidone; Serotonin; Time Factors | 1996 |
Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics.
Topics: Animals; Antipsychotic Agents; Clozapine; Haloperidol; Male; Maze Learning; Rats; Rats, Wistar; Risperidone | 1996 |
Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cebus; Clozapine; Dose-Response Relationship, Drug; Haloperidol; Imidazoles; Indoles; Risperidone | 1996 |
Seroquel restores sensorimotor gating in phencyclidine-treated rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Haloperidol; Male; Phencyclidine; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Reflex, Startle; Risperidone | 1996 |
Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Brain; Clozapine; Haloperidol; Male; Pimozide; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Risperidone; Tritium | 1996 |
Antipsychotics with inverse agonist activity at the dopamine D3 receptor.
Topics: Animals; Antipsychotic Agents; Calcium; CHO Cells; Clozapine; Colforsin; Cricetinae; Cyclic AMP; DNA Replication; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Flupenthixol; Glioma; Haloperidol; Humans; Hybrid Cells; Naphthalenes; Neuroblastoma; Pertussis Toxin; Phenothiazines; Pimozide; Pyrrolidines; Quinpirole; Receptors, Dopamine D2; Receptors, Dopamine D3; Recombinant Proteins; Risperidone; Salicylamides; Second Messenger Systems; Sulpiride; Tetrahydronaphthalenes; Tumor Cells, Cultured; Virulence Factors, Bordetella | 1996 |
Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzamides; Brain Mapping; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon | 1996 |
Effects of risperidone, clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons of the rat brain.
Topics: Animals; Antipsychotic Agents; Basal Ganglia; Clozapine; Dopamine Antagonists; Dose-Response Relationship, Drug; Electrophysiology; Haloperidol; Injections, Intravenous; Male; Neurons; Rats; Rats, Wistar; Receptors, Dopamine D2; Reticulocytes; Risperidone; Serotonin Antagonists; Substantia Nigra | 1997 |
Effects of acute or chronic administration of risperidone on motor and sexual behavior of male rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Behavior, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Haloperidol; Male; Motor Activity; Rats; Risperidone; Sexual Behavior, Animal; Statistics, Nonparametric | 1997 |
BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; CHO Cells; Clozapine; Corpus Striatum; COS Cells; Cricetinae; Dibenzothiazepines; Dopamine; Female; Guinea Pigs; Haloperidol; Indoles; Kidney; Male; Microdialysis; Neuroblastoma; Nucleus Accumbens; Olanzapine; Piperazines; Pirenzepine; Prefrontal Cortex; Pyridines; Quetiapine Fumarate; Radioligand Assay; Rats; Rats, Sprague-Dawley; Risperidone; Tritium; Tumor Cells, Cultured | 1997 |
Use of risperidone in psychotic disorder following ischemic brain damage.
Topics: Adult; Brain Ischemia; Haloperidol; Humans; Male; Perphenazine; Psychotic Disorders; Risperidone | 1996 |
Differential response of psychotic and obsessive symptoms to risperidone in an adolescent.
Topics: 1-Naphthylamine; Adolescent; Antidepressive Agents; Antipsychotic Agents; Clomipramine; Hallucinations; Haloperidol; Humans; Male; Obsessive-Compulsive Disorder; Psychotic Disorders; Risperidone; Sertraline; Trifluoperazine | 1996 |
Effects of clozapine, thioridazine, risperidone and haloperidol on behavioral tests related to extrapyramidal motor function.
Topics: Animals; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Conditioning, Operant; Extrapyramidal Tracts; Haloperidol; Jaw; Male; Rats; Rats, Sprague-Dawley; Risperidone; Tacrine; Thioridazine | 1997 |
Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Brain Mapping; Dopamine Antagonists; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Tomography, Emission-Computed, Single-Photon | 1997 |
Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs.
Topics: Antipsychotic Agents; Artifacts; Chromatography, High Pressure Liquid; Haloperidol; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Reproducibility of Results; Risperidone; Spectrophotometry, Ultraviolet | 1997 |
Disruption of latent inhibition in the rat by the 5-HT2 agonist DOI: effects of MDL 100,907, clozapine, risperidone and haloperidol.
Topics: Amphetamines; Animals; Antipsychotic Agents; Clozapine; Conditioning, Operant; Fluorobenzenes; Haloperidol; Male; Piperidines; Rats; Rats, Sprague-Dawley; Reflex, Startle; Reinforcement, Psychology; Risperidone; Serotonin Antagonists; Serotonin Receptor Agonists | 1997 |
A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Psychotic Disorders; Risperidone; Schizophrenia; Treatment Failure | 1997 |
The effects of the atypical antipsychotics clozapine, remoxipride and risperidone on the contractile characteristics of rat skeletal muscle in vitro.
Topics: Animals; Antipsychotic Agents; Caffeine; Clozapine; Dantrolene; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Halothane; In Vitro Techniques; Muscle Contraction; Muscle Relaxants, Central; Muscle, Skeletal; Rats; Rats, Sprague-Dawley; Remoxipride; Risperidone; Trifluoperazine | 1997 |
Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alternative Splicing; Animals; Antipsychotic Agents; Autoradiography; Binding, Competitive; Brain Chemistry; Clozapine; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Gene Expression; Haloperidol; In Situ Hybridization; Male; Pimozide; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Risperidone; RNA, Messenger; Sodium Chloride; Tritium | 1998 |
Activation of midline thalamic nuclei by antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Brain; Haloperidol; Male; Proto-Oncogene Proteins c-fos; Raclopride; Rats; Rats, Sprague-Dawley; Risperidone; Salicylamides; Thalamic Nuclei; Thioridazine | 1998 |
Catatonia in an adolescent with Prader-Willi Syndrome.
Topics: Adolescent; Antipsychotic Agents; Catatonia; Haloperidol; Humans; Lorazepam; Male; Neurologic Examination; Neuropsychological Tests; Prader-Willi Syndrome; Risperidone; Treatment Outcome | 1997 |
Effects of risperidone and haloperidol on tachykinin and opioid precursor peptide mRNA levels in the caudate-putamen and nucleus accumbens of the rat.
Topics: Animals; Antipsychotic Agents; Caudate Nucleus; Corpus Striatum; Enkephalins; Haloperidol; Male; Nucleus Accumbens; Protein Precursors; Putamen; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Ritanserin; RNA, Messenger; Tachykinins | 1998 |
Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
Topics: Adult; Antipsychotic Agents; Benzamides; Clozapine; Female; Haloperidol; Humans; Imidazoles; Indoles; Iodine Radioisotopes; Male; Middle Aged; Neostriatum; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1998 |
Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzamides; Brain; Dopamine Antagonists; Haloperidol; Humans; Middle Aged; Psychomotor Disorders; Pyrrolidines; Reaction Time; Receptors, Dopamine; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1998 |
Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Brain; Clozapine; Contrast Media; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Iodine Radioisotopes; Male; Middle Aged; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1998 |
APA Practice Guideline for schizophrenia: risperidone equivalents. American Psychiatric Association.
Topics: Drug Administration Schedule; Haloperidol; Humans; Practice Guidelines as Topic; Psychiatry; Risperidone; Schizophrenia; Societies, Medical; Therapeutic Equivalency | 1998 |
[A study of neuroleptic malignant syndrome in the presenium and senium].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Female; Haloperidol; Humans; Male; Methotrimeprazine; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Risperidone; Schizophrenia | 1998 |
Research and treatment strategies in first-episode psychoses. The Pittsburgh experience.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain Diseases; Developmental Disabilities; Episode of Care; Female; Haloperidol; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Prospective Studies; Risperidone; Schizophrenia | 1998 |
Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain.
Topics: Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Clozapine; Haloperidol; Imidazoles; Indoles; Injections, Intraperitoneal; Male; Neural Inhibition; Olanzapine; Pirenzepine; Prazosin; Rats; Rats, Wistar; Reflex, Startle; Remoxipride; Risperidone; Ritanserin; Serotonin Antagonists | 1997 |
Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine; Dopamine Agonists; Extracellular Space; Haloperidol; Male; Norepinephrine; Olanzapine; Piperazines; Pirenzepine; Prefrontal Cortex; Rats; Rats, Wistar; Reference Values; Risperidone; Tetrahydronaphthalenes; Thiazoles | 1998 |
Prolongation of QT interval in isolated feline hearts by antipsychotic drugs.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Cats; Clozapine; Electrocardiography; Haloperidol; Heart; Humans; Imidazoles; In Vitro Techniques; Indoles; Risperidone | 1998 |
Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Topics: Antipsychotic Agents; Baltimore; Chronic Disease; Delayed-Action Preparations; Disease-Free Survival; Female; Fluphenazine; Haloperidol; Humans; Length of Stay; Male; Patient Readmission; Risperidone; Schizophrenia; Time Factors | 1998 |
Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone.
Topics: Adult; Female; Haloperidol; Humans; Male; Middle Aged; Mood Disorders; Prospective Studies; Risperidone; Schizophrenia | 1999 |
A cost-effectiveness clinical decision analysis model for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; Decision Support Systems, Clinical; Haloperidol; Humans; Markov Chains; Olanzapine; Pirenzepine; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Treatment Outcome; United States | 1998 |
Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone.
Topics: Adult; Antipsychotic Agents; Dopamine Antagonists; Haloperidol; Humans; Male; Middle Aged; Pituitary Hormones; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Testicular Hormones | 1999 |
Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo.
Topics: 3T3 Cells; Animals; Antipsychotic Agents; Benzodiazepines; Cell Line; Clozapine; Dendrites; Fluorobenzenes; Haloperidol; Mianserin; Mice; Olanzapine; Piperidines; Pirenzepine; Prefrontal Cortex; Pyramidal Cells; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Recombinant Proteins; Risperidone; Ritanserin; Serotonin Antagonists; Transfection | 1999 |
Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.
Topics: Aged; Antipsychotic Agents; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Incidence; Male; Mental Disorders; Middle Aged; Proportional Hazards Models; Prospective Studies; Risk Factors; Risperidone; Time Factors | 1999 |
Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Nortropanes; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Risperidone; Schizophrenia | 1999 |
Stimulation of dopamine release in the bed nucleus of stria terminalis. A trait of atypical antipsychotics?
Topics: Amygdala; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine; Haloperidol; Indoles; Male; Olanzapine; Pirenzepine; Pyridines; Raclopride; Rats; Rats, Sprague-Dawley; Risperidone; Salicylamides; Thalamus | 1999 |
In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats.
Topics: Animals; Antipsychotic Agents; Binding, Competitive; Cerebral Cortex; Clozapine; Corpus Striatum; Dopamine Antagonists; Haloperidol; Male; Nucleus Accumbens; Pyrrolidines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 1999 |
Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors.
Topics: Amisulpride; Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Dopamine Agonists; Free Radical Scavengers; Guinea Pigs; Haloperidol; Head Movements; Male; Mice; Phenazocine; Phencyclidine; Piperazines; Pyrrolidines; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin; Receptors, sigma; Risperidone; Serotonin; Serotonin Antagonists; Stereotyped Behavior; Sulpiride; Tartrates | 1999 |
Some behavioural effects of risperidone in rats: comparison with haloperidol.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Drug Evaluation, Preclinical; Exploratory Behavior; Haloperidol; Male; Maze Learning; Motor Activity; Rats; Rats, Wistar; Risperidone; Schizophrenia | 1999 |
Negative symptoms due to sleep apnea syndrome in a patient with a delusional disorder.
Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Delusions; Haloperidol; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Risperidone; Severity of Illness Index; Sleep Apnea Syndromes | 1999 |
Effects of atypical antipsychotic drugs vs. haloperidol on expression of heat shock protein in the discrete brain regions of phencyclidine-treated rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Corpus Striatum; Gene Expression Regulation; Gyrus Cinguli; Haloperidol; HSP70 Heat-Shock Proteins; Male; Nucleus Accumbens; Olanzapine; Phencyclidine; Pirenzepine; Prefrontal Cortex; Rats; Rats, Wistar; Risperidone; RNA, Messenger | 1999 |
Recommended haloperidol and risperidone doses in first-episode psychosis.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Psychotic Disorders; Risperidone; Schizophrenia; Treatment Outcome | 1999 |
[Neuro-cognition and schizophrenia. 11th World Congress for Psychiatry. Hamburg, 8 August 1999].
Topics: Antipsychotic Agents; Cognition Disorders; Haloperidol; Humans; Risperidone; Schizophrenia | 1999 |
Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Prolactin; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome | 1999 |
Olanzapine. Keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clinical Trials as Topic; Dopamine Antagonists; Double-Blind Method; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2000 |
The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Clozapine; Corpus Striatum; Dopamine; Fluorobenzenes; Haloperidol; Male; Microdialysis; Nucleus Accumbens; Piperazines; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Risperidone; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Tritium | 2000 |
Effect of atypical antipsychotics on phencyclidine-induced expression of arc in rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cytoskeletal Proteins; Gene Expression; Haloperidol; Male; Nerve Tissue Proteins; Olanzapine; Phencyclidine; Pirenzepine; Rats; Rats, Wistar; Risperidone; RNA, Messenger; Tissue Distribution | 2000 |
Treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Haloperidol; Humans; Risperidone | 2000 |
Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Dose-Response Relationship, Drug; Haloperidol; Humans; Incidence; Risperidone; Schizophrenia | 2000 |
The discriminative stimulus properties of the atypical antipsychotic olanzapine in rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Discrimination Learning; Generalization, Psychological; Haloperidol; Male; Olanzapine; Pirenzepine; Raclopride; Rats; Rats, Sprague-Dawley; Risperidone; Ritanserin; Scopolamine | 2000 |
Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory.
Topics: Animals; Antipsychotic Agents; Benzazepines; Brain; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Interneurons; Male; Memory Disorders; Memory, Short-Term; Phencyclidine; Rats; Risperidone; Schizophrenia; Spiperone | 2000 |
Treating Charles Bonnet syndrome: understanding inconsistency.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Hallucinations; Haloperidol; Humans; Male; Psychotic Disorders; Risperidone; Syndrome | 2000 |
[Diminution of hand writing area and D2-dopamine receptor blockade. Results from treatment with typical and atypical neuroleptics].
Topics: Adult; Aged; Antipsychotic Agents; Benzamides; Clozapine; Dopamine Antagonists; Female; Haloperidol; Handwriting; Humans; Male; Middle Aged; Neostriatum; Pyrrolidines; Receptors, Dopamine; Risperidone; Schizophrenia, Paranoid; Therapeutic Equivalency; Tomography, Emission-Computed, Single-Photon | 2000 |
Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Dizocilpine Maleate; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Haloperidol; Immunohistochemistry; In Situ Hybridization; Limbic System; Nervous System; Olanzapine; Pirenzepine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Risperidone; RNA, Messenger | 2000 |
Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration.
Topics: Animals; Antipsychotic Agents; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Feeding Behavior; Haloperidol; Hippocampus; Male; Mesencephalon; Organ Size; Osmolar Concentration; Rats; Rats, Wistar; Receptor, trkB; Risperidone; Time Factors | 2000 |
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Utilization; Female; Haloperidol; Humans; Male; Olanzapine; Pharmacoepidemiology; Pirenzepine; Practice Patterns, Physicians'; Prospective Studies; Risperidone; Schizophrenia | 2000 |
Increased levels of transcription factors Elk-1, cyclic adenosine monophosphate response element-binding protein, and activating transcription factor 2 in the cerebellar vermis of schizophrenic patients.
Topics: Activating Transcription Factor 2; Adult; Aged; Animals; Cerebellum; Cyclic AMP Receptor Protein; Cyclic AMP Response Element-Binding Protein; DNA-Binding Proteins; ets-Domain Protein Elk-1; Female; Haloperidol; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins; Rats; Risperidone; Schizophrenia; Signal Transduction; Transcription Factors | 2000 |
Effects of typical and atypical antipsychotics on neuropeptide Y in rat brain tissue and microdialysates from ventral striatum.
Topics: Animals; Antipsychotic Agents; Basal Ganglia; Dextroamphetamine; Haloperidol; Male; Microdialysis; Neuropeptide Y; Rats; Rats, Wistar; Risperidone; Sympathomimetics | 2000 |
Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Costs and Cost Analysis; Haloperidol; Health Care Costs; Humans; Markov Chains; Models, Economic; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; United Kingdom | 2000 |
The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus.
Topics: Animals; Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Haloperidol; Hippocampus; Hydroxyindoleacetic Acid; Ketanserin; Male; Raclopride; Rats; Rats, Wistar; Risperidone; Serotonin | 2000 |
Severe self-injurious behavior associated with treatment-resistant schizophrenia: treatment with maintenance electroconvulsive therapy.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Electroconvulsive Therapy; Haloperidol; Humans; Male; Risperidone; Schizophrenia; Schizophrenic Psychology; Self-Injurious Behavior | 2000 |
Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone.
Topics: Antipsychotic Agents; Haloperidol; Humans; Risperidone; Schizophrenia | 2000 |
Characterization of inhibition by risperidone of the inwardly rectifying K(+) current in pituitary GH(3) cells.
Topics: Action Potentials; Animals; Antipsychotic Agents; Calcium Channels; Haloperidol; Hyperprolactinemia; Membrane Potentials; Pituitary Gland; Potassium Channels; Rats; Receptors, Dopamine; Risperidone; Tumor Cells, Cultured | 2000 |
The effect of the antipsychotic drug mosapramine on the expression of Fos protein in the rat brain: comparison with haloperidol, clozapine and risperidone.
Topics: Animals; Antipsychotic Agents; Benzazepines; Brain; Clozapine; Corpus Striatum; Gene Expression Regulation; Genes, fos; Haloperidol; Immunohistochemistry; Male; Neurons; Nucleus Accumbens; Prefrontal Cortex; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Risperidone | 2000 |
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone | 2000 |
The serotonin 5-HT(2A) receptor subtype does not mediate apomorphine-induced aggressive behaviour in male Wistar rats.
Topics: Aggression; Animals; Apomorphine; Behavior, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Haloperidol; Ketanserin; Male; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Ritanserin; Serotonin Antagonists; Time Factors | 2000 |
The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex.
Topics: Animals; Clozapine; Cocaine; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Frontal Lobe; Haloperidol; Ketanserin; Male; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Risperidone; Ritanserin; Serotonin Antagonists; Synaptosomes; Tritium | 2000 |
Full remission of panic attacks in a schizophrenic patient after switching from haloperidol to risperidone.
Topics: Adult; Female; Haloperidol; Humans; Panic Disorder; Remission, Spontaneous; Risperidone; Schizophrenia | 2001 |
Acute phase of schizophrenia: impact of atypical antipsychotics.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Haloperidol; Humans; Prognosis; Recurrence; Risperidone; Schizophrenia; Severity of Illness Index; Sulpiride | 2000 |
Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Drug Therapy, Combination; Emergency Services, Psychiatric; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Lorazepam; Male; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Risperidone; Treatment Outcome; Violence | 2001 |
Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone.
Topics: Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Male; Risperidone; Schizophrenia; Sexual Dysfunction, Physiological | 2001 |
Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Risperidone; Treatment Outcome | 2001 |
Neuroleptic malignant syndrome during a change from haloperidol to risperidone.
Topics: Antipsychotic Agents; Haloperidol; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Risperidone; Schizophrenia | 2001 |
A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Databases, Factual; Double-Blind Method; Factor Analysis, Statistical; Female; Haloperidol; Humans; Male; Middle Aged; Risperidone; Schizophrenia | 2001 |
Asymmetrical hand force persistence and neuroleptic treatment in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Functional Laterality; Haloperidol; Hand Strength; Humans; Isometric Contraction; Male; Motor Skills; Neuropsychological Tests; Risperidone; Schizophrenia | 2001 |
Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
Topics: Adult; Antipsychotic Agents; Clomipramine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; Male; Prolactin; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Risperidone; Schizophrenia; Serotonin Antagonists | 2001 |
Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Binding Sites; Binding, Competitive; Cell Line; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Haloperidol; Humans; Neurons; Norepinephrine; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Rats; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Risperidone; Serotonin; Serotonin Antagonists; Thiazoles | 2001 |
Chronic treatment with certain antipsychotic drugs preserves upregulation of regulator of G-protein signalling 2 mRNA in rat striatum as opposed to c-fos mRNA.
Topics: Animals; Antipsychotic Agents; Clozapine; Drug Administration Schedule; GTP-Binding Proteins; Haloperidol; In Situ Hybridization; Male; Neostriatum; Neurons; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; RGS Proteins; Risperidone; RNA, Messenger; Signal Transduction; Up-Regulation | 2001 |
Atypical neuroleptic drugs downregulate dopamine sensitivity in rat cortical and striatal astrocytes.
Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Antipsychotic Agents; Astrocytes; Benzodiazepines; Calcium; Calcium Signaling; Cells, Cultured; Cerebral Cortex; Clozapine; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Down-Regulation; Haloperidol; Intracellular Fluid; Neostriatum; Olanzapine; Pirenzepine; Rats; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D4; Risperidone; Serotonin Antagonists; Sulpiride | 2001 |
Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzamides; Brain; Clozapine; Dopamine Antagonists; Dose-Response Relationship, Drug; Fluorine Radioisotopes; Haloperidol; Macaca mulatta; Male; Neostriatum; Pyrrolidines; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Risperidone; Tomography, Emission-Computed | 2001 |
Global index of safety (GIS): a new instrument to assess drug safety.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Benzodiazepines; Consumer Product Safety; Drug Monitoring; Haloperidol; Humans; Olanzapine; Pharmacoepidemiology; Pirenzepine; Risperidone; Schizophrenia | 2001 |
Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.
Topics: Animals; Benzodiazepines; Binding, Competitive; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Guanosine 5'-O-(3-Thiotriphosphate); Guinea Pigs; Haloperidol; HeLa Cells; Humans; Ileum; In Vitro Techniques; Indoles; Lysergic Acid; Muscle Contraction; Olanzapine; Ondansetron; Pirenzepine; Quetiapine Fumarate; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Sulfur Radioisotopes; Tritium; Tropisetron | 2001 |
A behavioural pattern analysis of hypoglutamatergic mice--effects of four different antipsychotic agents.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Dizocilpine Maleate; Dopamine Antagonists; Drug Combinations; Excitatory Amino Acid Antagonists; Fluorobenzenes; Glutamic Acid; Haloperidol; Injections, Intraperitoneal; Male; Mice; Motor Activity; Piperidines; Risperidone; Serotonin Antagonists | 2001 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Patient Compliance; Research Support as Topic; Risperidone; Schizophrenia; Secondary Prevention | 2002 |
Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
Topics: Adolescent; Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cohort Studies; Drug Interactions; Female; Haloperidol; Humans; Male; Middle Aged; Netherlands; Olanzapine; Pirenzepine; Risk Factors; Risperidone | 2001 |
Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects.
Topics: Activities of Daily Living; Affect; Aged; Alzheimer Disease; Antipsychotic Agents; Dementia, Vascular; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Prospective Studies; Psychomotor Agitation; Risperidone; Social Behavior Disorders | 2002 |
Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).
Topics: Adult; Antipsychotic Agents; Attitude to Health; Basal Ganglia Diseases; Benzodiazepines; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Patient Compliance; Prospective Studies; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2001 |
Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Cholinesterase Inhibitors; Clozapine; Corpus Striatum; Haloperidol; Male; Nucleus Accumbens; Olanzapine; Oxotremorine; Piperazines; Pirenzepine; Rats; Rats, Sprague-Dawley; Risperidone; Scopolamine; Sulpiride; Thiazoles; Thioridazine | 2002 |
Quetiapine for tic disorder: a case report.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Female; Haloperidol; Humans; Quetiapine Fumarate; Risperidone; Tic Disorders | 2001 |
Effects of antipsychotic drugs on operant responding after acute and repeated administration.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Conditioning, Operant; Dibenzothiazepines; Dose-Response Relationship, Drug; Haloperidol; Imidazoles; Indoles; Male; Olanzapine; Pirenzepine; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Remoxipride; Risperidone; Thioridazine; Time Factors | 2002 |
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Mental Disorders; Olanzapine; Pirenzepine; Prospective Studies; Risperidone; Weight Gain | 2002 |
Biochemical evidence that the atypical antipsychotic drugs clozapine and risperidone block 5-HT(2C) receptors in vivo.
Topics: Animals; Antipsychotic Agents; Chromatography, High Pressure Liquid; Clozapine; Dopamine; Electrochemistry; Extracellular Space; Haloperidol; Male; Microdialysis; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Risperidone; Serotonin Antagonists | 2002 |
Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Polysomnography; Psychiatric Status Rating Scales; Receptors, Serotonin; Risperidone; Schizophrenia; Sleep Stages | 2002 |
Decreased [(3)H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study.
Topics: Adult; Aged; Antipsychotic Agents; Binding Sites; Binding, Competitive; Butaclamol; Down-Regulation; Gyrus Cinguli; Haloperidol; Humans; Mianserin; Middle Aged; Neurons; Neurotransmitter Agents; Radioligand Assay; Receptors, Neurotransmitter; Risperidone; Schizophrenia; Spiperone; Tritium | 2002 |
Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Dialysis Solutions; Dopamine Antagonists; Extracellular Space; Haloperidol; Hippocampus; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Microdialysis; Olanzapine; Piperazines; Pirenzepine; Rats; Rats, Wistar; Risperidone; Serotonin Antagonists; Thiazoles; Thioridazine | 2002 |
Effects of haloperidol and risperidone on neurotensin levels in brain regions and neurotensin efflux in the ventral striatum of the rat.
Topics: Animals; Antipsychotic Agents; Basal Ganglia; Brain; Central Nervous System Stimulants; Dextroamphetamine; Dialysis Solutions; Haloperidol; Male; Microdialysis; Neurotensin; Rats; Rats, Wistar; Risperidone; Tissue Distribution | 2002 |
Reducing ability of the striatum and cerebral cortex in rats following acute administration of risperidone or haloperidol: an estimation by in vivo electron paramagnetic resonance imaging.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; Corpus Striatum; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Half-Life; Haloperidol; Image Processing, Computer-Assisted; Male; Oxidation-Reduction; Pyrrolidines; Rats; Rats, Wistar; Risperidone | 2002 |
Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing.
Topics: Amisulpride; Animals; Antipsychotic Agents; Clozapine; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Haloperidol; Male; Mastication; Neostriatum; Nerve Degeneration; Neural Pathways; Neurons; Rats; Rats, Sprague-Dawley; Risperidone; Substance Withdrawal Syndrome; Substantia Nigra; Sulpiride | 2002 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Patient Dropouts; Risperidone; Schizophrenia; Secondary Prevention | 2002 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Hyperkinesis; Psychomotor Agitation; Risperidone; Schizophrenia; Secondary Prevention | 2002 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Patient Compliance; Risperidone; Schizophrenia; Secondary Prevention | 2002 |
Prolongation of QTc interval and antipsychotics.
Topics: Antipsychotic Agents; Death, Sudden, Cardiac; Drug Administration Schedule; Drug Labeling; Drug Monitoring; Haloperidol; Humans; Long QT Syndrome; Piperazines; Risperidone; Thiazoles | 2002 |
Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Cell Cycle; Cell Survival; Clozapine; DNA Fragmentation; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Iatrogenic Disease; Mice; Mice, Inbred ICR; Neurons; Neurotoxins; Perphenazine; Pregnancy; Risperidone; Tumor Cells, Cultured | 2001 |
Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
Topics: Antipsychotic Agents; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Neuropsychological Tests; Patient Selection; Research Design; Risperidone; Schizophrenia; Schizophrenic Psychology | 2002 |
Antipsychotic profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562) in rats.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine; Dose-Response Relationship, Drug; Haloperidol; Male; Piperidines; Rats; Rats, Wistar; Risperidone; Thiazoles | 2002 |
Sexual side effects of novel antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Clozapine; Erectile Dysfunction; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Sexual Behavior | 2002 |
Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Caudate Nucleus; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Hypertrophy; Male; Neostriatum; Neuronal Plasticity; Neurons; Putamen; Rats; Rats, Sprague-Dawley; Risperidone; Schizophrenia; Time Factors | 2002 |
Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia.
Topics: Adult; Aged; Female; Haloperidol; Humans; Middle Aged; Prolactin; Risperidone; Schizophrenia; Statistics, Nonparametric | 2002 |
Atypical neuroleptics stimulate neurogenesis in adult rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Brain Chemistry; Cell Differentiation; Haloperidol; Immunohistochemistry; Male; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Risperidone | 2002 |
Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone.
Topics: Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Depression; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Treatment Outcome | 2002 |
Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Dibenzothiazepines; Drinking; Female; Haloperidol; Learning; Male; Olanzapine; Pirenzepine; Pregnancy; Prenatal Exposure Delayed Effects; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Retention, Psychology; Risperidone; Spatial Behavior | 2002 |
In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl] ethyl] piperidine (NRA0161).
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Binding, Competitive; Blood Pressure; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Mice; Mice, Inbred ICR; Motor Activity; Piperidines; Radioligand Assay; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, Dopamine; Receptors, Drug; Receptors, Serotonin; Risperidone; Stereotyped Behavior | 2002 |
Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats.
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Female; Haloperidol; Maze Learning; Memory, Short-Term; Neural Pathways; Nicotine; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine; Risperidone; Schizophrenia | 2002 |
Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration.
Topics: Animals; Antipsychotic Agents; Blotting, Northern; Brain-Derived Neurotrophic Factor; Clozapine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation; Haloperidol; Hippocampus; In Situ Hybridization; Male; Rats; Rats, Wistar; Remoxipride; Risperidone; Ritanserin; RNA, Messenger; Time Factors | 2002 |
Re: Chan et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 16: 1156 - 1162.
Topics: Alzheimer Disease; Antipsychotic Agents; China; Double-Blind Method; Haloperidol; Humans; Mental Disorders; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risperidone | 2002 |
Case study of circadian rhythm sleep disorder following haloperidol treatment: reversal by risperidone and melatonin.
Topics: Adult; Antipsychotic Agents; Chronotherapy; Circadian Rhythm; Haloperidol; Humans; Male; Melatonin; Motor Activity; Risperidone; Sleep Disorders, Circadian Rhythm; Tourette Syndrome | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Female; Haloperidol; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Olanzapine; Pirenzepine; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Triglycerides; Weight Gain | 2002 |
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data.
Topics: Adult; Aged; Antipsychotic Agents; Arrhythmias, Cardiac; Clozapine; Cohort Studies; Confidence Intervals; Death, Sudden, Cardiac; Female; Haloperidol; Heart Arrest; Humans; Male; Medicaid; Middle Aged; Risperidone; Schizophrenia; Thioridazine; United States | 2002 |
Comparable dopamine 2 receptor occupancy.
Topics: Benzodiazepines; Cognition Disorders; Dopamine Antagonists; Haloperidol; Humans; Olanzapine; Pirenzepine; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2002 |
Glucose intolerance with atypical antipsychotics.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Chlorpromazine; Clozapine; Diabetes Mellitus; Glucose Intolerance; Haloperidol; Humans; Hyperglycemia; Olanzapine; Pirenzepine; Risk Factors; Risperidone; World Health Organization | 2002 |
Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents.
Topics: Adrenalectomy; Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Clozapine; Corticosterone; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Gonadal Steroid Hormones; Haloperidol; Male; Olanzapine; Pirenzepine; Pregnanolone; Progesterone; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Risperidone | 2003 |
Discriminative stimulus properties in rats of the novel antipsychotic quetiapine.
Topics: Amisulpride; Analysis of Variance; Animals; Antipsychotic Agents; Chlorpromazine; Clozapine; Dibenzothiazepines; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Female; Generalization, Psychological; Haloperidol; Loxapine; Quetiapine Fumarate; Quinoxalines; Rats; Rats, Wistar; Risperidone; Sulpiride | 2002 |
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Cognition Disorders; Female; Haloperidol; Humans; Male; Olanzapine; Patient Compliance; Pirenzepine; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2002 |
Cerebral metabolism and risperidone treatment in schizophrenia.
Topics: Adult; Antipsychotic Agents; Cerebellum; Cerebral Cortex; Chronic Disease; Energy Metabolism; Female; Fluorine Radioisotopes; Glucose; Haloperidol; Humans; Longitudinal Studies; Male; Psychiatric Status Rating Scales; Risperidone; Schizophrenia, Paranoid; Tomography, Emission-Computed | 2003 |
Atypical antipsychotic drugs improve cognition in schizophrenia.
Topics: Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Follow-Up Studies; Haloperidol; Humans; Neuropsychological Tests; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2003 |
Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markers and spatial learning performance in rats.
Topics: Animals; Brain; Choline O-Acetyltransferase; Cholinergic Fibers; Clozapine; Haloperidol; Male; Maze Learning; Rats; Rats, Wistar; Risperidone; Spatial Behavior | 2003 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
Comparative behavioural effects of typical and atypical antipsychotic drugs in rhesus monkey.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Behavior, Animal; Chlorpromazine; Dose-Response Relationship, Drug; Drinking Behavior; Feeding Behavior; Female; Haloperidol; Injections, Intramuscular; Macaca mulatta; Male; Motor Activity; Risperidone; Social Behavior; Time Factors; Videotape Recording | 2003 |
Acute effects of antipsychotic drugs on cardiovascular responses to stress.
Topics: Animals; Antipsychotic Agents; Blood Pressure; Clozapine; Dose-Response Relationship, Drug; Exploratory Behavior; Haloperidol; Heart Rate; Male; Motor Activity; Rats; Rats, Inbred F344; Risperidone; Stress, Psychological | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Research Design; Risperidone; Schizophrenia; Treatment Outcome | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Chronic Disease; Clozapine; Cohort Effect; Cohort Studies; Haloperidol; Humans; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Chronic Disease; Cohort Effect; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Research Design; Risperidone; Schizophrenia; Treatment Outcome | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Pirenzepine; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risperidone; Schizophrenia; Treatment Outcome | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Pirenzepine; Research Design; Research Support as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2003 |
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Estrogens; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Olanzapine; Pirenzepine; Prolactin; Risk Factors; Risperidone; Schizophrenia; Sex Characteristics | 2003 |
Role of ethnicity in predicting antipsychotic medication adherence.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Ethnicity; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Compliance; Pirenzepine; Risperidone; Schizophrenia | 2003 |
Comparison of the effects of antipsychotics on a delayed radial maze task in the rat.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Dose-Response Relationship, Drug; Food Deprivation; Haloperidol; Male; Maze Learning; Memory; Olanzapine; Piperazines; Pirenzepine; Rats; Rats, Sprague-Dawley; Risperidone; Thiazoles | 2003 |
Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Male; Mice; Motor Activity; Random Allocation; Reserpine; Risperidone | 2003 |
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Spain; Weight Gain | 2003 |
Risperidone-associated diabetes mellitus: a pharmacovigilance study.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Child; Diabetes Mellitus; Drug Therapy, Combination; Drug Utilization Review; Female; Haloperidol; Humans; Hyperglycemia; Male; MEDLINE; Middle Aged; Product Surveillance, Postmarketing; Risk Factors; Risperidone; United States | 2003 |
Rehospitalization risk with second-generation and depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Data Collection; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; Male; Olanzapine; Patient Readmission; Pirenzepine; Risperidone; Schizophrenia; Secondary Prevention; Time Factors; Treatment Outcome | 2003 |
Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Corpus Striatum; Dopamine; Haloperidol; Limbic System; Male; Mice; Mice, Inbred ICR; Piperazines; Quinolones; Risperidone; Time Factors | 2003 |
Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Cost-Benefit Analysis; Drug Administration Schedule; Employment; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Risperidone; Schizophrenia; Time Factors | 2003 |
Antipsychotic drugs differentially modulate apolipoprotein D in rat brain.
Topics: Animals; Antipsychotic Agents; Apolipoproteins; Apolipoproteins D; Benzodiazepines; Brain; Haloperidol; Male; Neuronal Plasticity; Neurons; Olanzapine; Pirenzepine; Rats; Rats, Wistar; Risperidone | 2003 |
Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: a controlled, double dissociation study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Case-Control Studies; Clozapine; Corpus Striatum; Dissociative Disorders; Female; Frontal Lobe; Haloperidol; Humans; Male; Neural Pathways; Neuropsychological Tests; Obsessive-Compulsive Disorder; Predictive Value of Tests; Prefrontal Cortex; Risperidone; Schizophrenia | 2003 |
Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea.
Topics: Adult; Amenorrhea; Analysis of Variance; Antipsychotic Agents; Dibenzothiazepines; Female; Haloperidol; Humans; Prolactin; Quetiapine Fumarate; Recovery of Function; Risperidone; Schizophrenia; Time Factors | 2003 |
[Neuroleptics and cognition].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Pirenzepine; Product Surveillance, Postmarketing; Risperidone; Schizophrenia; Schizophrenic Psychology | 2003 |
Effect of haloperidol and risperidone on amyloid precursor protein levels in vivo.
Topics: Amyloid beta-Protein Precursor; Animals; Blotting, Western; Cerebral Cortex; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Injections, Intraperitoneal; Male; Rats; Rats, Sprague-Dawley; Risperidone; Time Factors | 2003 |
Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Choline O-Acetyltransferase; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Haloperidol; Hippocampus; Immunohistochemistry; Male; Nerve Growth Factor; Olanzapine; Rats; Rats, Wistar; Risperidone; Septum of Brain | 2004 |
Different effects of five dopamine receptor subtypes on nuclear factor-kappaB activity in NG108-15 cells and mouse brain.
Topics: Animals; Antipsychotic Agents; Brain; Cell Line; Colforsin; DNA; Dopamine Antagonists; Electrophoretic Mobility Shift Assay; Frontal Lobe; Gene Expression Regulation; Haloperidol; Mice; Mitogen-Activated Protein Kinases; NF-kappa B; Protein Binding; Rats; Receptors, Dopamine; Risperidone | 2004 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2003 |
Excitability of the motor cortex in schizophrenia following typical and atypical antipsychotics: two serial case reports.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Electromagnetic Fields; Electromyography; Evoked Potentials, Motor; Haloperidol; Humans; Male; Motor Cortex; Psychiatric Status Rating Scales; Risperidone; Schizophrenia | 2003 |
[Altered behavioral response to centrally acting drugs in mice lacking PACAP].
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Disease Models, Animal; Fluoxetine; Haloperidol; Mice; Mice, Knockout; Neuropeptides; Pituitary Adenylate Cyclase-Activating Polypeptide; Risperidone | 2003 |
Haloperidol versus risperidone on rat "early onset" vacuous chewing.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Male; Mastication; Rats; Rats, Sprague-Dawley; Risperidone; Stereotyped Behavior; Time Factors | 2004 |
Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Black or African American; Drug Utilization; Haloperidol; Hispanic or Latino; Humans; Logistic Models; Medicaid; Middle Aged; Minority Groups; Multivariate Analysis; Olanzapine; Practice Patterns, Physicians'; Retrospective Studies; Risperidone; Schizophrenia; Texas; United States; White People | 2004 |
Nicotine-antipsychotic drug interactions and attentional performance in female rats.
Topics: Animals; Antipsychotic Agents; Attention; Central Nervous System Stimulants; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Female; Haloperidol; Nicotine; Photic Stimulation; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Risperidone | 2004 |
Risperidone-induced leucopenia and neutropenia: a case report.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delusions; Dementia, Vascular; Hallucinations; Haloperidol; Humans; Leukopenia; Male; Neutropenia; Pneumonia; Recurrence; Risperidone | 2004 |
Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Chlorpromazine; Clozapine; Gene Expression Regulation; Haloperidol; Hippocampus; In Situ Hybridization; Male; Microfilament Proteins; Microtubule-Associated Proteins; Nerve Tissue Proteins; Neurites; Olanzapine; Rats; Rats, Sprague-Dawley; Risperidone; RNA, Messenger; Tissue Distribution | 2004 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Catalepsy; Chlorpromazine; Dibenzothiazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Haloperidol; Hyperkinesis; Injections, Intraperitoneal; Male; Methamphetamine; Mice; Piperazines; Pyridines; Quetiapine Fumarate; Receptor, Serotonin, 5-HT1A; Risperidone; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists | 2004 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Hyperprolactinemia; International Classification of Diseases; Male; Observation; Olanzapine; Prospective Studies; Quetiapine Fumarate; Risperidone; Schizophrenia; Severity of Illness Index; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Weight Gain | 2004 |
Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents.
Topics: Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Behavior, Animal; Benzodiazepines; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; GABA Antagonists; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Haloperidol; Injections, Intraventricular; Male; Motor Activity; Neurotransmitter Agents; Olanzapine; Pregnanolone; Rats; Rats, Sprague-Dawley; Risperidone; Social Isolation | 2004 |
Efficacy of risperidone in treating the hyperactive symptoms of delirium.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Psychomotor Agitation; Retrospective Studies; Risperidone; Severity of Illness Index; Treatment Outcome | 2004 |
COMT158 polymorphism and hostility.
Topics: Antipsychotic Agents; Benzodiazepines; Catechol O-Methyltransferase; Clozapine; Genotype; Haloperidol; Hostility; Humans; Methionine; Olanzapine; Polymorphism, Genetic; Risperidone; Schizophrenia; Schizophrenic Psychology; Valine | 2004 |
Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.
Topics: Antipsychotic Agents; Attitude of Health Personnel; Drug Administration Schedule; Drug Costs; Drug Utilization; Haloperidol; Health Care Surveys; Humans; Mexico; Practice Guidelines as Topic; Practice Patterns, Physicians'; Psychiatry; Risperidone; Schizophrenia; Schizophrenic Psychology; Socioeconomic Factors; Surveys and Questionnaires | 2004 |
Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Cells, Cultured; Colforsin; Cyclic AMP Response Element-Binding Protein; Haloperidol; Hippocampus; Immunohistochemistry; Mitogen-Activated Protein Kinases; Neurons; Phosphorylation; Rats; Risperidone | 2004 |
Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol.
Topics: Animals; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cells, Cultured; Dopamine Antagonists; Embryo, Mammalian; Haloperidol; Immunohistochemistry; Neurons; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Risperidone | 2004 |
Effects of typical and atypical antipsychotic drugs on maternal behavior in postpartum female rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Female; Haloperidol; Maternal Behavior; Postpartum Period; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Risperidone | 2004 |
Effects of serotonin-dopamine antagonists on prepulse inhibition and neurotransmitter contents in the rat cortex.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; Cognition; Dopamine; Dopamine Antagonists; Haloperidol; Indoles; Isoindoles; Male; Neurotransmitter Agents; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Reflex, Startle; Risperidone; Serotonin; Serotonin Antagonists; Thiazoles | 2004 |
Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out.
Topics: Antipsychotic Agents; Computer Simulation; Haloperidol; Humans; Longitudinal Studies; Models, Statistical; Patient Dropouts; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2004 |
Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats.
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Eating; Estrous Cycle; Female; Haloperidol; Organ Size; Rats; Risperidone; Time Factors; Uterus; Weight Gain | 2004 |
Effects of typical and atypical antipsychotics on human glycine transporters.
Topics: Amino Acid Transport Systems, Neutral; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chloride Channels; Choriocarcinoma; Clozapine; Female; Glycine; Glycine Plasma Membrane Transport Proteins; Haloperidol; Humans; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Olanzapine; Rats; Receptors, N-Methyl-D-Aspartate; Risperidone; Schizophrenia; Sodium Channels; Synapses; Uterine Neoplasms | 2004 |
Chronic antidopaminergic medication might affect amygdala structure in patients with schizophrenia.
Topics: Amygdala; Antipsychotic Agents; Brain; Clopenthixol; Dose-Response Relationship, Drug; Epilepsy, Temporal Lobe; Factor Analysis, Statistical; Flupenthixol; Haloperidol; Hippocampus; Humans; Psychotic Disorders; Risperidone; Schizophrenia; Trifluoperazine | 2004 |
A mood stabilizer with risperidone or haloperidol for mania.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Ethics, Research; Haloperidol; Humans; Lithium; Patient Selection; Placebos; Randomized Controlled Trials as Topic; Research Design; Risperidone; Valproic Acid | 2004 |
A mood stabilizer with risperidone or haloperidol for mania.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Haloperidol; Humans; Randomized Controlled Trials as Topic; Research Design; Risperidone; Treatment Outcome; Valproic Acid | 2004 |
The impact of neuroleptic medication on seizure threshold and duration in electroconvulsive therapy.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Brain; Clopenthixol; Clozapine; Dibenzothiazepines; Electric Impedance; Electroconvulsive Therapy; Electroencephalography; Electromyography; Female; Fluphenazine; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Quetiapine Fumarate; Risperidone; Seizures; Sulpiride | 2004 |
[Anesthesia for cesarean section in a parturient taking risperidone and haloperidol].
Topics: Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antipsychotic Agents; Cesarean Section; Female; Fetal Blood; Haloperidol; Humans; Pregnancy; Risperidone; Schizophrenia | 2005 |
Improvement in tardive dyskinesia with aripiprazole use.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Long-Term Care; Middle Aged; Piperazines; Quinolones; Risperidone; Valproic Acid | 2005 |
Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Cell Membrane; CHO Cells; Colforsin; Cricetinae; Cricetulus; Cyclic AMP; DNA, Complementary; Dopamine; Dopamine Agonists; Dopamine Antagonists; Haloperidol; Humans; Lisuride; Piperazines; Piperidines; Quinolones; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Risperidone; Transfection; Tritium | 2005 |
Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Benzofurans; Brain Chemistry; Cataplexy; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Synergism; Haloperidol; Histamine; Histamine Antagonists; Imidazoles; Ketoconazole; Male; Metabolic Clearance Rate; Piperidines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Histamine H3; Risperidone; Schizophrenia | 2005 |
Impact of haloperidol and risperidone on gene expression profile in the rat cortex.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; DNA, Complementary; Down-Regulation; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation; Haloperidol; Nerve Tissue Proteins; Neuronal Plasticity; Oligonucleotide Array Sequence Analysis; Prospective Studies; Rats; Rats, Sprague-Dawley; Risperidone; RNA, Messenger; Time Factors; Transcriptional Activation; Up-Regulation | 2005 |
Atypical antipsychotics produce within-session decrements on self-stimulation of the rat medial prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Clozapine; Haloperidol; Male; Prefrontal Cortex; Rats; Rats, Wistar; Risperidone; Self Stimulation | 2005 |
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Risperidone; Schizophrenia; Thiazoles | 2005 |
Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Haloperidol; Humans; Male; Nervous System Diseases; Neuropsychological Tests; Olanzapine; Risperidone; Schizophrenia; Severity of Illness Index | 2005 |
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chlorpromazine; Dopamine Antagonists; Drug Administration Schedule; Family Practice; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Risperidone; Schizophrenia; Sex Factors | 2005 |
The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats.
Topics: Adaptor Proteins, Signal Transducing; Amphetamine; Animals; Antipsychotic Agents; Benzazepines; beta Catenin; Blotting, Western; Central Nervous System Stimulants; Clozapine; Cytoskeletal Proteins; Dishevelled Proteins; Dopamine Agonists; Female; Glycogen Synthase Kinase 3; Haloperidol; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Male; Mesencephalon; Phosphoproteins; Quinpirole; Rats; Rats, Sprague-Dawley; Risperidone; Signal Transduction; Trans-Activators; Wnt Proteins; Wnt1 Protein | 2005 |
[Case of obsessive-compulsive disorder associated with neuroleptics-induced deficit syndrome (NIDS): successfully treated by discontinuation of neuroleptics followed by SSRI].
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Fluvoxamine; Haloperidol; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Personality Disorders; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2005 |
Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Odds Ratio; Olanzapine; Risperidone; Stroke | 2005 |
Pharmacological treatment to augment hole board habituation in prenatal Vitamin D-deficient rats.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Exploratory Behavior; Female; Glycine; Habituation, Psychophysiologic; Haloperidol; Male; Phenylacetates; Pregnancy; Prenatal Exposure Delayed Effects; Random Allocation; Rats; Risperidone; Vitamin D Deficiency | 2006 |
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cerebrovascular Disorders; Cohort Studies; Dementia; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Patient Admission; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Thiazoles | 2005 |
Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Indoles; Isoindoles; Male; Mice; Mice, Inbred ICR; Motor Activity; Obsessive-Compulsive Disorder; Piperazines; Receptor, Serotonin, 5-HT1A; Risperidone; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles | 2005 |
Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Confidence Intervals; Dementia, Vascular; Drug Therapy, Combination; Female; Follow-Up Studies; Haloperidol; Homes for the Aged; Humans; Korea; Male; Mental Disorders; Mental Status Schedule; Nursing Homes; Proportional Hazards Models; Prospective Studies; Risk; Risperidone; Survival Analysis | 2005 |
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Linear Models; Male; Meta-Analysis as Topic; Middle Aged; Olanzapine; Placebo Effect; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome; Weight Gain | 2005 |
Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Catalepsy; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Immunohistochemistry; Male; Motor Activity; Oncogene Proteins v-fos; Piperazines; Prolactin; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Risperidone | 2006 |
Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Male; Rats; Rats, Sprague-Dawley; Risperidone; Stereotyped Behavior | 2006 |
Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Longitudinal Studies; Male; Middle Aged; Risperidone; Saccades; Schizophrenia; Time Factors | 2006 |
Optimization of the separation of some psychotropic drugs and their respective metabolites by liquid chromatography.
Topics: Acetonitriles; Buffers; Chromatography, High Pressure Liquid; Cyclohexanols; Haloperidol; Hydrogen-Ion Concentration; Methanol; Models, Theoretical; Psychotropic Drugs; Risperidone; Solvents; Time Factors; Venlafaxine Hydrochloride | 2006 |
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
Topics: Antipsychotic Agents; Belgium; Benzodiazepines; Cost of Illness; Cost-Benefit Analysis; Decision Trees; Delayed-Action Preparations; Economics, Pharmaceutical; Haloperidol; Humans; Olanzapine; Risperidone; Schizophrenia | 2005 |
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Cost of Illness; Cost-Benefit Analysis; Delayed-Action Preparations; Economics, Pharmaceutical; Germany; Haloperidol; Humans; Models, Economic; Olanzapine; Quality-Adjusted Life Years; Risperidone; Schizophrenia | 2005 |
Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
Topics: Administration, Oral; Antipsychotic Agents; Canada; Cost of Illness; Cost-Benefit Analysis; Delayed-Action Preparations; Economics, Pharmaceutical; Haloperidol; Hospitalization; Humans; Models, Economic; Monte Carlo Method; Patient Compliance; Risperidone; Schizophrenia | 2005 |
Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Chlorpromazine; Corpus Striatum; Haloperidol; Hippocampus; Male; Nerve Growth Factor; Olanzapine; Rats; Rats, Wistar; Risperidone; Time | 2006 |
Haloperidol and atypical antipsychotics share a same action of decreasing P75(NTR) mRNA levels in PC12 cells.
Topics: Animals; Antipsychotic Agents; Cell Survival; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression; Haloperidol; PC12 Cells; Quetiapine Fumarate; Rats; Receptor, Nerve Growth Factor; Risperidone; RNA, Messenger; Time Factors | 2006 |
Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Corpus Striatum; Drug Administration Schedule; Drug Interactions; Extracellular Fluid; Haloperidol; Male; Microdialysis; Neuropeptide Y; Neurotensin; Radioimmunoassay; Rats; Rats, Wistar; Risperidone; Time Factors | 2006 |
Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Dibenzothiazepines; Drug Costs; Haloperidol; Health Care Costs; Humans; Models, Econometric; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thailand; Thiazoles; Treatment Outcome | 2005 |
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chlorpromazine; Clozapine; Cross-Over Studies; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Haloperidol; Lipid Peroxidation; Male; Membrane Lipids; Olanzapine; Rats; Rats, Wistar; Risperidone; Schizophrenia; Superoxide Dismutase | 2007 |
Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation.
Topics: Animals; Anisoles; Antipsychotic Agents; Benzazepines; Butaclamol; Caspase Inhibitors; Cell Death; Cells, Cultured; Chlorpromazine; Clozapine; Domperidone; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Ginkgo biloba; Haloperidol; Hippocampus; Indans; Isoxazoles; Neurons; Neuroprotective Agents; Peptides; Piperidines; Plant Extracts; Propylamines; Raclopride; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptors, N-Methyl-D-Aspartate; Remoxipride; Risperidone; Sulpiride | 2006 |
Risperidone: new indication. Behavioural disorders in children with autism or mental disabilities: no progress.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Child, Preschool; Clinical Trials as Topic; Cost-Benefit Analysis; France; Haloperidol; Humans; Lithium; Risperidone; Treatment Outcome | 2006 |
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Haloperidol; Humans; Incidence; Psychiatric Status Rating Scales; Psychometrics; Psychotic Disorders; Risperidone | 2006 |
Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Disease Models, Animal; Dopamine Antagonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Exploratory Behavior; Haloperidol; Infusion Pumps, Implantable; Male; Motor Activity; Phenotype; Rats; Rats, Sprague-Dawley; Risperidone | 2006 |
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Female; Galactorrhea; Gynecomastia; Haloperidol; Humans; Hyperprolactinemia; Male; Olanzapine; Piperazines; Pituitary Neoplasms; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Sex Factors; Thiazoles; United States; United States Food and Drug Administration | 2006 |
Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat.
Topics: Algorithms; Analysis of Variance; Animals; Antipsychotic Agents; Benzodiazepines; Binding, Competitive; Cerebellum; Corpus Striatum; Dose-Response Relationship, Drug; Haloperidol; Male; Olanzapine; Raclopride; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D2; Risperidone; Tritium | 2006 |
Time course of the antipsychotic effect and the underlying behavioral mechanisms.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Benzodiazepines; Brain; Brain Chemistry; Chlordiazepoxide; Conditioning, Psychological; Dose-Response Relationship, Drug; Drug Resistance; Drug Tolerance; Haloperidol; Male; Models, Animal; Olanzapine; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Risperidone; Time Factors | 2007 |
Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.
Topics: Animals; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodiazepines; Chlorpromazine; Clozapine; Cyclosporins; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Flow Cytometry; Fluorescent Dyes; Haloperidol; Isoxazoles; Kidney; Liver; LLC-PK1 Cells; Olanzapine; Paliperidone Palmitate; Pyrimidines; Quetiapine Fumarate; Rhodamine 123; Risperidone; Swine; Transfection | 2006 |
Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Dopamine; Dronabinol; Haloperidol; Inhibition, Psychological; Male; Mice; Nucleus Accumbens; Piperidines; Prefrontal Cortex; Pyrazoles; Reflex, Startle; Rimonabant; Risperidone; Rotarod Performance Test | 2006 |
Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Haloperidol; Humans; Immunoenzyme Techniques; Male; Middle Aged; Olanzapine; Prolactin; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Sex Factors | 2005 |
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Appetite; Body Weight; Corticosterone; Diabetes Mellitus, Type 2; Endocrine System; Energy Intake; Glucagon; Haloperidol; Hyperinsulinism; Insulin; Insulin Resistance; Insulin Secretion; Lipid Metabolism; Male; Obesity; Rats; Rats, Sprague-Dawley; Risperidone; Species Specificity; Testosterone; Weight Gain | 2006 |
Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Genotype; Haloperidol; Humans; Interleukin 1 Receptor Antagonist Protein; Male; Olanzapine; Polymorphism, Genetic; Risperidone; Schizophrenia; Spain; Tandem Repeat Sequences; Treatment Outcome; White People | 2006 |
Chronic high-dose haloperidol has qualitatively similar effects to risperidone and clozapine on immediate-early gene and tyrosine hydroxylase expression in the rat locus coeruleus but not medial prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Cell Count; Clozapine; Gene Expression; Genes, Immediate-Early; Haloperidol; Immediate-Early Proteins; Immunohistochemistry; Locus Coeruleus; Male; Neurons; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Risperidone; Tyrosine 3-Monooxygenase | 2007 |
Possible antipsychotic effects of minocycline in patients with schizophrenia.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Antipsychotic Agents; Electroencephalography; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Minocycline; Psychiatric Status Rating Scales; Risperidone; Schizophrenia, Catatonic; Tomography, X-Ray Computed | 2007 |
The effect of chronic antipsychotic treatment on sexual behaviour, hormones and organ size in the male rat.
Topics: Animals; Antipsychotic Agents; Copulation; Female; Genitalia, Male; Haloperidol; Luteinizing Hormone; Male; Organ Size; Rats; Rats, Sprague-Dawley; Risperidone; Sexual Behavior, Animal; Testosterone | 2007 |
Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Excitatory Amino Acid Antagonists; Haloperidol; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Models, Animal; Motor Activity; Olanzapine; Receptors, N-Methyl-D-Aspartate; Reflex, Startle; Risperidone | 2006 |
Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Chlorpromazine; Cohort Studies; Female; Fluphenazine; Haloperidol; Hospitals, Veterans; Humans; Hyperglycemia; Incidence; Male; Middle Aged; Olanzapine; Perphenazine; Retrospective Studies; Risk Assessment; Risk Factors; Risperidone; Southeastern United States; Time Factors; Veterans | 2007 |
5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
Topics: Animals; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Fluid; Haloperidol; Hippocampus; Male; Microdialysis; Piperazines; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Serotonin; Serotonin Antagonists; Sulfonamides; Synaptic Transmission | 2007 |
Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental brain trauma.
Topics: Animals; Antipsychotic Agents; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Administration Schedule; Escape Reaction; Haloperidol; Head Injuries, Closed; Injections, Intraperitoneal; Male; Maze Learning; Memory, Short-Term; Motor Skills; Neurologic Examination; Orientation; Postural Balance; Rats; Rats, Sprague-Dawley; Risperidone | 2007 |
Assertion that risperidone is superior to haloperidol for treatment of behavioural and psychological symptoms of dementia.
Topics: Antipsychotic Agents; Dementia; Haloperidol; Humans; Risperidone; Therapeutic Equivalency | 2007 |
Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Dose-Response Relationship, Drug; Haloperidol; Ketanserin; Male; Olanzapine; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; Receptors, Catecholamine; Receptors, Neurotransmitter; Receptors, Serotonin, 5-HT2; Risperidone | 2007 |
Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Cell Line; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Haloperidol; Interferon-gamma; Interleukin-1beta; Interleukin-6; Mice; Microglia; Nitric Oxide; Risperidone; Schizophrenia; Tumor Necrosis Factor-alpha | 2007 |
[Psychiatry and sleep disorders--delirium].
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; International Classification of Diseases; Japan; Male; Mianserin; Middle Aged; Neoplasms; Risperidone; Sex Factors; Tiapamil Hydrochloride; Treatment Outcome | 2006 |
Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Body Weight; Chlorpromazine; Clozapine; Dopamine; Dyskinesia, Drug-Induced; Haloperidol; Male; Norepinephrine; Prosencephalon; Rats; Rats, Wistar; Risperidone; Serotonin | 2007 |
Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Imidazoles; Indoles; Male; Maze Learning; Phencyclidine; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Risperidone; Schizophrenic Psychology | 2007 |
Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance.
Topics: Animals; Antipsychotic Agents; Enzyme-Linked Immunosorbent Assay; Haloperidol; Hand Strength; Hippocampus; Male; Maze Learning; Membrane Transport Proteins; Memory; Motor Activity; Neurons; Parasympathetic Nervous System; Postural Balance; Psychomotor Performance; Rats; Rats, Wistar; Receptor, Nerve Growth Factor; Receptor, trkA; Receptors, Nerve Growth Factor; Recognition, Psychology; Risperidone; Vesicular Acetylcholine Transport Proteins | 2007 |
Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Humans; Male; Risperidone; Schizophrenia; Severity of Illness Index | 2007 |
Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Topics: Aged; Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Double-Blind Method; Haloperidol; Humans; Mental Disorders; Randomized Controlled Trials as Topic; Risperidone; Therapeutic Equivalency; Treatment Outcome | 2007 |
Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Injections, Intramuscular; Injections, Intravenous; Male; Retrospective Studies; Risperidone | 2007 |
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Perphenazine; Psychiatric Status Rating Scales; Reference Values; Risperidone; Schizophrenia; Weight Gain | 2007 |
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.
Topics: Animals; Antipsychotic Agents; Attention; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzothiazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Hallucinogens; Haloperidol; Impulsive Behavior; Male; Olanzapine; Phencyclidine; Quetiapine Fumarate; Rats; Rats, Wistar; Reaction Time; Risperidone; Schizophrenia | 2007 |
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Drug Administration Schedule; Drug Therapy, Combination; Female; Haloperidol; Hospitalization; Humans; Lithium Carbonate; Male; Obesity; Olanzapine; Risperidone; Smoking; Valproic Acid | 2008 |
Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Haloperidol; Humans; Models, Theoretical; Olanzapine; Risperidone; Schizophrenia; United States | 2007 |
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Brain Chemistry; Catalepsy; Dizocilpine Maleate; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Haloperidol; Head Movements; Male; Mice; Mice, Inbred Strains; Motor Activity; Piperidines; Prolactin; Rats; Rats, Sprague-Dawley; Risperidone; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Urea | 2007 |
The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Arginine Vasopressin; Clozapine; Deamino Arginine Vasopressin; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Habituation, Psychophysiologic; Haloperidol; Neural Inhibition; Neurotensin; Rats; Rats, Brattleboro; Rats, Long-Evans; Rats, Mutant Strains; Reflex, Startle; Risperidone; Schizophrenia; Statistics, Nonparametric | 2007 |
(+/-) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics.
Topics: Animals; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Ketamine; Lamotrigine; Male; Pyridines; Rats; Rats, Sprague-Dawley; Reflex, Startle; Risperidone; Schizophrenia; Sulfonamides; Thiophenes; Triazines | 2007 |
Effect of antipsychotic medication use on memory in patients with Alzheimer's disease: Assessing the potential risk for accelerated recent autobiographical memory loss.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Autobiographies as Topic; Benzodiazepines; Dibenzothiazepines; Drug Monitoring; Female; Geriatric Assessment; Haloperidol; Humans; Male; Memory; Mental Status Schedule; Neuropsychological Tests; Nursing Assessment; Olanzapine; Pilot Projects; Quetiapine Fumarate; Retrospective Studies; Risk Assessment; Risk Factors; Risperidone; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2007 |
In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Coagulation; Blood Platelets; Clozapine; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; In Vitro Techniques; Male; Middle Aged; Olanzapine; Partial Thromboplastin Time; Platelet Adhesiveness; Platelet Aggregation; Prothrombin Time; Risperidone; Thromboembolism; Venous Thrombosis | 2007 |
Time dependent decreases in central alpha7 nicotinic acetylcholine receptors associated with haloperidol and risperidone treatment in rats.
Topics: Administration, Oral; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Autoradiography; Enzyme-Linked Immunosorbent Assay; Haloperidol; Prefrontal Cortex; Prosencephalon; Rats; Rats, Wistar; Receptors, Nicotinic; Risperidone; Time Factors | 2007 |
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Retrospective Studies; Risperidone | 2007 |
The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Benzodiazepines; Benzoxazoles; Catalepsy; Haloperidol; Intracellular Signaling Peptides and Proteins; Locomotion; Male; Naphthyridines; Neuropeptides; Olanzapine; Orexins; Prolactin; Rats; Rats, Sprague-Dawley; Risperidone; Urea | 2007 |
Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Fetal Blood; Haloperidol; Humans; Infant, Low Birth Weight; Infant, Newborn; Intensive Care Units, Neonatal; Maternal-Fetal Exchange; Olanzapine; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risperidone | 2007 |
Pretrial medication bias in randomized antipsychotic drug trials.
Topics: Antipsychotic Agents; Bias; Drug Administration Schedule; Haloperidol; Humans; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome | 2007 |
Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsych
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Animals, Outbred Strains; Benzodiazepines; Cebus; Citalopram; Clozapine; Cognition; Dihydropyridines; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Haloperidol; Haplorhini; Humans; Indoles; Male; Mice; Molecular Structure; Motor Activity; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Dopamine D4; Risperidone; Selective Serotonin Reuptake Inhibitors; Sulfonamides | 2007 |
Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chromatography, Liquid; Clozapine; Haloperidol; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Pyrimidines; Rats; Reproducibility of Results; Risperidone; Tandem Mass Spectrometry; Thiazoles | 2007 |
Phosphodiesterase inhibitors--are they potential neuroleptic drugs?
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Dose-Response Relationship, Drug; Haloperidol; Male; Motor Activity; Papaverine; Phosphodiesterase Inhibitors; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Risperidone; Rolipram | 2008 |
Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Databases, Factual; Female; Haloperidol; Hospitals, University; Humans; Long-Term Care; Male; Middle Aged; Olanzapine; Outpatient Clinics, Hospital; Retrospective Studies; Risperidone; Schizophrenia; Treatment Outcome; Treatment Refusal; Turkey | 2007 |
Long-term effects of JL 13, a potential atypical antipsychotic, on ionotropic glutamate receptors.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autoradiography; Benzodiazepines; Brain; Caudate Nucleus; Cerebral Cortex; Clozapine; Haloperidol; Hippocampus; Male; Olanzapine; Oxazepines; Piperazines; Putamen; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Risperidone; Tritium | 2007 |
Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale.
Topics: Antipsychotic Agents; Computer Simulation; Controlled Clinical Trials as Topic; Data Interpretation, Statistical; Factor Analysis, Statistical; Female; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Psychometrics; Reproducibility of Results; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index | 2007 |
Effective electroconvulsive therapy in a 92-year-old dementia patient with psychotic feature.
Topics: Aged, 80 and over; Antipsychotic Agents; Combined Modality Therapy; Dementia, Multi-Infarct; Electroconvulsive Therapy; Female; Haloperidol; Humans; Injections, Intravenous; Long QT Syndrome; Psychotic Disorders; Risperidone; Treatment Outcome | 2007 |
Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Cognition Disorders; Female; Haloperidol; Humans; Male; Psychometrics; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Surveys and Questionnaires | 2007 |
Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine.
Topics: Adult; Age of Onset; Antipsychotic Agents; Brazil; Clozapine; Epidemiologic Methods; Female; Haloperidol; Hospitals, Psychiatric; Humans; Length of Stay; Male; Patient Discharge; Patient Readmission; Risperidone; Schizophrenia; Time Factors | 2007 |
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Emotions; Facial Expression; Female; Haloperidol; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Perception; Treatment Outcome | 2007 |
Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Databases, Factual; Dibenzothiazepines; Female; Follow-Up Studies; Haloperidol; Humans; Male; Medicaid; Middle Aged; Olanzapine; Patient Compliance; Phenothiazines; Proportional Hazards Models; Quetiapine Fumarate; Retrospective Studies; Risperidone | 2007 |
Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats.
Topics: Acetylcholine; Administration, Oral; Animals; Antipsychotic Agents; Basal Nucleus of Meynert; Brain; Cholinergic Fibers; Cognition Disorders; Down-Regulation; Drug Administration Schedule; Haloperidol; Learning Disabilities; Male; Maze Learning; Memory Disorders; Nerve Growth Factor; Neurons; Rats; Rats, Wistar; Receptor, trkA; Risperidone; Space Perception; Time | 2007 |
The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux.
Topics: Acetylcholine; Analysis of Variance; Animals; Dopamine; Dopamine Antagonists; Drug Synergism; Haloperidol; Male; Microdialysis; Neurotensin; Peptide Fragments; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Risperidone | 2007 |
Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Databases, Factual; Dementia, Vascular; Dibenzothiazepines; Female; Haloperidol; Humans; Kaplan-Meier Estimate; Male; Medicare Part A; Multivariate Analysis; Olanzapine; Quetiapine Fumarate; Risk Assessment; Risk Factors; Risperidone; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans | 2007 |
Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.
Topics: Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Biperiden; Central Nervous System Stimulants; Clonazepam; Dyskinesia, Drug-Induced; Hallucinations; Haloperidol; Humans; Male; Methamphetamine; Olanzapine; Posture; Psychoses, Substance-Induced; Risperidone | 2007 |
Maximal response to electroconvulsive therapy for the treatment of catatonic symptoms.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Catatonia; Diazepam; Dose-Response Relationship, Drug; Electroconvulsive Therapy; Female; Haloperidol; Humans; Hypnotics and Sedatives; Infusions, Intravenous; Lorazepam; Male; Middle Aged; Retreatment; Risperidone; Schizophrenia, Catatonic; Treatment Outcome | 2007 |
Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Isoxazoles; Pyrimidines; Risperidone; Schizophrenia; Treatment Outcome | 2007 |
The chakragati mouse shows deficits in prepulse inhibition of acoustic startle and latent inhibition.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Clozapine; Conditioning, Psychological; Disease Models, Animal; Electroshock; Female; Haloperidol; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Neural Inhibition; Reflex, Startle; Risperidone; Schizophrenia | 2008 |
Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice.
Topics: Animals; Antipsychotic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Haloperidol; Isoxazoles; Male; Mice; Mice, Knockout; Motor Activity; Paliperidone Palmitate; Pyrimidines; Risperidone; Time Factors | 2008 |
Chronic antipsychotic drug administration alters the expression of neuregulin 1beta, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus.
Topics: Animals; Antibody Specificity; Antipsychotic Agents; Blotting, Western; Clozapine; ErbB Receptors; Glycoproteins; Haloperidol; Hippocampus; Immunohistochemistry; Male; Nerve Tissue Proteins; Neuregulin-1; Prefrontal Cortex; Rats; Rats, Wistar; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Risperidone | 2008 |
Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.
Topics: Benzodiazepines; Case-Control Studies; Ethics, Clinical; Feasibility Studies; Haloperidol; Humans; Olanzapine; Patient Dropouts; Pilot Projects; Randomized Controlled Trials as Topic; Registries; Risperidone; Schizophrenia; Time Factors | 2008 |
Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task.
Topics: Animals; Avoidance Learning; Behavior, Animal; Dizocilpine Maleate; Haloperidol; Male; Rats; Rats, Wistar; Risperidone; Ritanserin; Time Factors | 2008 |
Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Brain; Cerebrovascular Disorders; Clozapine; Cognition; Drug Resistance; Female; Haloperidol; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Psychiatric Status Rating Scales; Retrospective Studies; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Failure | 2008 |
A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats.
Topics: Animals; Antipsychotic Agents; Attention; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Excitatory Amino Acid Antagonists; Female; Habituation, Psychophysiologic; Haloperidol; Phencyclidine; Pilot Projects; Rats; Rats, Inbred Strains; Risperidone; Set, Psychology; Sex Factors; Statistics, Nonparametric | 2008 |
Three cases of schizophrenia for which olanzapine was effective after early acute phase.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Follow-Up Studies; Gambling; Haloperidol; Humans; Japan; Male; Mental Disorders; Middle Aged; Olanzapine; Patient Admission; Patient Compliance; Risperidone; Schizophrenia, Disorganized; Schizophrenia, Paranoid; Treatment Outcome | 2008 |
Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Benzodiazepines; Binding, Competitive; Clozapine; Conditioning, Psychological; Dopamine Antagonists; Haloperidol; Imidazoles; Indoles; Injections, Subcutaneous; Male; Models, Biological; Olanzapine; Protein Binding; Raclopride; Rats; Rats, Wistar; Receptors, Dopamine D2; Reproducibility of Results; Risperidone | 2008 |
Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
Topics: Administration, Oral; Adult; Age Factors; Ambulatory Care; Antipsychotic Agents; Clozapine; Cross-Sectional Studies; Delayed-Action Preparations; Female; Fluphenazine; Haloperidol; Health Knowledge, Attitudes, Practice; Humans; Long-Term Care; Male; Middle Aged; Patient Compliance; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Yugoslavia | 2008 |
[Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Prescriptions; Female; Follow-Up Studies; Haloperidol; Humans; Male; Mental Status Schedule; Olanzapine; Overweight; Risperidone; Schizophrenia; Treatment Outcome; Trifluoperazine | 2007 |
Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat--a back translational study.
Topics: Animals; Antipsychotic Agents; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition Disorders; Conditioning, Operant; Discrimination, Psychological; Excitatory Amino Acid Antagonists; Haloperidol; Imidazoles; Indoles; Male; Modafinil; Phencyclidine; Psychomotor Performance; Rats; Risperidone; Schizophrenic Psychology | 2009 |
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
Topics: Adult; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzothiazepines; Erectile Dysfunction; Female; Galactorrhea; Gynecomastia; Haloperidol; Humans; Hungary; International Cooperation; Libido; Male; Menstruation Disturbances; Middle Aged; Olanzapine; Outpatients; Patient Admission; Patient Compliance; Prospective Studies; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index | 2007 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Humans; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2008 |
[Atypical antipsychotics in elderly patients with dementia].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Haloperidol; Humans; Methotrimeprazine; Middle Aged; Olanzapine; Risk Factors; Risperidone; Stroke | 2008 |
Antipsychotics in individuals with intellectual disability.
Topics: Antipsychotic Agents; Behavior Control; Haloperidol; Humans; Intellectual Disability; Randomized Controlled Trials as Topic; Risperidone | 2008 |
Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics.
Topics: Adenine; Adult; Algeria; Antipsychotic Agents; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Family; Female; Gene Frequency; Guanine; Haloperidol; Humans; Lithium Carbonate; Male; Patient Selection; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT2A; Risperidone; Schizophrenia; Treatment Outcome | 2008 |
Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Patient Compliance; Piperazines; Quality of Life; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2008 |
Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Electrocardiography; Female; Haloperidol; Heart Rate; Hemodynamics; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Sex Characteristics; Smoking; Young Adult | 2009 |
Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Topics: Adult; Alleles; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Genetic Markers; Genotype; Haloperidol; Humans; Male; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Serotonin Plasma Membrane Transport Proteins | 2008 |
Case of acute psychosis from herbal supplements.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dietary Supplements; Female; Haloperidol; Humans; Lorazepam; Plant Extracts; Psychoses, Substance-Induced; Risperidone; Treatment Outcome | 2008 |
A comparison of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in DBA/2 and C57BL/6 inbred mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Discrimination Learning; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Olanzapine; Risperidone | 2008 |
Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Inhibition, Psychological; Male; Mice; Mice, Inbred Strains; Olanzapine; Piperazines; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Reflex, Startle; Risperidone; Serotonin Receptor Agonists; Species Specificity | 2008 |
Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Topics: Amisulpride; Amphetamine; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Blood-Brain Barrier; Brain; Clozapine; Conditioning, Psychological; Haloperidol; Male; Models, Animal; Motor Activity; Phencyclidine; Prefrontal Cortex; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Serotonin; Risperidone; Sulpiride | 2008 |
Effects of haloperidol and risperidone on the expression of heat shock protein 70 in MK-801-treated rat C6 glioma cells.
Topics: Animals; Cell Line, Tumor; Dizocilpine Maleate; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Gene Expression; Glioma; Haloperidol; HSP70 Heat-Shock Proteins; Linear Models; Rats; Risperidone; Time Factors | 2008 |
An autoregressive linear mixed effects model for the analysis of longitudinal data which include dropouts and show profiles approaching asymptotes.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Haloperidol; Humans; Linear Models; Longitudinal Studies; Patient Dropouts; Risperidone; Schizophrenia | 2008 |
The antagonistic effect of antipsychotic drugs on a HEK293 cell line stably expressing human alpha1A1-adrenoceptors.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Arteries; Binding, Competitive; Calcium; Cell Line; Haloperidol; Humans; Imidazoles; Indoles; Phenylephrine; Prazosin; Protein Isoforms; Radioligand Assay; Receptors, Adrenergic, alpha-1; Recombinant Proteins; Risperidone; Skin; Tritium; Vascular Resistance | 2008 |
Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.
Topics: Amisulpride; Animals; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Clozapine; Corpus Striatum; Depressive Disorder; Dose-Response Relationship, Drug; GTP-Binding Protein alpha Subunits; Haloperidol; Injections, Intraperitoneal; Male; Olanzapine; Rats; Rats, Wistar; Risperidone; Sulpiride; Time Factors | 2008 |
Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits.
Topics: Animals; Antipsychotic Agents; Brain; Brain Injuries; Cognition; Haloperidol; Male; Motor Activity; Neuropsychological Tests; Rats; Rats, Sprague-Dawley; Risperidone | 2008 |
Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia.
Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Electric Stimulation; Excitatory Amino Acid Antagonists; Haloperidol; Ketamine; Male; Morphine; Motor Activity; Pain; Pain Measurement; Rats; Rats, Sprague-Dawley; Risperidone; Schizophrenia; Schizophrenic Psychology | 2009 |
Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury.
Topics: Aggression; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Brain Injuries; Haloperidol; Male; Maze Learning; Memory; Postural Balance; Psychomotor Agitation; Rats; Rats, Sprague-Dawley; Recovery of Function; Risperidone; Space Perception; Swimming | 2008 |
Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost of Illness; Dibenzothiazepines; Female; Follow-Up Studies; Haloperidol; Humans; Kaplan-Meier Estimate; Long-Term Care; Male; Middle Aged; Olanzapine; Prospective Studies; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Animals; Antipsychotic Agents; Biological Clocks; Central Nervous System Stimulants; Disease Models, Animal; Drug Interactions; Electroencephalography; Evoked Potentials, Auditory; Excitatory Amino Acid Antagonists; Haloperidol; Ketamine; Male; Mice; Mice, Inbred C57BL; Reaction Time; Risperidone; Schizophrenia | 2009 |
Differential brain activation during facial emotion discrimination in first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain; Brain Mapping; Cues; Discrimination, Psychological; Echo-Planar Imaging; Emotions; Facial Expression; Female; Germany; Haloperidol; Humans; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Nerve Net; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Task Performance and Analysis; Young Adult | 2009 |
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Belgium; Benzodiazepines; Brief Psychiatric Rating Scale; Dyskinesia, Drug-Induced; Female; Haloperidol; Health Care Costs; Hospitalization; Humans; Male; Olanzapine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Weight Gain | 2009 |
Acute disseminated encephalomyelitis presenting as acute psychotic disorder.
Topics: Acute Disease; Anti-Inflammatory Agents; Antipsychotic Agents; Child; Child, Preschool; Diagnosis, Differential; Encephalomyelitis, Acute Disseminated; Female; Haloperidol; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Neuroprotective Agents; Psychotic Disorders; Risperidone | 2008 |
Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Cytokines; Haloperidol; Interleukin-10; Interleukin-6; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Olanzapine; Poly I-C; Risperidone; Serotonin Antagonists; Tumor Necrosis Factor-alpha | 2009 |
Effects of yokukansan, a traditional Japanese medicine, on aggressiveness induced by intracerebroventricular injection of amyloid beta protein into mice.
Topics: Aggression; Amyloid beta-Peptides; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Haloperidol; Male; Medicine, Traditional; Mice; Motor Activity; Plant Extracts; Risperidone | 2009 |
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Female; Follow-Up Studies; Galactorrhea; Gynecomastia; Haloperidol; Humans; Injections; Male; Menstruation Disturbances; Psychiatric Status Rating Scales; Psychotic Disorders; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Severity of Illness Index; South Africa; Treatment Outcome; Young Adult | 2008 |
Internal capsule size associated with outcome in first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Follow-Up Studies; Haloperidol; Hippocampus; Humans; Internal Capsule; Lateral Ventricles; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome; Young Adult | 2009 |
Antipsychotics affect multiple calcium calmodulin dependent proteins.
Topics: Animals; Antipsychotic Agents; Calcineurin; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinase Type 4; Calcium-Calmodulin-Dependent Protein Kinases; Calmodulin; Clozapine; Corpus Striatum; Dopamine Antagonists; Haloperidol; Male; Psychotropic Drugs; Raclopride; Rats; Rats, Sprague-Dawley; Risperidone; RNA, Messenger | 2009 |
Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
Topics: Amphetamine-Related Disorders; Animals; Antipsychotic Agents; Apomorphine; Corpus Striatum; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Female; Haloperidol; Limbic System; Long-Term Care; Mesencephalon; Mice; Motor Activity; Neural Pathways; Receptors, Dopamine D2; Risperidone; Stereotyped Behavior; Substance Withdrawal Syndrome; Substantia Nigra; Up-Regulation | 2009 |
Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Conditioning, Operant; Dose-Response Relationship, Drug; Haloperidol; Injections, Subcutaneous; Male; Memory; Olanzapine; Psychotropic Drugs; Rats; Rats, Sprague-Dawley; Risperidone | 2010 |
Haloperidol changes mRNA expression of a QKI splice variant in human astrocytoma cells.
Topics: Alternative Splicing; Antipsychotic Agents; Aripiprazole; Astrocytoma; Benzodiazepines; Cell Line, Tumor; Clozapine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Risperidone; RNA-Binding Proteins; RNA, Messenger; Time Factors | 2009 |
[Peculiarities of neuroleptic syndrome in women treated with typical and atypical neuroleptics].
Topics: Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Risperidone; Sexuality; Treatment Outcome | 2009 |
Effects of typical (haloperidol) and atypical (risperidone) antipsychotic agents on protein expression in rat neural stem cells.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Cells, Cultured; Cytoskeleton; Databases, Factual; Electrophoresis, Gel, Two-Dimensional; Fluorescent Antibody Technique; Haloperidol; Image Processing, Computer-Assisted; Mass Spectrometry; Nerve Tissue Proteins; Neurons; Oxidative Stress; Rats; Risperidone; Stem Cells | 2009 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzodiazepines; Benzoxazoles; Catalepsy; Clozapine; Dibenzothiazepines; Dioxanes; Dopamine Antagonists; Female; Haloperidol; Macaca fascicularis; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Remoxipride; Risperidone; Serotonin Receptor Agonists; Thiazoles; Tropanes; Video Recording | 2009 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Fluphenazine; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia | 2009 |
Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population.
Topics: Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Dibenzothiazepines; Dyslipidemias; Female; Haloperidol; Humans; Hypertriglyceridemia; Male; Olanzapine; Quetiapine Fumarate; Retrospective Studies; Risk Assessment; Risperidone; Time Factors; United States; United States Department of Veterans Affairs | 2009 |
Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Dopamine; Dopamine D2 Receptor Antagonists; Drug Synergism; Extracellular Space; Fluorobenzenes; Glutamic Acid; Haloperidol; Imidazoles; Indoles; Male; Microdialysis; Piperidines; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Risperidone; Serotonin 5-HT2 Receptor Antagonists | 2009 |
Risperidone and haloperidol promote survival of stem cells in the rat hippocampus.
Topics: Adult Stem Cells; Animals; Antipsychotic Agents; Bromodeoxyuridine; Cell Proliferation; Cell Survival; Gene Expression Regulation; Haloperidol; Hippocampus; In Situ Nick-End Labeling; Male; Models, Animal; Nerve Tissue Proteins; Rats; Rats, Sprague-Dawley; Risperidone; RNA, Messenger; Time Factors | 2010 |
The d-amphetamine-treated Göttingen miniature pig: an animal model for assessing behavioral effects of antipsychotics.
Topics: Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; Hyperkinesis; Male; Risperidone; Swine; Swine, Miniature | 2009 |
Transient prenatal vitamin D deficiency is associated with changes of synaptic plasticity in the dentate gyrus in adult rats.
Topics: Animals; Dentate Gyrus; Female; Haloperidol; Long-Term Potentiation; Male; Neuronal Plasticity; Pregnancy; Rats; Rats, Sprague-Dawley; Risperidone; Time Factors; Vitamin D Deficiency | 2009 |
Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
Topics: Antipsychotic Agents; Benzodiazepines; Brazil; Cost-Benefit Analysis; Drug Costs; Haloperidol; Humans; Markov Chains; Medication Adherence; Olanzapine; Quality of Life; Quality-Adjusted Life Years; Recurrence; Risperidone; Schizophrenia | 2009 |
The effects of the second generation antipsychotics and a typical neuroleptic on collagen-induced platelet aggregation in vitro.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Collagen; Female; Haloperidol; Humans; In Vitro Techniques; Male; Olanzapine; Platelet Activation; Platelet Aggregation; Risperidone | 2010 |
[Complex therapy of schizophrenia].
Topics: Adolescent; Adult; Antipsychotic Agents; Art Therapy; Benzodiazepines; Clinical Trials as Topic; Clozapine; Cognitive Behavioral Therapy; Combined Modality Therapy; Dance Therapy; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Music Therapy; Occupational Therapy; Olanzapine; Psychotherapy; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology; Single-Blind Method; Suicide; Treatment Outcome; Young Adult | 2009 |
Different antipsychotics elicit different effects on magnocellular oxytocinergic and vasopressinergic neurons as revealed by Fos immunohistochemistry.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Haloperidol; Hypothalamus; Immunohistochemistry; Male; Neurons; Olanzapine; Oxytocin; Paraventricular Hypothalamic Nucleus; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Risperidone; Supraoptic Nucleus; Vasopressins | 2010 |
The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders?
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Mice; Mice, Knockout; Motor Activity; Neuropsychological Tests; Receptors, Dopamine D2; Receptors, G-Protein-Coupled; Reflex, Startle; Risperidone | 2009 |
Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Asian People; Female; Haloperidol; Humans; Kaplan-Meier Estimate; Male; Psychiatric Status Rating Scales; Retrospective Studies; Risperidone; Schizophrenia; Socioeconomic Factors; Treatment Outcome; Trifluoperazine; Young Adult | 2010 |
Risperidone and dementia-related aggression: new indication. A last resort, no better than haloperidol.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dementia; Drug Approval; Europe; France; Haloperidol; Humans; Randomized Controlled Trials as Topic; Risperidone | 2009 |
Effects of atypical (risperidone) and typical (haloperidol) antipsychotic agents on astroglial functions.
Topics: Animals; Antipsychotic Agents; Astrocytes; Brain Chemistry; Cell Line; Glutamate-Ammonia Ligase; Glutamic Acid; Glutathione; Haloperidol; Humans; Reactive Oxygen Species; Risperidone; Schizophrenia | 2010 |
Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study.
Topics: Adult; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Female; Finland; Haloperidol; Humans; Male; Perphenazine; Quetiapine Fumarate; Risperidone; Schizophrenia; Suicide; Survival Rate | 2010 |
Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Case-Control Studies; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Risperidone; Schizophrenia; Sulpiride; Treatment Failure | 2010 |
The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation.
Topics: Adenosine Diphosphate; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Haloperidol; Humans; Male; Olanzapine; Platelet Activation; Platelet Aggregation; Risperidone | 2010 |
The dose-dependent effect of chronic administration of haloperidol, risperidone, and quetiapine on sexual behavior in the male rat.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dibenzothiazepines; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Haloperidol; Humans; Male; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Risperidone; Serotonin Antagonists; Sexual Behavior, Animal; Sexual Dysfunction, Physiological; Statistics as Topic; Time Factors | 2011 |
Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain Mapping; Carrier Proteins; Corpus Striatum; Gene Expression Regulation; Haloperidol; Homer Scaffolding Proteins; Male; Olanzapine; Random Allocation; Rats; Rats, Sprague-Dawley; Risperidone; RNA, Messenger; Sulpiride | 2010 |
The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Topics: Adult; Alleles; Antipsychotic Agents; Bipolar Disorder; Clozapine; Cytochrome P-450 CYP2D6; Dibenzothiazepines; Drug Therapy, Combination; Fluphenazine; Genetic Carrier Screening; Genotype; Haloperidol; Humans; Lithium Carbonate; Male; Neuroleptic Malignant Syndrome; Perazine; Polymorphism, Genetic; Psychotic Disorders; Quetiapine Fumarate; Receptors, Dopamine D2; Recurrence; Risperidone | 2010 |
Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Utilization; Female; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Kaplan-Meier Estimate; Length of Stay; Male; Microspheres; Middle Aged; Patient Discharge; Proportional Hazards Models; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics.
Topics: Aged; Antipsychotic Agents; Cinnarizine; Cohort Studies; Diagnosis, Differential; Female; Flunarizine; Haloperidol; Humans; Male; Methotrimeprazine; Movement Disorders; Outpatient Clinics, Hospital; Parkinsonian Disorders; Psychotic Disorders; Risperidone; Severity of Illness Index; Time Factors; Valproic Acid | 2010 |
Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Carbon Radioisotopes; Cerebellar Cortex; Cerebral Cortex; Computer Graphics; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Humans; Hyperprolactinemia; Male; Mathematical Computing; Middle Aged; Olanzapine; Pituitary Gland; Positron-Emission Tomography; Prolactin; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Salicylamides; Schizophrenia; Statistics as Topic; Sulpiride; Temporal Lobe; Young Adult | 2010 |
The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro.
Topics: Animals; Antipsychotic Agents; Autoradiography; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Haloperidol; Humans; In Vitro Techniques; Male; Olanzapine; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Risperidone; Tritium; Vitamin K 1 | 2010 |
Acute respiratory distress due to antipsychotic drugs.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Drug Therapy, Combination; Dystonia; Fatal Outcome; Haloperidol; Humans; Larynx; Male; Olanzapine; Respiratory Distress Syndrome; Respiratory Insufficiency; Risperidone; Schizophrenia | 2010 |
A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Blood Glucose; Clozapine; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Glucose Tolerance Test; Haloperidol; Insulin; Insulin Resistance; Rats; Rats, Sprague-Dawley; Risperidone | 2010 |
Atypical anti-psychotics in delusional parasitosis: a retrospective case series of 20 patients.
Topics: Antipsychotic Agents; Benzodiazepines; Ectoparasitic Infestations; Female; Fluoxetine; Haloperidol; Humans; Imipramine; Male; Middle Aged; Olanzapine; Pimozide; Retrospective Studies; Risperidone; Schizophrenia, Paranoid; Sertraline | 2010 |
Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Comorbidity; Dementia; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Olanzapine; Proportional Hazards Models; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Sex Factors; Veterans | 2010 |
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Carnitine; Clozapine; Energy Metabolism; Fatty Acids, Nonesterified; Female; Haloperidol; Insulin Resistance; Lipolysis; Male; Malonyl Coenzyme A; Mice; Olanzapine; Piperazines; Rats; Rats, Sprague-Dawley; Risperidone; Thiazoles; Vitamin B Complex | 2012 |
An early improvement threshold to predict response and remission in first-episode schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Germany; Haloperidol; Humans; Male; Middle Aged; Psychotic Disorders; Remission Induction; Risperidone; ROC Curve; Schizophrenia; Time Factors; Treatment Outcome; Young Adult | 2010 |
Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics.
Topics: Adult; Antioxidants; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Glutathione Peroxidase; Haloperidol; Humans; Lipid Peroxidation; Malondialdehyde; Middle Aged; Olanzapine; Oxidative Stress; Quetiapine Fumarate; Risperidone; Schizophrenia; Superoxide Dismutase | 2010 |
Serotonin-dopamine antagonism ameliorates impairments of spontaneous alternation and locomotor hyperactivity induced by repeated electroconvulsive seizures in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Dopamine Antagonists; Electroshock; Haloperidol; Hyperkinesis; Ketanserin; Male; Motor Activity; Random Allocation; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT2; Risperidone; Seizures; Serotonin Antagonists; Sulpiride | 2010 |
Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Ketamine; Male; Mice; Motor Activity; Psychotic Disorders; Random Allocation; Risperidone; Schizophrenia; Substance Withdrawal Syndrome; Swimming | 2011 |
Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Catalepsy; Cholinergic Antagonists; Cholinesterase Inhibitors; Disease Models, Animal; Extrapyramidal Tracts; Galantamine; Haloperidol; Male; Mecamylamine; Motor Activity; Nicotinic Antagonists; Rats; Rats, Wistar; Receptors, Muscarinic; Risperidone; Schizophrenia; Scopolamine | 2011 |
Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: involvement of dopamine D2 and 5-HT2A receptors.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Benzazepines; Clozapine; Dopamine Agents; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Haloperidol; Ketanserin; Male; Memantine; Mice; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Reflex, Startle; Risperidone; Sensory Gating | 2011 |
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Psychotic Disorders; Receptors, Dopamine D2; Risperidone; Schizophrenia; Self Report; Severity of Illness Index; Young Adult | 2011 |
Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor.
Topics: Animals; Antipsychotic Agents; Breeding; Catalepsy; Haloperidol; Male; Mice; Motor Activity; Receptor, Muscarinic M4; Risperidone; Scopolamine | 2011 |
The interaction of antipsychotic drugs with lipids and subsequent lipid reorganization investigated using biophysical methods.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antipsychotic Agents; Calorimetry, Differential Scanning; Cell Membrane; Cholesterol; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Haloperidol; Isoxazoles; Membrane Lipids; Membranes, Artificial; Microscopy, Fluorescence; Models, Molecular; Molecular Conformation; Molecular Structure; Paliperidone Palmitate; Phosphatidylcholines; Pyrimidines; Receptors, Dopamine D2; Risperidone; Sphingomyelins; Structure-Activity Relationship; Surface Plasmon Resonance; X-Ray Diffraction | 2011 |
Role of the dopamine transporter in mediating the neuroleptic-induced reduction of tyrosine hydroxylase-immunoreactive midbrain neurons.
Topics: Animals; Antipsychotic Agents; Clozapine; Dopamine Plasma Membrane Transport Proteins; Haloperidol; Immunohistochemistry; Mesencephalon; Neurons; Rats; Rats, Sprague-Dawley; Risperidone; Tyrosine 3-Monooxygenase | 2011 |
Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Drug Interactions; Hallucinogens; Haloperidol; Humans; Male; Models, Animal; Motor Activity; Phencyclidine; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Reflex, Startle; Risperidone | 2011 |
[Effect of haloperidol and risperidone on neuromarkers and indices of endothelial dysfunction in patients with acute schizophrenia].
Topics: Adult; Antipsychotic Agents; Autoantibodies; Biomarkers; Brain-Derived Neurotrophic Factor; Female; Glial Fibrillary Acidic Protein; Haloperidol; Humans; Male; Nitric Oxide; Receptors, N-Methyl-D-Aspartate; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2011 |
Contributions to the study of morphofunctional interrelations in the liver of the rats treated with certain antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Chlorpromazine; Haloperidol; Liver; Male; Rats; Rats, Wistar; Risperidone | 2011 |
Differential effects of antipsychotic medications on polyunsaturated fatty acid biosynthesis in rats: Relationship with liver delta6-desaturase expression.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drinking Water; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Fatty Acids, Unsaturated; Haloperidol; Isoxazoles; Linoleoyl-CoA Desaturase; Liver; Male; Olanzapine; Paliperidone Palmitate; Pyrimidines; Quetiapine Fumarate; Rats; Rats, Long-Evans; Risperidone; RNA, Messenger | 2011 |
An importance of dose in antipsychotic combination therapy for schizophrenia.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Haloperidol; Humans; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency | 2011 |
Antipsychotic drugs suppress the AKT/NF-κB pathway and regulate the differentiation of T-cell subsets.
Topics: Antipsychotic Agents; CD4-Positive T-Lymphocytes; Cell Differentiation; Cells, Cultured; Clozapine; GATA3 Transcription Factor; Haloperidol; Humans; NF-kappa B; Oncogene Protein v-akt; Risperidone; Schizophrenia; Signal Transduction; T-Box Domain Proteins; T-Lymphocyte Subsets; Th1-Th2 Balance | 2011 |
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Models, Economic; National Health Programs; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sweden | 2011 |
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hallucinations; Haloperidol; Humans; Hungary; Male; Marijuana Abuse; Olanzapine; Paranoid Disorders; Piperazines; Psychomotor Performance; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology | 2011 |
Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells.
Topics: Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Haloperidol; Humans; Isoxazoles; Neuroblastoma; Neuroprotective Agents; Paliperidone Palmitate; Pyrimidines; Risperidone | 2012 |
Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool.
Topics: Antipsychotic Agents; Catecholamines; Diagnosis, Differential; Dibenzothiazepines; Dopamine; Female; Haloperidol; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Quetiapine Fumarate; Risperidone; Serotonin; Serotonin Syndrome | 2011 |
Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Catalepsy; Drug Synergism; Glutamic Acid; Glycine Plasma Membrane Transport Proteins; Haloperidol; Male; Membrane Potentials; Olanzapine; Oxadiazoles; Piperidines; Prefrontal Cortex; Rats; Rats, Wistar; Receptors, AMPA; Risperidone; Synaptic Transmission; Tetrahydronaphthalenes | 2012 |
Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-α-directed cell apoptosis in neutrophils.
Topics: Adult; Antipsychotic Agents; Apoptosis; Cell Differentiation; Cytokines; Dendritic Cells; Dopamine Antagonists; Haloperidol; Humans; Neutrophils; Risperidone; Serotonin Antagonists; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2012 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Medical Records; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome | 2011 |
Risk of mortality among individual antipsychotics in patients with dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Olanzapine; Propensity Score; Quetiapine Fumarate; Retrospective Studies; Risk; Risperidone; Time Factors; Valproic Acid | 2012 |
Randomised control trials for delirium: current evidence and statistical methods.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Humans; Male; Risperidone | 2012 |
Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.
Topics: Adult; Amisulpride; Analysis of Variance; Antipsychotic Agents; Attention; Benzodiazepines; Dibenzothiazepines; Emotions; Fluphenazine; Haloperidol; Humans; Memory; Middle Aged; Olanzapine; Perazine; Perphenazine; Quetiapine Fumarate; Recognition, Psychology; Risperidone; Schizophrenia; Sulpiride | 2012 |
Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Combinations; Drug Interactions; Female; Haloperidol; Humans; Piperazines; Psychoses, Substance-Induced; Psychotic Disorders; Quinolones; Recurrence; Risperidone | 2012 |
Antipsychotics leading to neuroleptic malignant syndrome in pregnancy.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Pregnancy; Pregnancy Complications; Psychotic Disorders; Risperidone | 2012 |
Perphenazine suspension: a new, old treatment, side effects and continuous use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Clinical Trials as Topic; Drug Compounding; Drug Delivery Systems; Female; Fluphenazine; Haloperidol; Hospitals, Psychiatric; Humans; Male; Movement Disorders; Olanzapine; Patient Discharge; Perphenazine; Risperidone; Suspensions; Treatment Outcome | 2012 |
Effectiveness of sulpiride in adult patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Proportional Hazards Models; Retrospective Studies; Risperidone; Schizophrenia; Sulpiride; Treatment Outcome; Young Adult | 2013 |
Quality of life of schizophrenic patients treated with haloperidol depot and injection preparation of long-lasting risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Female; Haloperidol; Humans; Male; Middle Aged; Quality of Life; Risperidone; Schizophrenia; Young Adult | 2011 |
Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cause of Death; Comorbidity; Dementia; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Epidemiologic Methods; Female; Haloperidol; Humans; Male; Medical Assistance; Mortality; Nursing Homes; Quetiapine Fumarate; Risperidone; United States | 2012 |
Molecular combination of the dopamine and serotonin scaffolds yield in novel antipsychotic drug candidates - characterization by in vivo experiments.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Biological Availability; Calcium; Catalepsy; Cells, Cultured; Dopamine; Female; Haloperidol; Humans; Motor Activity; Neuroglia; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Serotonin; Structure-Activity Relationship; Tetrazolium Salts; Thiazoles | 2012 |
The effect of chronic antipsychotic drug on hypothalamic expression of neural nitric oxide synthase and dopamine D2 receptor in the male rat.
Topics: Animals; Antipsychotic Agents; Haloperidol; Hypothalamus; Immunohistochemistry; Male; Nitric Oxide Synthase Type I; Rats; Receptors, Dopamine D2; Risperidone | 2012 |
Antipsychotic induced alteration of growth and proteome of rat neural stem cells.
Topics: Animals; Antipsychotic Agents; Apoptosis; Cell Proliferation; Gene Expression Profiling; Haloperidol; Neural Stem Cells; Oxidative Stress; Proteome; Proteomics; Rats; Risperidone | 2012 |
Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Haloperidol; Immobility Response, Tonic; Ketamine; Male; Motor Activity; Rats; Rats, Wistar; Reproducibility of Results; Risperidone; Schizophrenia; Swimming | 2012 |
Sex differences in human lymphoblastoid cells sensitivities to antipsychotic drugs.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Antineoplastic Agents; Antipsychotic Agents; Cell Division; Cell Survival; Cells, Cultured; Cytostatic Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Resistance; Dystonic Disorders; Female; Haloperidol; Humans; Lymphocytes; Male; Paroxetine; Risperidone; Schizophrenia; Sex Characteristics; Sex Distribution | 2013 |
13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients.
Topics: Adult; Animals; Antipsychotic Agents; Breath Tests; Carbon Isotopes; Chronic Disease; Dopamine; Haloperidol; Humans; Male; Middle Aged; Phenylalanine; Rats; Rats, Wistar; Risperidone; Schizophrenia; Spectrophotometry, Infrared | 2012 |
Nitric oxide in patients with schizophrenia: the relationship with the severity of illness and the antipsychotic treatment.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Female; Haloperidol; Humans; Male; Middle Aged; Nitrates; Nitric Oxide; Olanzapine; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Severity of Illness Index; Young Adult | 2012 |
Two-dimensional gel electrophoresis revealed antipsychotic drugs induced protein expression modulations in C6 glioma cells.
Topics: Animals; Antipsychotic Agents; Cell Line, Tumor; Clozapine; Electrophoresis, Gel, Two-Dimensional; Frontal Lobe; Gene Expression; Glioma; Haloperidol; Rats; Risperidone; Time Factors | 2013 |
Choline acetyltransferase expression in rat prefrontal cortex and hippocampus after acute and chronic exposure to amisulpride, haloperidol, and risperidone.
Topics: Amisulpride; Animals; Antipsychotic Agents; Choline O-Acetyltransferase; Dose-Response Relationship, Drug; Haloperidol; Hippocampus; Male; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Risperidone; Sulpiride; Time Factors | 2012 |
Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone.
Topics: Animals; Antipsychotic Agents; Cell Line, Tumor; Cytokines; Enzyme-Linked Immunosorbent Assay; Glial Fibrillary Acidic Protein; Glioma; Glutathione; Haloperidol; Hippocampus; Immunohistochemistry; Interleukin-1beta; Interleukin-6; Interleukin-8; L-Lactate Dehydrogenase; Nerve Growth Factors; Neuroglia; Nitric Oxide; Oxidative Stress; Rats; Rats, Wistar; Reactive Oxygen Species; Risperidone; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Tetrazolium Salts; Thiazoles; Tumor Necrosis Factor-alpha | 2013 |
White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.
Topics: Adolescent; Adult; Anisotropy; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Brain Mapping; Case-Control Studies; Dibenzothiazepines; Diffusion Tensor Imaging; Female; Frontal Lobe; Gyrus Cinguli; Haloperidol; Humans; Image Processing, Computer-Assisted; Male; Nerve Fibers, Myelinated; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Treatment Outcome; Young Adult | 2013 |
The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Haloperidol; Hyperbilirubinemia; Inhibition, Psychological; Locomotion; Male; Neuropsychological Tests; Piperazines; Quinolones; Rats; Rats, Gunn; Reflex, Startle; Risperidone; Schizophrenia; Social Behavior; Treatment Outcome | 2013 |
Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; Injections; Isoxazoles; Medication Adherence; Olanzapine; Paliperidone Palmitate; Palmitates; Risperidone; Schizophrenia | 2013 |
Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Brain; Cohort Studies; Haloperidol; Humans; Neocortex; Rats; Risperidone; RNA, Messenger; Schizophrenia; Shaw Potassium Channels; Treatment Outcome | 2014 |
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Haloperidol; Humans; Hyperprolactinemia; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Prolactin; Prospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Sexual Dysfunction, Physiological; Sulpiride | 2013 |
A biological basis for the sex bias of antipsychotic drugs adverse events.
Topics: Aged; Antipsychotic Agents; Cell Line; Cell Proliferation; Dementia; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; In Vitro Techniques; Male; Risperidone; Sex Factors | 2013 |
Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Data Interpretation, Statistical; Dizocilpine Maleate; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Fluorobenzenes; Haloperidol; Male; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Reflex, Startle; Risperidone; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Sulfonamides; Thiophenes | 2014 |
Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Cohort Studies; Dementia; Female; Haloperidol; Humans; Longitudinal Studies; Male; Norway; Proportional Hazards Models; Risperidone; Survival Analysis | 2014 |
Differential long-term effects of haloperidol and risperidone on the acquisition and performance of tasks of spatial working and short-term memory and sustained attention in rats.
Topics: Animals; Antipsychotic Agents; Attention; Conditioning, Operant; Dose-Response Relationship, Drug; Haloperidol; Male; Maze Learning; Memory, Short-Term; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Risperidone; Serial Learning; Space Perception; Time | 2013 |
Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Delirium; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Prospective Studies; Quetiapine Fumarate; Risperidone; Treatment Outcome | 2013 |
Differential effects upon brain and serum BDNF levels in rats as response to continuous and intermittent administration strategies of two second generation antipsychotics.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Brain; Brain-Derived Neurotrophic Factor; Drug Administration Schedule; Follow-Up Studies; Haloperidol; Male; Rats; Rats, Sprague-Dawley; Risperidone | 2013 |
Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost of Illness; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Female; Haloperidol; Health Care Costs; Hospitalization; Humans; Isoxazoles; Male; Middle Aged; Models, Econometric; Olanzapine; Paliperidone Palmitate; Palmitates; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Sweden | 2014 |
Should remission in schizophrenia data be combined from different studies?
Topics: Activities of Daily Living; Behavioral Symptoms; Female; Haloperidol; Humans; Male; Remission Induction; Risperidone; Schizophrenia | 2014 |
Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Female; Genetic Association Studies; Genotype; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Pharmacogenetics; Polymorphism, Single Nucleotide; Predictive Value of Tests; Risperidone; Schizophrenia; Treatment Outcome | 2014 |
The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
Topics: Amino Acids; Animals; Antipsychotic Agents; Banisteriopsis; Brain Waves; Bridged Bicyclo Compounds, Heterocyclic; Clozapine; Excitatory Amino Acid Agonists; Functional Neuroimaging; Hallucinogens; Haloperidol; Magnetic Resonance Imaging; Male; Methoxydimethyltryptamines; Prefrontal Cortex; Pyramidal Cells; Rats; Risperidone; Visual Cortex | 2014 |
Despite expert recommendations, second-generation antipsychotics are not often prescribed in the emergency department.
Topics: Administration, Oral; Adult; Alcoholic Intoxication; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Droperidol; Drug Prescriptions; Drug Therapy, Combination; Emergency Service, Hospital; Female; Haloperidol; Hospitals, University; Humans; Male; Middle Aged; Olanzapine; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2014 |
Haloperidol treatment downregulates DCC expression in the ventral tegmental area.
Topics: Animals; Antipsychotic Agents; Clozapine; DCC Receptor; Dose-Response Relationship, Drug; Down-Regulation; Haloperidol; Male; Mice, Inbred C57BL; Netrin Receptors; Receptors, Cell Surface; Risperidone; Time Factors; Tumor Suppressor Proteins; Ventral Tegmental Area | 2014 |
Effect of antipsychotic drugs on gene expression in the prefrontal cortex and nucleus accumbens in the spontaneously hypertensive rat (SHR).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; DNA Methylation; Gene Expression; Haloperidol; Male; Neurotransmitter Agents; Nucleus Accumbens; Prefrontal Cortex; Promoter Regions, Genetic; Rats, Inbred SHR; Risperidone; Schizophrenia | 2014 |
Generalized estimating equation model and long-term exposure effect of antipsychotics on SH-SY5Y cells against oxidative stressors.
Topics: 1-Methyl-4-phenylpyridinium; Amyloid beta-Peptides; Antipsychotic Agents; Benzodiazepines; Cell Line, Tumor; Cell Survival; Glutathione; Haloperidol; Humans; Hydrogen Peroxide; Models, Biological; Neuroprotective Agents; Olanzapine; Oxidative Stress; Paliperidone Palmitate; Peptide Fragments; Protein Carbonylation; Risperidone | 2014 |
Adverse effects of antipsychotics on micro-vascular endothelial cells of the human blood-brain barrier.
Topics: Antipsychotic Agents; Apoptosis; Blood-Brain Barrier; Capillary Permeability; Caspase 3; Caspase 8; Caspase 9; Cell Survival; Cells, Cultured; Chlorpromazine; Clozapine; DNA Breaks; Endothelial Cells; Haloperidol; Humans; Microvessels; Oxidative Stress; Reactive Oxygen Species; Risperidone | 2014 |
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Dementia; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Risperidone | 2015 |
Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea.
Topics: Antiphospholipid Syndrome; Child; Chorea; Dopamine Antagonists; Haloperidol; Humans; Immunoglobulins, Intravenous; Risperidone | 2014 |
Divergent long-term consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on traumatic brain injury-induced cognitive deficits.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Brain Injuries; Bromocriptine; Cognition Disorders; Dopamine Agonists; Haloperidol; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Recovery of Function; Risperidone; Time Factors | 2015 |
A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics.
Topics: Administration, Intravenous; Animals; Antipsychotic Agents; Chlorpromazine; Clozapine; Dopamine; Haloperidol; Male; Microdialysis; Nucleus Accumbens; Prefrontal Cortex; Raclopride; Rats; Rats, Sprague-Dawley; Risperidone; Time Factors | 2015 |
Differential effects of clozapine, metoclopramide, haloperidol and risperidone on acquisition and performance of operant responding in rats.
Topics: Animals; Antipsychotic Agents; Clozapine; Conditioning, Operant; Dopamine D2 Receptor Antagonists; Haloperidol; Male; Metoclopramide; Prefrontal Cortex; Rats; Rats, Wistar; Risperidone | 2015 |
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Disease Models, Animal; Epilepsy; Haloperidol; Mental Disorders; Olanzapine; Quetiapine Fumarate; Rats; Risperidone; Seizures | 2015 |
Regulation of neutrophil phagocytosis of Escherichia coli by antipsychotic drugs.
Topics: Antipsychotic Agents; Blotting, Western; Clozapine; Escherichia coli; Haloperidol; HL-60 Cells; Humans; Interleukin-8; Macrophage-1 Antigen; Neutrophils; Peroxidase; Phagocytosis; Risperidone | 2014 |
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Delirium; Female; Half-Life; Haloperidol; Humans; Male; Middle Aged; Neoplasms; Olanzapine; Quetiapine Fumarate; Risperidone; Severity of Illness Index | 2016 |
Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Dementia; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Psychotropic Drugs; Quetiapine Fumarate; Registries; Retrospective Studies; Risk; Risperidone; United States; Veterans | 2015 |
The serotonin 5-HT₁A receptor agonist tandospirone improves executive function in common marmosets.
Topics: Animals; Antipsychotic Agents; Callithrix; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Executive Function; Haloperidol; Isoindoles; Male; Piperazines; Piperidines; Psychological Tests; Psychotropic Drugs; Pyrimidines; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1; Risperidone; Serotonin 5-HT1 Receptor Agonists | 2015 |
A comparison of risperidone and haloperidol for the risk of ischemic stroke in the elderly: a propensity score-matched cohort analysis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Brain Ischemia; Cohort Studies; Female; Haloperidol; Humans; Male; National Health Programs; Propensity Score; Republic of Korea; Risk; Risperidone; Stroke | 2015 |
The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
Topics: Adolescent; Adult; Alleles; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Genotype; Haloperidol; Heterozygote; Humans; Male; Middle Aged; Pimozide; Polymorphism, Single Nucleotide; Retrospective Studies; Risperidone; Schizophrenia; Young Adult | 2015 |
Differential Pharmacological Regulation of Sensorimotor Gating Deficit in CB1 Knockout Mice and Associated Neurochemical and Histological Alterations.
Topics: Animals; Cannabinoid Receptor Antagonists; Central Nervous System Agents; Cerebral Cortex; Cholecystokinin; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Immunohistochemistry; Male; Methylphenidate; Mice, Knockout; Neurons; Parvalbumins; Peptide Fragments; Piperidines; Prepulse Inhibition; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Adrenergic, alpha-2; Risperidone; Time Factors | 2015 |
A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Cost-Benefit Analysis; Drug Costs; Haloperidol; Health Care Costs; Humans; Middle Aged; Olanzapine; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Uganda | 2015 |
Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cohort Studies; Female; Finland; Follow-Up Studies; Haloperidol; Humans; Male; Prevalence; Quetiapine Fumarate; Registries; Risperidone; Time Factors; Treatment Outcome | 2015 |
Low expression of Gria1 and Grin1 glutamate receptors in the nucleus accumbens of Spontaneously Hypertensive Rats (SHR).
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Gene Expression; Glycine Plasma Membrane Transport Proteins; Haloperidol; Male; Nucleus Accumbens; Prefrontal Cortex; Rats; Rats, Inbred SHR; Receptors, AMPA; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Reverse Transcriptase Polymerase Chain Reaction; Risperidone; Schizophrenia | 2015 |
Examining Huntington's disease patient and informant concordance on frontally mediated behaviors.
Topics: Adult; Aged; Antipsychotic Agents; Awareness; Cognition Disorders; Disease Progression; Female; Frontal Lobe; Haloperidol; Humans; Huntington Disease; Male; Mental Disorders; Middle Aged; Retrospective Studies; Risperidone; Severity of Illness Index | 2015 |
Haloperidol and Risperidone at high concentrations activate an in vitro inflammatory response of RAW 264.7 macrophage cells by induction of apoptosis and modification of cytokine levels.
Topics: Animals; Antipsychotic Agents; Apoptosis; Cell Survival; Cytokines; Dose-Response Relationship, Drug; Haloperidol; Inflammation; Macrophage Activation; Mice; Nitric Oxide; RAW 264.7 Cells; Risperidone | 2016 |
A comparison of the effectiveness of risperidone, haloperidol and flupentixol long-acting injections in patients with schizophrenia--A nationwide study.
Topics: Adult; Antipsychotic Agents; Drug Delivery Systems; Female; Flupenthixol; Haloperidol; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Statistics, Nonparametric; Treatment Outcome | 2015 |
The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
Topics: Action Potentials; Animals; Cerebral Cortex; Dopamine Antagonists; Dose-Response Relationship, Drug; Hallucinogens; Haloperidol; Male; Methoxydimethyltryptamines; Mice; Mice, Inbred C57BL; Mice, Transgenic; Patch-Clamp Techniques; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Risperidone; Serotonin; Serotonin Agents | 2016 |
Risk of Mortality Among Patients Treated With Antipsychotic Medications: A Nationwide Population-Based Study in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chlorpromazine; Critical Illness; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Mortality; Proportional Hazards Models; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Taiwan; Time Factors; Young Adult | 2016 |
Use of haloperidol and risperidone in highly aggressive Swiss Webster mice by applying the model of spontaneous aggression (MSA).
Topics: Aggression; Animals; Exploratory Behavior; Haloperidol; Male; Mice; Models, Animal; Motor Activity; Random Allocation; Risperidone; Tranquilizing Agents | 2016 |
In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.
Topics: Animals; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; Benzodiazepines; Blood-Brain Barrier; Brain; Cerebrospinal Fluid; Clozapine; Haloperidol; Male; Neuropharmacology; Olanzapine; Paliperidone Palmitate; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Risperidone | 2016 |
Effects of prolonged antipsychotic administration on neuregulin-1/ErbB signaling in rat prefrontal cortex and myocardium: implications for the therapeutic action and cardiac adverse effect.
Topics: Animals; Antipsychotic Agents; Cardiovascular Diseases; Clozapine; Comorbidity; Genetic Predisposition to Disease; Haloperidol; Injections, Intraperitoneal; Male; Myocardium; Neuregulin-1; Phosphorylation; Prefrontal Cortex; Rats, Sprague-Dawley; Receptor, ErbB-2; Receptor, ErbB-4; Risk; Risperidone; Schizophrenia; Signal Transduction; Time Factors | 2016 |
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Depression; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Prolactin; Risperidone; Schizophrenia; Schizophrenic Psychology; Young Adult | 2015 |
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Preparations; Haloperidol; Hospitalization; Humans; Olanzapine; Paliperidone Palmitate; Portugal; Quality-Adjusted Life Years; Recurrence; Risperidone; Schizophrenia | 2016 |
Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Corpus Striatum; Cytokines; Haloperidol; Male; Movement Disorders; Rats, Wistar; Risperidone | 2016 |
Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models.
Topics: Antioxidants; Antipsychotic Agents; Benzodiazepines; Biphenyl Compounds; Clozapine; Free Radical Scavengers; Haloperidol; Humans; Models, Biological; Neutrophil Activation; Neutrophils; Olanzapine; Picrates; Piperazines; Quetiapine Fumarate; Reactive Oxygen Species; Risperidone; Tetradecanoylphorbol Acetate; Thiazoles | 2016 |
Sedative effect of Clozapine is a function of 5-HT
Topics: Animals; Antipsychotic Agents; Caffeine; Central Nervous System Stimulants; Clozapine; Dose-Response Relationship, Drug; Environment; Exploratory Behavior; Genotype; Haloperidol; Inhibition, Psychological; Mice; Mice, Knockout; Receptor, Serotonin, 5-HT2A; Risperidone; Serotonin Antagonists | 2017 |
Assessing a surrogate predictive value: a causal inference approach.
Topics: Antipsychotic Agents; Biomarkers; Causality; Data Interpretation, Statistical; Endpoint Determination; Haloperidol; Humans; Models, Statistical; Monte Carlo Method; Risperidone; Schizophrenia | 2017 |
Effects of antipsychotics on intestinal motility in zebrafish larvae.
Topics: Animals; Antipsychotic Agents; Atropine; Clozapine; Drug Evaluation, Preclinical; Gastrointestinal Motility; Gastrointestinal Tract; Haloperidol; Larva; Muscarinic Antagonists; Risperidone; Zebrafish | 2017 |
In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo.
Topics: Antipsychotic Agents; Delirium; Double-Blind Method; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Different influence of antipsychotics on the balance between pro- and anti-inflammatory cytokines depends on glia activation: An in vitro study.
Topics: Animals; Antipsychotic Agents; Cell Differentiation; Cell Survival; Cells, Cultured; Chlorpromazine; Culture Media; Cytokines; Haloperidol; In Vitro Techniques; Inflammation; Interleukin-10; Interleukin-1beta; Lipopolysaccharides; Neuroglia; Rats; Risperidone; Tumor Necrosis Factor-alpha | 2017 |
Synthesis and Characterization of new Azecine-Derivatives as Potential Neuroleptics.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Catalepsy; Dose-Response Relationship, Drug; Esters; Female; Haloperidol; Heterocyclic Compounds, 3-Ring; Hydrolysis; Locomotion; Prodrugs; Radioligand Assay; Rats; Risperidone | 2017 |
Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study.
Topics: Adult; Antipsychotic Agents; Belgium; Benzodiazepines; Delayed-Action Preparations; Drug Administration Schedule; Female; Haloperidol; Humans; Medication Adherence; Netherlands; Olanzapine; Paliperidone Palmitate; Retrospective Studies; Risperidone; Schizophrenia; Treatment Outcome | 2017 |
Neuroleptics for Delirium: More Research Is Needed.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Neuroleptics for Delirium: More Research Is Needed.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Neuroleptics for Delirium: More Research Is Needed.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Neuroleptics for Delirium: More Research Is Needed.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Neuroleptics for Delirium: More Research is Needed-Reply.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Female; Food Addiction; Hallucinations; Haloperidol; HLA-DQ beta-Chains; Humans; Learning Disabilities; Methylphenidate; Modafinil; Narcolepsy; Orexins; Pediatric Obesity; Polysomnography; Psychotic Disorders; Risperidone; Sleep Deprivation; Sleep Latency; Social Isolation; Sodium Oxybate; Suicidal Ideation | 2017 |
The role of oxidative stress in antipsychotics induced ovarian toxicity.
Topics: Animals; Antipsychotic Agents; Caspases; Cell Survival; Cells, Cultured; Chlorpromazine; Clozapine; Female; Glutathione; Haloperidol; Oxidative Stress; Rats, Sprague-Dawley; Reactive Oxygen Species; Risperidone; Theca Cells | 2017 |
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Preparations; Haloperidol; Humans; Netherlands; Olanzapine; Paliperidone Palmitate; Quality-Adjusted Life Years; Recurrence; Risperidone; Schizophrenia | 2017 |
Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Dendritic Spines; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopaminergic Neurons; Female; Haloperidol; Male; Mice; Mice, Inbred ICR; Prefrontal Cortex; Pregnancy; Prenatal Exposure Delayed Effects; Risperidone; Social Behavior; Valproic Acid | 2017 |
Periodic catatonia with long-term treatment: a case report.
Topics: Antipsychotic Agents; Catatonia; Clozapine; Drug Therapy, Combination; Female; Haloperidol; Humans; Loxapine; Middle Aged; Risperidone; Schizophrenia | 2017 |
The Impact of Antipsychotic Drugs on Long-term Care, Nursing Home Admission, and Death in Dementia Patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Butyrophenones; Cohort Studies; Dementia; Female; Germany; Haloperidol; Homes for the Aged; Humans; Institutionalization; Long-Term Care; Male; Middle Aged; Nursing Homes; Proportional Hazards Models; Quetiapine Fumarate; Risk Factors; Risperidone | 2018 |
Meditation induced psychosis: Case report.
Topics: Adult; Antipsychotic Agents; GABA Modulators; Haloperidol; Humans; Lorazepam; Male; Meditation; Promethazine; Psychotic Disorders; Risperidone | 2018 |
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.
Topics: Administration, Oral; Adult; Algorithms; Antipsychotic Agents; Clozapine; Commitment of Mentally Ill; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Methotrimeprazine; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Failure; Treatment Outcome | 2019 |
Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.
Topics: Animals; Antioxidants; Behavioral Symptoms; Brain; Brain-Derived Neurotrophic Factor; Catalase; Disease Models, Animal; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Flavonoids; Haloperidol; Ketamine; Male; Memory, Short-Term; Mice; NADPH Oxidases; Risperidone; Schizophrenia; Stereotyped Behavior; Superoxide Dismutase; Swimming | 2018 |
Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability.
Topics: Antipsychotic Agents; Autonomic Nervous System; Cardiovascular Diseases; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Therapy, Combination; Haloperidol; Humans; Male; Paliperidone Palmitate; Risperidone; Schizophrenia; Tachycardia, Sinus; Treatment Outcome; Young Adult | 2018 |
Differential effects of typical and atypical antipsychotics on astroglial cells in vitro.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Astrocytes; Cell Membrane; Cytokines; Cytoskeleton; Glutathione; Haloperidol; Heme Oxygenase-1; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Rats; Risperidone | 2018 |
A maximum entropy approach for the evaluation of surrogate endpoints based on causal inference.
Topics: Antipsychotic Agents; Bayes Theorem; Biomarkers; Causality; Endpoint Determination; Entropy; Haloperidol; Humans; Probability; Risperidone; Schizophrenia; Treatment Outcome | 2018 |
Prenatal Exposure to Antipsychotics Disrupts the Plasticity of Dentate Neurons and Memory in Adult Male Mice.
Topics: Animals; Antipsychotic Agents; Dentate Gyrus; Female; Haloperidol; Male; Memory; Mice, Inbred C57BL; Neurogenesis; Neuronal Plasticity; Neurons; Pregnancy; Prenatal Exposure Delayed Effects; Random Allocation; Receptors, N-Methyl-D-Aspartate; Risperidone | 2019 |
Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance).
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Child; Databases, Factual; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Pharmacovigilance; Pituitary Neoplasms; Pregnancy; Quetiapine Fumarate; Retrospective Studies; Risperidone; Sulpiride; Young Adult | 2019 |
Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Haloperidol; Hippocampus; Methylazoxymethanol Acetate; Mice; Motor Activity; Pregnancy; Prenatal Exposure Delayed Effects; Prepulse Inhibition; Risperidone; Schizophrenia | 2019 |
Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Damage; Dopamine D2 Receptor Antagonists; Drug Synergism; Glioblastoma; Haloperidol; Histones; Humans; In Vitro Techniques; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Transplantation; Neoplastic Stem Cells; Receptors, Dopamine D2; Risperidone; RNA, Messenger; Temozolomide | 2019 |
Increased Protein Insolubility in Brains From a Subset of Patients With Schizophrenia.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Brain; Case-Control Studies; Female; Gas Chromatography-Mass Spectrometry; Haloperidol; Humans; Male; Mass Spectrometry; Middle Aged; Nerve Tissue Proteins; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Risperidone; Schizophrenia; Solubility; Temporal Lobe; Ubiquitination | 2019 |
Adverse Events in a Breastfed Infant Exposed to Risperidone and Haloperidol.
Topics: Antipsychotic Agents; Dietary Exposure; Drug Therapy, Combination; Female; Haloperidol; Humans; Infant, Newborn; Milk, Human; Pregnancy; Risperidone; Schizophrenia; Young Adult | 2019 |
Real-life persistence of long-acting injectable antipsychotics in schizophrenic patients: A retrospective observational study in France
.
Topics: Antipsychotic Agents; Delayed-Action Preparations; France; Haloperidol; Humans; Injections; Paliperidone Palmitate; Retrospective Studies; Risperidone; Schizophrenia | 2019 |
Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections; Male; Paliperidone Palmitate; Patient Acceptance of Health Care; Republic of Korea; Risperidone; Schizophrenia | 2019 |
Serotonin 5-HT
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Animals; Antipsychotic Agents; Brain Waves; Cortical Synchronization; Dopamine Agonists; Dopamine Antagonists; Electroencephalography; Fluorobenzenes; Gamma Rhythm; Haloperidol; Hippocampus; Locomotion; Mice; Neural Pathways; Piperazines; Piperidines; Prefrontal Cortex; Pyridines; Quinpirole; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Risperidone; Serotonin Antagonists; Serotonin Receptor Agonists | 2019 |
Anticholinergic Load and Nutritional Status in Older Individuals.
Topics: Aged; Aged, 80 and over; Chlorpromazine; Cholinergic Antagonists; Female; Geriatric Assessment; Haloperidol; Hospitalization; Humans; Hydroxyzine; Japan; Linear Models; Longitudinal Studies; Male; Malnutrition; Metoclopramide; Multivariate Analysis; Nutrition Assessment; Nutritional Status; Patient Discharge; Regression Analysis; Retrospective Studies; Risperidone | 2020 |
Haloperidol bound D
Topics: Antipsychotic Agents; Crystallography, X-Ray; Haloperidol; Humans; Protein Conformation; Receptors, Dopamine D2; Risperidone | 2020 |
[Hypothermia due to antipsychotic drug: A case report].
Topics: Adult; Antipsychotic Agents; Consciousness Disorders; Drug Substitution; Female; Haloperidol; Humans; Hypothermia; Long QT Syndrome; Risperidone | 2020 |
Cycloid psychosis and its longitudinal diagnosis: case report.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Female; Haloperidol; Humans; Hypnotics and Sedatives; Lorazepam; Psychotic Disorders; Recurrence; Risperidone; Sertraline; Sleep Initiation and Maintenance Disorders | 2020 |
Situational analysis of prevailing practices in the management of first-episode psychosis in Chennai, India.
Topics: Haloperidol; Humans; India; Olanzapine; Psychotic Disorders; Risperidone | 2021 |
Haloperidol Discontinuation for People with Schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Risperidone; Schizophrenia | 2020 |
Risperidone and 5-HT2A Receptor Antagonists Attenuate and Reverse Cocaine-Induced Hyperthermia in Rats.
Topics: Animals; Benzazepines; Cocaine; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Haloperidol; Hyperthermia; Ketanserin; Male; Rats; Rats, Wistar; Risperidone; Ritanserin; Serotonin 5-HT2 Receptor Antagonists | 2020 |
Electromembrane extraction of chlorprothixene, haloperidol and risperidone from whole blood and urine.
Topics: Acids; Animals; Antipsychotic Agents; Body Fluids; Chlorprothixene; Chromatography, Liquid; Electricity; Haloperidol; Humans; Male; Membranes, Artificial; Rats, Sprague-Dawley; Reproducibility of Results; Risperidone; Solvents; Tandem Mass Spectrometry; Time Factors; Water | 2020 |
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Lipid Metabolism; Male; Metabolome; Methylazoxymethanol Acetate; Olanzapine; Rats, Sprague-Dawley; Risperidone; Schizophrenia | 2020 |
Overcoming Complications in Management of a Difficult-to-Treat Adolescent with Schizoaffective Disorder.
Topics: Adolescent; Adolescent Psychiatry; Antidepressive Agents; Antipsychotic Agents; Diphenhydramine; Female; Haloperidol; Humans; Hypnotics and Sedatives; Lorazepam; Psychiatric Department, Hospital; Psychotic Disorders; Risperidone; Sertraline | 2020 |
Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Disease Models, Animal; Female; Haloperidol; Intra-Abdominal Fat; Methylazoxymethanol Acetate; Olanzapine; Pregnancy; Prenatal Exposure Delayed Effects; Proteomics; Rats; Rats, Sprague-Dawley; Risperidone; Schizophrenia; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Delirium in the NICU: Risk or Reality?
Topics: Adult; Antipsychotic Agents; Child; Delirium; Haloperidol; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Risperidone | 2021 |
Effects of Haloperidol, Risperidone, and Aripiprazole on the Immunometabolic Properties of BV-2 Microglial Cells.
Topics: Antipsychotic Agents; Aripiprazole; Cell Survival; Cells, Cultured; Haloperidol; Humans; Inflammation Mediators; Microglia; Risperidone | 2021 |
Proteome Analysis of PC12 Cells Reveals Alterations in Translation Regulation and Actin Signaling Induced by Clozapine.
Topics: Actin Cytoskeleton; Acute-Phase Reaction; Animals; Antipsychotic Agents; Ciliary Neurotrophic Factor; Clozapine; Haloperidol; PC12 Cells; Protein Biosynthesis; Proteome; Rats; rho GTP-Binding Proteins; Risperidone; Signal Transduction | 2021 |
Coexistence of serotonin syndrome and neuroleptic malignant syndrome: does it exist?
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Risperidone; Serotonin Syndrome; Young Adult | 2021 |
[Changes in adipokines in the blood of patients with the first episode of schizophrenia during treatment with haloperidol and risperidone].
Topics: Adipokines; Antipsychotic Agents; Haloperidol; Humans; Risperidone; Schizophrenia | 2021 |
Atypical, but Not Typical, Antipsychotic Drugs Reduce Hypersynchronized Prefrontal-Hippocampal Circuits during Psychosis-Like States in Mice: Contribution of 5-HT2A and 5-HT1A Receptors.
Topics: Animals; Antipsychotic Agents; Clozapine; Haloperidol; Hippocampus; Mice; Phencyclidine; Prefrontal Cortex; Psychotic Disorders; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Risperidone; Serotonin Antagonists | 2022 |
A Case Report of Stuttering Induced by Risperidone and Chlorpromazine.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Haloperidol; Humans; Male; Risperidone; Stuttering | 2022 |
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Drug-Related Side Effects and Adverse Reactions; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia | 2022 |
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Topics: Adenosine Monophosphate; Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Clopenthixol; Clozapine; Flupenthixol; Fluphenazine; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Pimozide; Quetiapine Fumarate; Risperidone; Sulpiride; Trifluoperazine | 2022 |
Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; Japan; Paliperidone Palmitate; Risperidone; Schizophrenia; Tardive Dyskinesia | 2022 |
[Neuroleptic malignant syndrome caused by olanzapine, risperidone and haloperidol].
Topics: Adult; Antipsychotic Agents; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Olanzapine; Risperidone | 2022 |
Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; Japan; Paliperidone Palmitate; Retrospective Studies; Risperidone; Schizophrenia | 2023 |
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Haloperidol; Humans; Risperidone; Sweden; United Kingdom | 2023 |
Antipsychotics Induced Reproductive Toxicity by Stimulating Oxidative Stress: A Comparative in Vivo and in Silico Study.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Haloperidol; Male; Quetiapine Fumarate; Rats; Risperidone; Semen | 2023 |
Practice of prescribing antipsychotics in schizophrenia during 2013-2018 based on data from the National Health Fund.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Olanzapine; Risperidone; Schizophrenia | 2022 |
Minocycline and antipsychotics inhibit inflammatory responses in BV-2 microglia activated by LPS via regulating the MAPKs/ JAK-STAT signaling pathway.
Topics: Antipsychotic Agents; Haloperidol; Humans; Interleukin-6; Lipopolysaccharides; Microglia; Minocycline; Nitric Oxide; Nitric Oxide Synthase Type II; Risperidone; Signal Transduction; Tumor Necrosis Factor-alpha | 2023 |
Comparative Safety Analysis of Oral Antipsychotics for In-Hospital Adverse Clinical Events in Older Adults After Major Surgery : A Nationwide Cohort Study.
Topics: Aged; Antipsychotic Agents; Cohort Studies; Emergence Delirium; Female; Haloperidol; Hospital Mortality; Hospitals; Humans; Ischemic Attack, Transient; Male; Olanzapine; Quetiapine Fumarate; Retrospective Studies; Risperidone | 2023 |
When the fever will not stop, stop the pills! A case report.
Topics: Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome; Quetiapine Fumarate; Risperidone | 2023 |